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Summary
Argonaute (AGO) proteins are the key components of small RNA-mediated regulatory
pathways. They bind small regulatory RNAs, for example microRNAs (miRNAs) gen-
erated by the ribonuclease Dicer, and assemble with several other factors into ribonu-
cleoprotein (RNP) complexes. These AGO-containing RNP complexes are guided to
target RNAs in a sequence specific manner by their bound small RNAs and regulate
transcription, translation and messenger RNA (mRNA) stability.
To gain a better understanding of the mechanisms of miRNA-mediated regulation, it is
important to characterize the underlying structural features. Therefore, it was aimed to
determine the structures of the human AGO2-Dicer complex, as well as of the methylo-
some, an AGO-modifying complex, by electron microscopy.
The accessory factors involved in the regulation of the activity and the assembly of AGO-
containing RNPs have been only partly defined so far. Therefore, quantitative proteomic
studies were carried out to identify the proteins interacting with murine AGO2. For this
purpose, the protein composition of AGO2-containing RNPs isolated from mouse embry-
onic fibroblasts (MEFs) by using a novel antibody specific for mouse AGO2 was analyzed.
In contradiction to the current opinion that AGO2 and Dicer form a stable complex, the
proteomic analysis of the endogenous AGO2-complexes suggested that Dicer may not
stably associate with AGO2 under basal cellular conditions. Furthermore, the influence
of miRNAs on the protein composition of AGO-containing RNPs was analyzed. For
this purpose, RNPs containing tagged AGO2 were isolated from wild type and MEFs
devoid of mature miRNAs due to a Dicer depletion. The comparison between the pro-
tein compositions revealed that several proteins specifically interacted with AGO2 only
in the presence or absence of miRNAs, whereas other proteins associated with AGO2
under both conditions. Opposing the current general assumption that AGO2 complexes
only associate with mRNAs when guided by miRNAs, it could be demonstrated that
AGO2-containing RNPs stably associated with large RNAs in a miRNA-independent
manner and that large RNA binding strongly influenced the protein composition of the
complex. The data was combined into an interaction network presenting an overview of
AGO2-associated proteins as well as the RNA requirements of the interactions, thereby
providing a detailed basis for further analyses of AGO2 function and regulation.
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1 Introduction
1.1 RNA Interference
Non-coding RNAs play an important role in various cellular processes such as transcrip-
tion, splicing, transposon control and translation. The first inhibitory function of RNAs
was observed in plants in 1990 when Napoli et al. introduced transgenes into petunia
to enhance flower coloring. Instead of an enhanced pigment synthesis, they observed
repression of both the transgene and the homologous endogenous sequence [233]. This
nucleotide sequence-specific gene silencing phenomenon, referred to as post transcrip-
tional gene silencing, was subsequently shown to be involved in viral defense in plants
[47, 190]. A comparable mechanism called quelling was soon after established in the fun-
gus Neurospora crassa [279]. Developmental studies in Caenorhabditis elegans revealed
that this pathway of posttranscriptional regulation is conserved in eukaryotes [176, 350].
The underlying molecular mechanism, termed RNA interference (RNAi), was discov-
ered in 1998 when long double stranded (ds) RNAs were identified as the trigger of
this type of post transcriptional gene silencing in C. elegans [83]. Subsequent studies
revealed that the long dsRNAs are processed into short fragments by the ribonuclease
Dicer [22, 106, 116, 133, 180]. These so called small interfering RNAs (siRNAs) are in-
corporated into a protein of the AGO family and guide the sequence specific degradation
of target mRNAs [118, 119, 214, 229, 362]. RNA interference was soon established as
a general regulatory mechanism conserved between species, including fruit flies, plants,
planaria, hydra, zebrafish and mammals [2, 16, 155, 200, 250, 346, 348].
Over the last years, RNAi has developed into a powerful tool to repress specific genes
experimentally and it is widely applied for the characterization of protein functions. The
employment of long dsRNAs as silencing triggers in the mammalian system proved to
be inapplicable because their transfection resulted in cell death [308]. However, efficient
RNAi can be triggered in mammalian cells by transfection of 21 nucleotides (nt) long
siRNA duplexes [66]. RNAi also has great potential for medical therapy but despite
several promising results [253, 307, 367], the outcome of these efforts is hard to predict.
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Besides siRNAs, several classes of endogenous small regulatory RNAs have been identi-
fied in plants, worms, flies and mammals (reviewed in [96]). These small RNAs regulate
gene expression by various, not yet fully elucidated mechanisms at the transcriptional
and postranscriptional level.
1.2 Classes and Biogenesis of Small RNAs
Many species of small RNAs have emerged over the last decade and are categorized into
the three main classes of siRNAs, miRNAs and PIWI-interacting RNAs (piRNAs) (for
review see Ref. [96]). These RNA species differ in their biogenesis, expression profiles,
RNA target nature and the mechanism of target regulation. They have in common
that they all bind to an effector protein, a member of the AGO protein family, and
guide the effector to the target RNA by base pairing. Small regulatory RNAs are only
known in eukaryotes, but AGO proteins are also present in some bacteria and archaeal
species. The most broadly distributed classes of small regulatory RNAs are siRNAs
and miRNAs. They are generated from long dsRNA precursors by cleavage through
the ribonuclease Dicer and associate with an AGO protein and auxiliary proteins to
form the RNA-induced silencing complex (RISC) that mediates target regulation. The
expression of the third well studied class of small regulatory RNAs, the piRNAs, is
restricted to the germline. PiRNAs are produced from single stranded RNA precursors
in a Dicer-independent fashion and bind to a protein of the P-element induced wimpy
testis (PIWI)-clade of Argonaute proteins ([36, 96, 161], see Section 1.5)
1.2.1 Biogenesis of Small Interfering RNAs
Small interfering RNAs derive from long, linear and perfectly base-paired dsRNAs (Fig-
ure 1.2.1). These precursor RNAs can be taken up from the environment or can be
experimentally introduced into the cytoplasm. Originally, siRNAs were observed in
plants as a response to transgene- or virus induced post transcriptional gene silencing
[116]. The long dsRNA precursor is cleaved into 21 nt long ds-siRNAs by the RNase III
type ribonuclease Dicer ([22], see Section "Dicer" on page 7 for a detailed description).
The RNA duplexes produced by Dicer processing have 5’ phosphates and 3’ hydroxyl
groups and a two nucleotides 3’ overhang [66, 67]. In Drosophila melanogaster, siRNAs
are methylated at the 3’ end [128]. The ds-siRNA is loaded into an AGO protein by the
RISC loading complex composed of Dicer and an RNA binding protein (RBP) cofactor
(TRBP in mammals, R2D2 in flies). One of the siRNA strands, the so called guide
strand, stays incorporated into the AGO protein and guides target recognition, whereas
2
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Figure 1.2.1: SiRNA biogenesis in mammals. SiRNA duplexes are generated through
cleavage of long dsRNA precursors by the endonuclease Dicer and are loaded into AGO2. The
passenger strand is cleaved and discarded whereas the guide strand stays incorporated and
directs target cleavage (Figure adapted from [96]).
the other strand, the passenger strand, is discarded (see Section "RISC loading and Mat-
uration" on page 11 for more details). Besides the siRNAs originating from exogenous
sources (exogenous siRNAs (exo-siRNAs)) several genomic loci have been identified as
sources for endogenous siRNAs (endo-siRNAs) in plants, C. elegans, flies and mammals
[36, 96]. Unlike exo-siRNAs, endo-siRNAs have an obligate nuclear phase and derive,
among others, from transposons or other repetitive elements, convergent mRNA tran-
scripts and hairpin RNAs (hpRNAs). With the exception of C. elegans, the biogenesis
of endo-siRNAs is also Dicer-dependent [36, 96].
RNAi is a very potent mechanism as a low number of dsRNA molecules can trigger
a strong response. In nematodes and plants, the initial RNAi triggers can induce the
synthesis of secondary siRNAs through the action of RNA-dependent RNA polymerases
(RdRPs) [51, 230, 249, 301]. A consequence of the siRNA amplification through RdRPs
is referred to as transitive RNAi. This term describes the appearance of secondary
siRNAs with target mRNA sequences not corresponding to the sequence of the initial
trigger siRNA, which can lead to the silencing of multiple transcripts with conserved
sequences [301, 302, 329]. RdRP-dependent siRNA amplification and transitive RNAi
have not been described in vertebrates and mammals so far [36, 96]. In nematodes
and plants, silencing can spread from its initiation site throughout the whole organism,
a process know as systemic silencing [83, 126, 251, 335]. Systemic silencing involves
the movement of mobile RNAs between adjacent cells and between organs and tissues
and it has been suggested to be a signaling mechanism associated with postranslational
regulation as well as epigenetic modifications (reviewed in [222]).
1.2.2 Biogenesis of MicroRNAs
MicroRNAs are endogenous small RNAs that are encoded by a diverse set of genes. A
few miRNAs are encoded in a separate transcription unit but most miRNAs are present
as clusters (Figure 1.2.2A). In many cases, miRNAs are encoded in introns of protein
3
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Figure 1.2.2: MicroRNA biogenesis. A) Canonical pathway from non-coding RNA tran-
scripts, B) Biogenesis of miRNAs from introns of protein coding transcripts, C) Drosha-
independent miRNA biogenesis pathway of mirtrons (Figure adapted from [161]).
coding transcripts (Figure 1.2.2B) [36]. Precursor transcripts, termed primary miRNAs
(pri-miRNAs), are transcribed by RNA polymerase II or III and transcripts are capped
and polyadenylated [29, 179]. In the canonical biogenesis pathway (Figure 1.2.2A), the
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stem-loop structured pri-miRNA transcripts are trimmed to the mature miRNA by two
sequential processing steps. The first processing step is carried out in the nucleus by
the Microprocessor complex consisting of the RNase Drosha in association with an RBP
cofactor (DGCR8 in mammals and Pasha in flies) [54, 103, 120, 172, 177]. Drosha
cleavage produces 60-79 nt long hairpin structured precursor miRNAs (pre-miRNAs)
[177] that are subsequently exported into the cytoplasm by Exportin 5 [25, 202, 358].
The second processing step is carried out in the cytoplasm by Dicer and its cofactors
TRBP and/or PACT (Dicer-1 and Loquacious in Drosophila) [43, 90, 178, 285]. By
excision of the terminal loop, Dicer produces 22 nt long miRNA duplexes [22]. In the
duplex, the strands are termed miRNA and miRNA* and correspond to the guide and
passenger strand of an siRNA. The miRNA strand is then incorporated into an AGO
protein, except for rare cases in which the miRNA* is incorporated [247], and form the
core of the so called micro-ribonuleoprotein (miRNP) or microRNA-induced silencing
complex (miRISC). MiRNAs then guide their effector complex to the target mRNAs for
posttranscriptional repression [36, 80].
An alternative, Drosha independent miRNA biogenesis pathway involves the pre-mRNA
splicing machinery (Figure 1.2.2C). So called mirtrons are spliced out from RNA tran-
scripts and form hairpin structures that mimic pre-miRNAs and are exported from the
nucleus and further processed by Dicer [241, 281]. MicroRNAs can also derive from
other non-coding small RNAs, for example small nucleolar RNAs (snoRNAs) or tRNAs
[13, 68]. Recently, a Dicer-independent miRNA biogenesis pathway has been described
for the murine miRNA 451. This miRNA is processed by Drosha, but its maturation
does not require Dicer but instead depends upon cleavage of the miRNA precursor by
AGO2 [40, 45].
MicroRNAs exhibit specific expression patterns [170]. This requires a tight regulation of
the miRNA biogenesis process, yet only two regulation mechanisms have been described
so far: the transcription of miRNA encoding genes can be controlled by a double-negative
feedback loop [186, 295] or the processing of the pri-miRNA through the Microprocessor
complex can be regulated by RBPs [52, 109].
1.2.3 Interactions of Small Interfering RNAs and MicroRNAs to Target
RNAs
SiRNAs show perfect complementarity to their target mRNAs and induce cleavage of
the target through the endonuclease activity of the AGO protein. In contrast, animal
miRNAs exhibit only partial complementarity to their target mRNAs (Figure 1.2.3)
and do not induce target mRNA cleavage but influence translational repression and
5
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Figure 1.2.3: Principles of miRNA to target mRNA interaction. MiRNAs show a
preference for an uridine or an adenine at the 5’ end and only a perfect complementarity of the 5’
nucleotides 2-8, the so called "seed region", is required for target recognition. A complementarity
of the 3’ nucleotides stabilizes the interaction with the target RNA. Mismatches or bulges in
the central region prevent an siRNA-like endonucleolytic cleavage of the target RNA (Figure
adapted from [82]).
degradation of the target. MiRNAs show a preference for an uridine or an adenine at
the 5’ end [82, 85] and only a perfect complementarity of the 5’ nucleotides 2-8, referred
to as the "seed sequence", is necessary for their function [185, 270]. Mismatches or bulges
in the central region (nucleotides 10-12) prevent an siRNA-like endonucleolytic cleavage
of the target RNA. A complementarity of the 3’ nucleotides is of minor importance but
stabilizes the interaction [80, 82]. Since full complementarity is not required for target
recognition, a single miRNA can control a large number of mRNAs. This displays a high
regulatory potential, but makes prediction of target mRNAs very difficult [18].
Usually, miRNA-binding sites are located in 3’ untranslated regions (UTRs) of the
mRNA target and are present in multiple copies [63, 107]. These clusters of multiple
miRNA-binding sites have a cooperative effect and increase efficiency [58, 105]. MiRNA-
binding sites are frequently located near AU-rich regions, close to the open reading
frame (ORF) or to the 3’ end of the 3’ UTR [105, 234, 270]. These factors reduce the
structure of the mRNA and enhance accessibility of the miRNA-binding sites [82]. In an-
imals, miRNAs can also target binding sites in the 5’ UTR or coding regions of mRNAs
and exert regulatory effects similar to those binding in the 3’ UTRs [62, 166, 204, 369].
RNAi and miRNA-mediated repression are not strictly separated pathways. If a miRNA
is fully complementary to the target RNA, it can induce cleavage and siRNAs with im-
perfect matching can influence translational repression and degradation of the target
in a miRNA-like fashion [53, 57, 357]. This interplay between the pathways offers ad-
ditional regulatory possibilities but causes problems when using siRNAs as a scientific
tool. Imperfect binding of the guide strand to unidentified targets leads to a miRNA-like
regulation of these targets. These regulatory effects, the so called off-target effects, often
overlap with the intended siRNA function and impair the use of RNAi for the definition
of gene function [139].
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1.3 Key Proteins in Small RNA-Mediated Functions
1.3.1 Drosha
Drosha is the catalytically active component of the Microprocessor complex and is re-
sponsible for pri-miRNA processing ([177], see Section 1.2.2). The protein is a member
of the RNase III family and localizes to the nucleus. Drosha contains an N-terminal
proline-rich region and an arginine- and serine-rich region, followed by two RNase III
domains and a double stranded RNA binding domain (dsRBD). Pri-miRNA cleavage
by Drosha produces 60-79 nt long hairpin structured pre-miRNAs with 2’ nt long over-
hangs at the 3’ end by excising the stem-loop structure from the pri-miRNA transcript
[177]. Correct processing depends on the stem-loop structure of the pri-miRNA, which
is normally a 33 nt long imperfectly base paired stem with a terminal loop and flanking
segments [18]. For effective and precise cleavage, Drosha requires its associated cofac-
tor DGCR8/Pasha [54, 103]. The cofactor serves as a molecular ruler that binds the
pri-miRNA hairpin and positions Drosha to cleave the stem exactly 11 bp away from
the junction between the stem and the flanking single stranded regions [121].
1.3.2 Dicer
Dicer is a dsRNA specific nuclease of the RNase III family. It cleaves dsRNAs into small
duplexes with lengths between 21-25 nt and was identified as the key enzyme for si- and
miRNA biogenesis [22]. Mammals and nematodes have only one Dicer protein, whereas
Drosphila has two and Arabidopsis thaliana expresses four different Dicer enzymes. If ex-
istent, multiple Dicers have specialized functions, for example in flies, Dicer-1 is involved
in miRNA biogenesis and Dicer-2 is required for siRNA production [180, 321].
The typical domain structure of Dicer enzymes from human and Giardia intestinalis
is depicted in Figure 1.3.1A. In human Dicer, an amino terminal DEXD/H ATPase
domain is followed by a DUF283, a PIWI-Argonaute-Zwille (PAZ) domain, two tandem
RNase III domains and a dsRBD near the C-terminus. The spatial arrangement of the
domains confers the ability of Dicer to produce dsRNAs with a specific length. PAZ
domains bind 3’ ends of single stranded (ss) RNAs [191, 305, 354] and the Dicer PAZ
domain specifically binds duplex RNAs with 2 nt 3’ overhangs [209]. In G. intestinalis
Dicer, the two RNase III domains are arranged in a way that they form an intramolecular
dimer closely resembling the homodimeric structure of prokaryotic RNase III and the
distance between the two active sites matches the width of the major groove of an
RNA helix. The duplex RNA with its 3’ nucleotide bound in the PAZ domain extents
approximately two helical turns on the protein surface until it reaches the active sites of
7
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Figure 1.3.1: Domain organization of
Dicer family proteins and structure
of Giardia intestinalis Dicer. A)
Schematic presentation of the domain or-
ganization of Dicer family enzymes. B)
Crystal structure of G. intestinalis Dicer
with a model of a bound dsRNA substrate.
Black arrows indicate cleavage sites (Figure
adapted from [145]).
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the RNase III domains. This distance corresponds to the length of a 25 nt RNA duplex.
Each of the RNAse III domains cleaves one strand, leading to staggered cleavage yielding
new 2 nt 3’ overhangs with 5’ monophosphates [210]. Therefore, the distance between
the PAZ domain and the processing center functions as an internal molecular ruler that
determines the length of the small RNA product starting from the 3’ end of the RNA
substrate ([209, 210], see Figure 1.3.1B). A recent study revealed that human Dicer
anchors the 5’ phosphate in a basic binding pocket in addition to binding of the 3’ end
in the PAZ domain. This 5’ end anchoring facilitates the precise cleavage of 3’ modified
pre-miRNAs and seems to also be critical for precise and efficient generation of canonical
miRNAs [256].
Less detail is known about the functions of the dsRBD and DEXD/H ATPase domains.
The dsRBD undergoes conformational changes upon RNA cleavage [59]. DsRBD mu-
tants show reduced cleavage activity, yet target binding is unaffected [205], suggesting
that this domain might be involved in target cleavage. Functions of the DEXD/H ATPase
domain vary between Dicer enyzymes. D. melanogaster Dicer-2 and the C. elegans Dicer
protein Dcr-1 are ATP-dependent [205, 239], while human Dicer is ATP-independent and
the ATPase domain actually has an autoinhibitory effect [205]. Thus, the domain func-
tion among the distinct Dicers remains generally unknown.
Dicer enzymes rely on different cofactors for the processing of different small RNA classes
[50], for example in flies binds Dicer-2 to R2D2 [197, 198] and Dicer-1 to Loquacious
8
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[90, 285]. The sole Dicer in human associates with two dsRBD cofactors, TRBP and
PACT [43, 167, 178]. This association with dsRBDs is not necessary for processing
activity but is involved in RISC loading and guide strand selection ([198, 320], see
Sections "RISC Loading and Maturation" on page 11 and "Small RNA Sorting" on
page 12).
1.3.3 The Argonaute Proteins
Argonaute proteins are the central component of RISC and a common feature of all
small RNA-mediated silencing pathways. SiRNA-induced silencing of target mRNAs is
achieved through endonucleolytic cleavage of perfectly complementary target mRNAs
by an AGO protein, a process referred to as slicing. The AGO family is divided into
three clades: the AGO, the PIWI and the nematode specific WAGO clade. Except
for Schizosaccharomyces pombe, most species contain multiple AGO genes, for example
five in D. melanogaster, ten in plants and 27 in C. elegans. Humans have eight AGO
genes. Four of them belong to the AGO clade (AGO 1-4) and are ubiquitously expressed.
HILI, HIWI, HIWI2 and HIWI 3 (MILI, MIWI and MIWI2 in mouse) are members of
the PIWI-clade. PIWI-proteins are only expressed in the germ line and bind specifically
to piRNAs (see Section 1.5). In plants, worms and flies, the functional specialization
of different AGO proteins is well described. For human the deep sequencing of small
RNAs associated with the four AGO proteins revealed little differences, so the functional
specialization in mammals remains unclear [36].
Structure
Argonaute proteins consist of four domains, the N-terminal, the PAZ, the middle (MID)
and a PIWI domain (Figure 1.3.2A). Crystal structures of bacterial AGO proteins re-
vealed a bilobal architecture wherein the MID and PIWI domains form one and the
N- and PAZ domain the other lobe [145]. The PIWI domain adopts a fold similar
to RNase H [257, 306, 361] and confers the slicer activity to RISC. AGO cleaves the
target RNA at the phosphodiester bond between the nucleotides that are paired with
nucleotides ten and eleven of the guide strand (counting from the 5’ end of the siRNA)
[66, 67] and generates 5’ products with a free 3’ hydroxyl group and a 3’ product that
carries a 5’ phosphate group [194, 215].
A conserved Asp-Asp-His motif and divalent cations are required for this catalytic activ-
ity in AGO proteins [194, 276]. Strikingly, among the four human AGO proteins, only
AGO2 has slicer activity [194, 220]. AGO1 and 4 have altered sequences at the cata-
lytic site and although AGO3 contains an Asp-Asp-His motif it does not display slicer
9
1 Introduction
Figure 1.3.2: Domain architecture and
structure of Thermus thermophilus
Argonaute. A) Schematic presentation of
the four domains of Argonaute proteins. B)
Crystal structure of T. thermophilus AGO
bound to a 21 nt guide DNA strand (red)
and a 20 nt target RNA (blue) with mis-
matches at nucleotides 10-11. Backbone
phosphorus atoms are depicted in yellow
(Figure B adapted from [344]).
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activity [194, 220]. In D. melanogaster, both AGO proteins, AGO1 and 2, feature the
Asp-Asp-His motif and are both capable of slicing. AGO2 cleaves targets efficiently but
AGO1 has a lower turnover rate because of slower target release [89]. These observations
and the fact that the population of small RNAs associated with human AGO1-4 show
only little differences are indications that slicer activity is not only determined by the
catalytic residues but by other internal or external factors [145].
The 3’ end of the guide strand RNA is inserted into a hydrophobic pocket in the PAZ
domain of the AGO protein [191, 305, 354]. This pocket is lined with aromatic residues
and the position of the terminal nucleotide is fixed by stacking against the aromatic
ring of a conserved phenylalanine residue [206]. In AGO proteins, the 5’ nt of the guide
strand does not base pair with the target RNA but is bound in a pocket at the interface
between the MID and PIWI domains via an interaction of the phosphate group to a
magnesium ion [27, 56, 207, 258]. Analyses of the crystal structure of the human AGO2-
MID domain revealed that adenosine monophosphate or uridine monophosphate bound
in the 5’ binding pocket stack against a tyrosine in the binding pocket and make contact
with the so called nucleotide specificity loop of the MID domain. This loop discriminates
against the binding of cytidine monophosphate and guanosine monophosphate and pro-
vides an explanation for the preference for adenine and uridine at the 5’ position of the
miRNA guide strand [85]. Interestingly, the MID-PIWI domain interface of eukaryotic
AGO was reported to feature a second ligand binding pocket. The function of the second
ligand is so far unknown, but it is suggested to have an allosteric effect and to possibly
bind to the m7GpppN group at the 5’ end, the so called 5’ cap, of the mRNA during
miRNA-mediated repression [27, 56].
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Crystal structures of Archaeoglobus fulgidus PIWI-RNA complex [207, 258] and T. the-
mophilus Argonaute with a DNA guide strand [345] revealed that the guide-target duplex
is stretched over a basic channel on the surface of the MID and PIWI domains. Mod-
eling of the guide-strand-target duplex places the phosphate bond of the target mRNA
into the catalytic site, which explains why specific cleavage occurs only at this fixed dis-
tance [207]. RNA-protein interactions are dominated by sequence-unspecific interactions
between positively charged amino acid residues on the protein surface with the sugar
phosphate backbone of the RNA. The bases of the seed region of the miRNA are ex-
posed and stacked in a helical conformation that allows for base pairing with the target
[345]. A structure of T. thermophilus Argonaute with a DNA guide strand paired to
a target RNA [344] (Figure 1.3.2B) shows that the bases of the seed region engage in
Watson-Crick base pairing with the target RNA in an A-form helical conformation. To
accommodate the helical structure, pronounced conformational changes, mainly rotation
of the N- and PAZ domain, are required [344]. The MID-PIWI lobe of an eukaryotic
AGO protein conserves the domain orientation compared to prokaryotic AGOs, though
it differs in the position of some residues at the MID-PIWI interface. These residues
were previously thought to participate in regulation of guide strand binding but appear
to be buried in the eukaryotic structure [26].
RISC Loading and Maturation
Single stranded siRNAs can be directly loaded onto AGO but siRNA and miRNA du-
plexes generated by Dicer depend on RISC assembly pathways [276]. One strand of the
duplex, the guide strand/miRNA stays bound to the AGO protein, whereas the other
strand, the passenger strand/miRNA* is removed. The identity of the guide and passen-
ger strand is determined by the thermodynamic stability of the 5’ end. According to this
asymmetry rule, the strand with the thermodynamically less stable end is preferentially
retained [156, 294]. The relative thermodynamic stabilities are sensed by either Dicer
itself or by a Dicer cofactor [197, 198, 237]. In D. melanogaster, the siRNA duplex is
bound by Dicer-2 in association with its cofactor R2D2 [197, 198]. Together with other
unknown protein factors a RISC loading complex (RLC) is formed that is transformed
into a pre-RISC by the addition of AGO2 [160]. The slicer activity of AGO2 cleaves the
passenger strand in an ATP-independent manner [184, 217, 225, 271] and discarding of
the passenger strand leads to formation of the mature holo-RISC [36, 303]. In humans,
Dicer, TRPB and AGO2 form the RISC loading complex [102, 212]. This complex is
capable of dsRNA binding, dicing, AGO2 loading and passenger strand removal leading
to active RISC formation [208]. The presence of a dsRNA trigger or other cofactors is
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not required for RLC formation and activity [208]. Dicer itself is not essential for RISC
loading in the murine system, as shown by the fact that Dicer-deficient cells are still
capable of siRNA-induced gene silencing [232].
Of the four human AGO proteins, only AGO2 has slicer activity but the other AGO
proteins are nevertheless loaded with ss-siRNAs [194, 221]. Despite the fact that miRNA
duplexes contain central mismatches that prevent cleavage of the passenger strand, ss-
miRNAs are bound into all AGO proteins [12]. Therefore, RISC maturation can also
occur in a slicer-independent mechanism that involves unwinding of the RNA duplex. In
contrast to passenger strand degradation, the loading of the small RNA duplex into RISC
is an ATP-dependent process [151, 239, 263, 360]. Structural studies predict that RNA
double helices are too bulky to easily fit into AGO and that conformational changes
are necessary to allow the binding of the small RNA duplex [207, 258, 341]. AGO
proteins interact with the chaperones HSP90 and HSP70 and a current model proposes
that the chaperone machinery uses ATP to mediate conformational changes of the AGO
protein which facilitate the loading of the small RNA [134, 138, 148, 226]. In the open
conformation, AGO is expected to be under structural tension and the release of this
tension is thought to drive unwinding of the miRNA-miRNA* duplex [151].
Other factors of the RISC machinery are also involved in RISC loading and maturation,
for example the putative RNA helicase Armitage (MOV10 in human), which associates
with AGO and is required for RISC maturation in flies and human [221, 320]. Another
human helicase, RNA helicase A/DDX9, is involved in guide strand incorporation [278].
Furthermore, in flies and mammals the endoribonuclease C3PO has been reported to
activate RISC by removing passenger strand cleavage products [199, 356].
Small RNA Sorting
For accurate RISC function, it is crucial that the correct small RNA is bound into the cor-
responding AGO protein. In plants, small RNA association with the correct AGO protein
depends on the identity and modifications of the 5’ nucleotide [303]. D. melanogaster
pre-miRNAs are processed by Dicer-1 in complex with the dsRBP Loquacious, whereas
siRNAs are generated by the Dicer-2-R2D2 heterodimer. Whether a small RNA pro-
duced by Dicer-1 is loaded into AGO1 for translational repression or into AGO2 for
target degradation is regulated by the Dicer-2-R2D2 complex and depends on the struc-
ture of the small RNA duplex [89, 319]. R2D2 has a binding preference for highly paired
duplexes and thereby promotes the binding of perfectly matched siRNAs to AGO2.
Small RNA duplexes with central bulges are poorly bound by R2D2 and thus routed
to AGO1. Perfectly base paired miRNA-miRNA* duplexes also enter AGO1, indicating
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that the AGO1 loading pathway is also selective and not a default pathway for small
RNAs rejected by AGO2 [152, 303].
Localization
Argonaute proteins are predominantly localized in the cytoplasm [182]. A fraction is con-
centrated in distinct cytoplasmic granules known as mRNA processing bodies (P-bodies)
[196, 298]. AGO also localizes to multivesicular bodies (MVBs) and, upon cellular
stresses, to stress granules (SGs). Localization of AGO in the nucleus has also been
reported [277, 282, 349].
P-bodies are cytoplasmic granules that function in storage and degradation of mRNAs
[70]. They are also referred to as GW-bodies as the GW182 protein (see Section 1.3.4)
is an integral component of P-bodies. AGO localizes to P-bodies in a predominantly
miRNA-independent manner and localization relies on direct interactions with P-body
components instead [19, 317, 359]. P-bodies are enriched in translationally repressed
mRNAs and proteins involved in 5’-3’ mRNA degradation such as the exonuclease XRN1,
the deadenylation complex including CAF1, CCR4 and NOT and the decapping enzymes
DCP1 and DCP2 [70]. In addition, nonsense-mediated mRNA decay (NMD) also takes
place in P-bodies [325]. Ribosomal proteins, the majority of translation initiation factors
and the 3’-5’ mRNA degradation machinery are absent from P-bodies [5, 300, 315].
P-bodies are highly dynamic structures [71, 187] and the depletion of GW182 or other
miRNA pathway proteins disrupts visible P-body formation [259, 355]. It seems as if the
disruption of P-bodies does not affect miRNA-mediated repression and it is suggested
that this process starts in the cytosol and that translationally repressed mRNAs are
consecutively transported to P-bodies for storage or degradation [71, 359]. Therefore,
P-body formation is assumed to be a consequence of and not a prerequisite for miRNA-
mediated repression [71]. Although mRNAs are necessary for P-body formation [70],
repression and storage of mRNAs in P-bodies are reversible processes since repressed
mRNAs can be released from storage upon cellular signals and translation resumes [23,
31].
Stress granules are sites where non-translating mRNAs accumulate when cells experience
stresses such as heat shock, osmotic or oxidative stress or when translation initiation is
specifically inhibited. They contain small ribosomal subunits, early translation initiation
factors and several RBPs, among them poly(A)-binding protein, cytoplasmic (PABPC),
RCK, XRN, HuR and FXR1 [3]. P-bodies and SGs are known to be dynamically asso-
ciated with each other and share several protein components [154]. AGO2 localizes to
stress granules in a miRNA-dependent way [182] and its recruitment to SGs as well as
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to P-bodies is regulated by HSP90 [255].
AGO proteins also associate with cellular membranes and multivesicular bodies [97, 311].
MVBs are specialized late endosomal compartments with a characteristic multivesicu-
lar morphology that colocalize with P-bodies and contribute to miRNA function and
miRISC turnover in mammals and flies [97, 181]. Some miRNAs and GW182, but not
AGO, are secreted from MVBs in exosome-like vesicles, a mechanism that might repre-
sent a measure to control RISC activity by eliminating components from the cell or a
way of miRNA-dependent cellular communication [330].
Post-Translational Modifications
Besides the nature of the small RNA and the protein composition of the RISC the
activity of AGO proteins is also influenced by post-translational modifications. Qi et al.
[269] reported that hydroxylation of human AGO2 at Pro700 is important for AGO2
stability. The mouse E3 ubiquitin ligase mLin41 mediates ubiquitinylation of AGO2,
thereby regulating AGO2 turnover [283]. Phosphorylation of Ser387 is related to P-body
localization of AGO [364] and phosphorylation of Tyr529 in the 5’ binding pocket of the
MID domain interferes with small RNA binding and AGO loading [284].
1.3.4 The GW182 Protein Family
GW182 was originally cloned from human cells and termed GW182 because of the pres-
ence of glycine-tryptophan repeat (GW-repeat) motifs and its molecular weight. The
protein localizes to distinct cytoplasmic foci, the so called GW-bodies, which turned out
to coincide with P-bodies [77, 78]. In human and D. melanogaster, the GW182 pro-
teins associate with AGO proteins and are essential for miRNA-mediated gene silencing
[195, 221, 273]. Insects express a single GW182 ortholog, whereas in the mammalian
system the GW182 protein family consists of the three paralogs trinucleotide repeat
containing 6 (TNRC6)A, TNRC6B and TNRC6C [19]. GW182 proteins contain several
N-terminal GW-repeats, an ubiquitin associated (UBA) domain and a glutamine (Q)-
rich domain (see Figure 1.3.3). The latter has been implicated in P-body localization
[19, 76], yet it is dispensable for the silencing activity since P-body localization and
silencing are not correlated [72]. The so called MID domain of the proteins consists
three domains (M1, poly(A)-binding protein-interacting motif 2 (PAM2) and M2) and
is followed by an RNA recognition motif (RRM) domain and a C-terminal domain (Fig-
ure 1.3.3) [324]. An interaction of the TNRC6 N-terminal GW-repeats with the AGO
PIWI domain is necessary for AGO function in translation inhibition and deadenylation
[73, 195]. Only a minimal fragment of two tandem GW-motifs, termed the AGO-hook,
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Figure 1.3.3: Domain Organization of GW182 Proteins. For the human TNRC6 pro-
teins only selected isoforms are shown. Hs, Homo sapiens; Dm, Drosophila melanogaster ; Ce,
Caenorhabditis elegans (Figure adapted from [324]).
is sufficient for mediation of this interaction [188, 313, 317]. The MID and C-terminal
domains of TNRC6 proteins together are called the bipartite silencing domain and have
autonomous silencing activity [72, 174, 368].
Recently, it emerged that the TNRC6 proteins also function as poly(A)-binding protein
interacting proteins (PAIPs). This interaction is mediated by binding of the PAM2 mo-
tif to the mademoiselle (Mlle) domain of the poly(A)-binding protein protein (PABP)
[79, 131, 146, 168] and indirect binding of the M2 and C-terminal domains to the RRMs
in PABPC1 [146, 363]. PABP binds the poly-(A) tails of mRNAs and is involved in
the deadenylation of mRNAs by its role in the recruitment of deadenylation factors (re-
viewed in [80]) and in translation initiation through its interaction with the translation
initiation factor eIF4G (reviewed in [140]). Therefore, the GW proteins present a link be-
tween PABP and miRNA-mediated deadenylation. Besides the molecular binding mech-
anism, this finding is supported by the observation that the depletion of PABP abolishes
miRNA-mediated deadenylation and that overexpression of PABP or a PAM2 peptide
suppresses miRNA-mediated silencing [79, 146, 339, 363]. In addition, the GW182-
proteins are likely to interfere with PABP function in translation and mRNA stabi-
lization, either by competing with eIF4G for PABP binding or by acting as a binding
platform for other proteins involved in miRNA-mediated silencing [79, 324, 363].
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1.4 Mechanisms of Small RNA Functions
1.4.1 Poststranscriptional Silencing by Short Interfering RNAs
Short interfering RNA guide strands direct RISCs to perfectly complementary target
RNAs, which are then cleaved by the slicer activity of the AGO protein. The cleaved
target dissociates and is further degraded by cellular exonucleases or oligouridylated at
the 3’ terminus and thereby targeted for decapping and 5’-3’ degradation [246, 299].
Target dissociation frees the RISC and allows for multiple rounds of target cleavage.
Highly purified RISCs fail to release the cleaved target RNA, suggesting that this process
depends on accessory factors [36, 89, 276]. Target cleavage is suppressed by mismatches
between target and siRNA and no target cleavage occurs despite perfect base pairing if
an siRNA is bound in an endonucleolytically inactive AGO protein. In those cases, the
siRNA mediates posttranscriptional silencing of the target RNA in a manner similar to
miRNA-mediated translational repression [36].
1.4.2 MicroRNA-Mediated Translational Repression
The repressive effect on translation is a well accepted miRNA function. In eukaryotes, the
process of translation is divided into three steps: initiation, elongation and termination.
At the initiation step, the ribosomal subunits assemble at the start codon of the mRNA
to form the 80S ribosome complex. The recruitment of the ribosome to the mRNA is
facilitated by the 5’ cap of the mRNA. During this cap-dependent translation initiation,
the mRNA is first bound by eIF4A, a helicase which is thought to unwind the mRNA,
followed by binding of the 5’ cap by eIF4E. The protein eIF4G binds to eIF4A and eIF4E
and functions as a scaffold for other proteins. The 3’ poly(A)-tail of the mRNA is bound
by PABP, which in turn interacts with eIF4G. This interaction leads to circularization
of the mRNA and an enhanced rate of translation initiation. The circularized mRNA
is bound by the ribosomal 43S pre-initiation complex that scans the mRNA for the
start codon. After initiation codon recognition, the so called 48S initiation complex is
formed. This complex is then joined by the 60S subunit, the 80S ribosome is formed
and translation begins. During the second step of translation, the elongation step, the
peptide chain is synthesized. The final termination step involves release of the newly
synthesized protein and dissociation of the ribosomal proteins from the mRNA [80, 140].
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There is an ongoing debate about the mechanisms that might be employed by miRNAs
to repress translation (Figure 1.4.1). Several studies provide evidence that miRNA-
mediated translational repression takes place at the translation initiation step. One in-
dication for a repression at translation initiation is the observation that miRNA-repressed
target mRNAs shift to lighter, non-translating fractions in polysome gradients [23, 265].
A possible explanation for this observation is that the miRNA interferes with bind-
ing of eIF4E to the 5’ cap [130]. This explanation is supported by the observation
that mRNAs without functional 5’ caps are not affected by miRNA-mediated repression
[130, 137, 216, 265, 316, 338, 340]. An alternative mechanism is that AGO binds di-
rectly to the 5’ cap structure and thereby prevents binding of eIF4E. The MID domain
of AGO has limited sequence homology to eIF4E and two aromatic residues in this se-
Figure 1.4.1: Possible mechanisms of miRNA-mediated translational repression.
Translation could be repressed at the initiation step by competing for cap binding (upper left) or
ribosome recruitment (lower left). MicroRNA-induced deadenylation of the target mRNA could
block circularization and thereby prevent translation initiation (bottom). At post-initiation
translation steps, miRNAs could induce ribosome drop off (lower right). Alternatively, miRNAs
can promote mRNA deadenylation followed by decapping and degradation (upper right) (Figure
taken from [36]).
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quence are required for translational repression [163]. This mechanism was supported by
the observation that the addition of the recombinant cap-binding complex eIF4F rescues
mRNAs from miRNA-mediated repression [216]. Later studies questioned this proposed
mechanism. No structural similarities between AGO2 and eIF4E were observed [162]
and the aromatic residues required for translational repression were shown to be unre-
lated to cap binding but to be required for the association of GW182 and AGO [73].
In addition, it was shown that the interaction between the AGO2 MID domain and the
cap-structure is not specific but is based on the general nucleotide binding ability of
the MID domain instead [84]. An impaired joining of the 60S subunit and formation of
the 80S subunit could also be the mechanism underlying miRNA-mediated translational
repression [316, 341]. This theory is supported by the fact that eIF6, a factor preventing
premature joining of the 60S subunit to the 40S subunit, associates with human RISC
[42].
It has also been suggested that miRNA-mediated translational repression takes place
during translation elongation since repressed miRNA target mRNAs were found in the
same polysome gradient fractions as actively translating polysomes [213, 243, 295]. Fur-
thermore, cap-independent, internal ribosome entry site (IRES)-driven translation is
also inhibited by miRNAs [204, 262]. In another model, miRNA-mediated translational
repression is mediated by the cotranslational degradation of nascent polypeptide chain
[238, 243, 262]. This model is highly improbable. Polypeptides that are targeted to the
endoplasmatic reticulum (ER) should not be accessible for degradation but a number of
ER proteins are regulated by miRNAs [265, 297]. Moreover, protease inhibitors have no
effect on miRNA-mediated repression [238, 262, 265].
Translation inhibition could also happen at the step of translation termination. Pe-
tersen et al. proposed a model in which repression is due to premature termination and
ribosome drop off [262].
1.4.3 Modulation of MicroRNA-Mediated Translational Regulation by
RNA Binding Proteins
MiRNA-mediated translational repression is regulated by RBPs. Some proteins activate
miRNA-mediated translational repression, for example the TRIM-NHL family proteins.
The murine TRIM-NHL protein TRIM32 binds to AGO1 and activates the miRNA let-7a
[291]. In C. elegans, the TRIM-NHL protein NHL-2 associates with miRISC components
and enhances the posttranscriptional repression of several miRNA targets [117]. The re-
lieve of miRNA-mediated repression through RBPs also takes place. DND1 can bind
miRNA target sites and thereby prevents miRNA binding in human and zebrafish [153].
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Another example is the relieve of miR-134-mediated translational repression of LIMK1
upon extracellular stimuli [290]. The modulation of miRNA repression is important for
developmental processes, e.g. the miR-430-based regulation of Nanos and TDRD7 is
suppressed by an unknown factor in the germline, but not in somatic cells of zebrafish
[224]. Some RBPs, such as HuR, show different regulatory functions depending on cel-
lular conditions, their RNA and protein cofactors and their target RNA. For example,
miRNA let-7 and HuR protein regulate the expression of cMyc by an interdependent
mechanism. HuR binds to the 3’UTR in close proximity to the let-7 binding site and
recruits let-7 loaded RISC, which represses mRNA translation [159]. In cooperation
with its protein cofactor AUF, HuR destabilizes p16 mRNA by recruiting RISC to the
3‘ UTR [39]. On the other hand, HuR rescues CAT1 mRNA from translational repres-
sion through miR-122 under stress conditions, most likely by interfering with miRNA
association to the target RNA [23].
Taken together, these examples of RBP function highlight the importance of the protein
composition of a messenger-ribonucleoprotein (mRNP) for miRNA-guided gene silenc-
ing and support the idea that RBPs and miRNAs regulate their respective activity by
competing or complementing their binding to the target RNAs [94].
1.4.4 MicroRNA-Mediated Deadenylation and Destabilization
Initial studies suggested that the mRNA stability is not affected by miRNA-mediated
repression but recent findings demonstrate that mRNA destabilization is the predomi-
nant mode of regulation by miRNAs in mammalian cells ([111, 124, 132], Figure 1.4.2).
A large fraction of down-regulation after miRNA transfection is accounted for by mRNA
degradation ([15, 189, 353]. An example for this mechanism is the miRNA-controlled
destruction of transiently required transcripts and maternal mRNAs during development
and cell differentiation [99, 352]. On the other hand, a set of enodgenous miRNA targets
are only translationally repressed but not degraded [19, 75, 297].
Recently several quantitative proteomic studies addressed the effect of miRNAs on pro-
teome level. Selbach et al. [297] observed that miRNA targeted mRNAs are only reg-
ulated at the translation level at early time points after miRNA transfection but that
protein and mRNA levels correlate strongly at a later time point [297]. A study by
Baek et al. shows that modestly repressed targets are translationally repressed, whereas
strong miRNA regulated repression was based on mRNA destabilization [14].
In general, messenger RNA decay starts with the removal of the poly(A)-tail through the
CCR4-NOT deadenylation complex. The deadenylated mRNAs are then either degraded
in 3’-5’ direction by the exosome or the 5’ cap is removed by the DCP1-DCP2 decap-
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ping complex. Decapped mRNAs are subsequently degraded in 5’-3’ direction by the
exonuclease XRN1 [80, 324]. Deadenylation is a widespread effect of miRNA-mediated
regulation [74, 99, 338, 353]. It is mediated by the CCR4-NOT1 complex [19, 74, 264]
and requires a GW182 protein, CAF1 and PABP [73, 79]. It is possible that the TNRC6-
PABP interaction (see Section 1.3.4) places the poly(A)-tail in close proximity to the
miRISC associated deadenylation complex [79].
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Figure 1.4.2: MicroRNA-mediated
mRNA degradation. (Figure taken from
[324]).
MicroRNA-mediated deadenylation pre-
cedes decapping of target mRNAs through
the DCP2 complex containing the de-
capping activators DCP1, Ge-1 and
RCK/DDX6 in flies [75, 273, 359]. The
interaction between the decapping com-
plex and repressed mRNAs has been sug-
gested to be mediated by UPF1 [143], a
helicase involved in NMD that associates
with DCP1, DCP2 and AGO2 [127, 203].
MiRNA-mediated deadenylation is inde-
pendent of the translation status of the
target mRNA. The process is not blocked
by translation inhibitors [79, 338] and
poorly translated transcripts are deadeny-
lated in a miRNA dependent manner [74, 353]. MicroRNA targets with defective cap
structures are also deadenylated [224, 338]. It is not clear whether additional mechanisms
besides deadenylation repress translation of polyadenylated miRNA targets. Addition-
ally, it appears as if deadenylation contributes to, but it is not absolutely required for
the establishment of silencing of polyadenylated mRNAs [132].
AU-rich elements (AREs) are regulatory signals located in the 3’ UTR of mRNAs. They
have been shown to influence translation and to decrease the stability of the mRNA
[337]. This involvement of AREs in mRNA decay is termed ARE-mediated mRNA decay
(AMD) [17] and growing evidence suggests that AMD is connected to miRNA mediated
gene silencing [17, 337]. Both processes involve the same effectors of degradation and
are localized to P-bodies and stress granules [86, 182, 196, 309]. Several studies have
reported miRNA targeting of AREs [23, 39, 159] and Jing et al. [147] showed that RISC
components and miR-16 are required for AMD of TNFα mRNA.
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1.4.5 MicroRNA-Mediated Translation Activation
MicroRNAs generally function as translation repressors but in some cases miRNAs me-
diate activation of translation. In human cells, miR-369-3-directed association of FXR1
and AGO2 to the ARE of TNFα mRNA during cell cycle arrest leads to translational
activation [331, 332]. Other well studied miRNAs, including let-7, also induce trans-
lation upregulation of mRNA targets during cell cycle arrest but repress translation in
proliferating cells [332]. Translational activation also occurs with miRNAs binding in the
5‘ UTR. Translational repression of ribosomal protein mRNAs during amino acid star-
vation is alleviated by miRNA binding in the 5‘ UTR [369] and the translation of viral
mRNAs is stimulated by miRNAs [125, 149]. Nevertheless, miRNA-mediated translation
activation seems a rare mechanism which applies only under certain cellular conditions
and further investigations are necessary to clarify the relevance of this miRNA function.
Furthermore, miRNAs can function as decoys by blocking RBP mediated translational
repression [65]. For example, the translation of CEBPA mRNA is inhibited by binding
of hnRNP E2 to a regulatory sequence in the 5’ UTR. The sequence of the miR-328 is
similar to the sequence of the hnRNPE2 binding site on the mRNA. MiR-328 is thereby
able to bind into the mRNA binding site of hnRNPE2. This association prevents the
binding of hnRNPE2 to the CEBPA mRNA and translational repression is relieved. It
is striking that the miR-328-hnRNPE2 interaction is AGO independent [65].
1.4.6 Small RNA-Mediated Transcriptional Gene Silencing
Small RNA-mediated gene silencing pathways are not restricted to the level of mRNA
translation and stability, but they also act at transcriptional and chromatin levels. First
evidence for small RNA-mediated transcriptional gene silencing was discovered in plants.
Here, viral RNAs or small RNAs derived from transgenes guide the methylation of ho-
mologous DNA sequences [223, 347]. Methylation of these homologous DNA sequences is
Dicer and AGO dependent [123, 366]. It is also linked to histone H3 lysine 9 methylation,
a classical mark of transcriptionally inactive chromatin [193]. In S. pombe, small RNAs
guide histone methylation through the AGO1-containing RNA-induced transcriptional
silencing (RITS) complex [333, 336]. The RITS complex associates with nascent tran-
scripts via siRNA-RNA base pairing and recruits the RNA-directed RNA polymerase
complex (RDRC) and the Clr4 methylase complex, resulting in dsRNA synthesis, siRNA
production, H3K9 methylation and chromatin compaction [192, 227, 228, 310]. In mam-
mals, siRNAs can direct histone methylation in an AGO1- and AGO2-dependent mecha-
nism [141, 158]. On the one hand, human miRNAs directed against promotors facilitate
transcriptional silencing [157]. On the other hand, it was found that promotor targeting
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RNAs are involved in transcription activation [142, 293]. This evidence and the nu-
clear localization of AGO proteins [349] suggest that small RNA-directed transcriptional
gene silencing pathways are conserved, but the endogenous mechanism by which this is
achieved in mammals remains for the most part unknown [69, 227].
1.5 The PIWI Subfamily of Argonaute Proteins and
PIWI-interacting RNAs
1.5.1 PIWI-interacting RNA Biogenesis
PIWI-interacting RNAs are the third well studied class of small RNAs. These endoge-
nous small RNAs are 24-29 nt long and are germ-line specific [8, 9]. They associate
with AGO proteins of the PIWI-clade in fly, mouse and zebrafish [7, 100, 129, 286].
Although a subset of fly piRNAs is involved in silencing protein encoding genes [236],
piRNAs are mainly involved in silencing of mobile genetic elements [11, 35]. In flies and
mammals, piRNAs are 2’-O-methylated at the 3’ end, but the biological significance of
this modification remains to be elucidated [128, 165, 240, 287, 327].
In D. melanogaster, piRNAs derive from piRNA clusters. Their sequences correspond to
retrotransposons and intergenic repetitive elements and are enriched in species that are
antisense to transposons [286, 327]. Distinct piRNA species associate with each PIWI-
protein. AUB- and PIWI-associated piRNAs arise from antisense transcripts and show
a preference for uridine at the 5’ end. AGO3, however, associates with piRNAs derived
from sense transcripts with a preference for an adenine at nucleotide 10 but no 5’ end bias
[7, 32, 110]. Since PIWI proteins have slicer activity [236, 286] and piRNA biogenesis is
Dicer independent [327], the current "ping-pong" model for piRNA biogenesis involves
the PIWI proteins themselves [7, 32, 110]. Antisense piRNAs bound into AUB and PIWI
guide the cleavage of the sense transcript, thereby generating the 5’ end of a sense piRNA.
The newly generated sense piRNA associates with AGO3, which subsequently cleaves an
antisense transcript and generates the 5’ end of an antisense piRNA. This piRNA then
again binds to PIWI or AUB and induces the next sense transcript cleavage. The factors
facilitating the generation of piRNA 3’ ends have not been identified so far. PiRNAs and
at least AUB are maternally inherited and initiate the amplification of piRNAs through
the "ping-pong" cycle [32, 33, 236]. Several other factors besides the PIWI proteins
are involved in piRNA biogenesis [159]. Some piRNAs are only found in PIWI and are
not produced by the ping-pong cycle but via a separate pathway known as the primary
processing pathway [11]. Ongoing discussions concern the role of piRNAs in somatic cells
and a possible interplay between piRNAs and endo-siRNAs as both small RNA species
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repress transposons. Endo-siRNAs might provide rapid response to new transposons in
the germ line and piRNAs, on the other hand, can provide robust and permanent control
of transposons [82].
Mammalian piRNAs have been shown to mediate transcriptional silencing of their target
genes by DNA methylation [10, 11, 35, 169]. Two classes of piRNAs have been described
in mammals. Murine pre-pachytene piRNAs are expressed before meiosis, derive from
repeat and transposon rich clusters and interact with MILI and MIWI2. Pachythene
piRNAs associate with MILI and MIWI and their sequences give no indications for
possible targets [159, 211]. The biogenesis of pre-pachytene piRNAs has been suggested
to occur through the ping-pong cycle, whereas pachythene piRNAs are likely to be
generated by primary processing pathways [10].
1.5.2 Regulation of PIWI Protein Interactions by Arginine Methylation
PIWI proteins in mammals, fly andXenopus laevi contain symmetrical dimethly arginines
(sDMA). Such arginine methylations modulate protein-protein interactions and thereby
regulate the biological activity of proteins [219, 304]. DMA modifications of PIWI pro-
teins are carried out by the protein methyltransferase 5 (PRMT5) [164]. PRMT5 is a
type II protein arginine methyltransferase that produces symmetric dimethylarginines
[30, 267, 275]. It localizes predominantly to the cytoplasma and methylates, amongst
others, myelin basic protein [267], histones [314] and the Sm proteins [87, 218]. By methy-
lation of target proteins, PRMT5 influences various cellular processes such as U snRNP
assembly [87, 218], cell cyle progression [122], pluripotency of ES cells [314] and tumor
growth [268]. PRMT5 associates with its co-factors MEP50 (also known as WDR77)
and different adaptor proteins for substrate recognition into a complex referred to as the
methylosome [87, 88, 108, 261].
First evidence of sDMA modification of PIWI proteins were reported for MILI and MIWI
in mice but they are also present in Drosophila and Xenopus. So far there are no in-
dications that the ubiquitously expressed AGO proteins are also methylated [304]. In
Drosophila, sDMAs were only mapped in AGO3 and AUB [235]. Mapping of methy-
lated arginines in murine PIWI proteins in mouse testes revealed several mono- and/or
dimethylated sites and all detected dimethylations were symmetric [41, 274, 328]. The
different studies show a discrepancy for the methylation status of PIWI proteins, which
indicates a dynamic regulation of the methylation status [304].
Symmetrical DMA modifications do not influence the association of PIWI proteins with
piRNAs [274] or the protein stability but affect transposon silencing [164] and subcellular
localization [235]. The methylosome complex associates with all three murine PIWI pro-
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teins in mouse testes [328] as well as in Drosphila [6] and the sDMA modification of the
PIWI proteins is required for their interaction with Tudor domain containing (TDRD)
family proteins in mouse and flies [41, 235, 274, 328, 343]. These sDMA mediated asso-
ciations between PIWI and TDRD proteins have been identified as a factor regulating
piRNA production and PIWI-protein to piRNA association [304].
1.6 Quantitative Proteomics
The mechanism of small RNA-mediated gene regulation is one of the examples for the
substantial influence of the protein complex composition on the function of an individual
protein. Although all small regulatory RNAs are bound into AGO proteins, the ensuing
activity of AGO is not only defined by the nature of the bound small RNA but is
significantly influenced by the other protein components in the RISC (see Section 1.4.3).
The protein composition of RISC is in turn dependent on the whole proteome of the
cell, which again varies between cell types and undergoes major changes upon external
stimulation. It is hence of great interest for the understanding of AGO function to unravel
the influence of the cellular proteome and to define the interplay between AGO and its
specific interaction partners under varying cellular conditions. Over the last decade,
mass-spectrometry (MS)-based proteomics has developed into a powerful method for
the global measurement of proteins. The development of high resolution instruments
and sophisticated data analysis tools greatly improved data reliability and facilitates
the identification of thousands of proteins from a complex mixture. MS can be applied
to identify the relative or absolute amount of proteins in a sample, for example the
abundance of proteins in a cell. Unlike mRNA microarrays or deep sequencing methods,
expression proteomics take posttranscriptional and translational expression regulation
into account and give detailed information about the protein composition of a cell in
a certain state. In combination with quantitative techniques, MS based proteomics
can be applied to compare the protein composition of different samples or to monitor
dynamic changes [49, 98]. MS itself is not quantitative but two methods, the label
free and isotope labeling approaches, add a quantitative dimension to MS. Label free
quantitation approaches such as spectral counting [194] and the exponentially modified
protein abundance index [135] are based on the fact that abundant proteins produce more
MS/MS spectra than low abundant proteins and provide a good estimation of relative
abundances. The drawback of label free quantitation is that samples to be compared
have to be measured separately, which introduces experimental variability [64].
Stable isotope labeling approaches introduce ’heavy’ stable isotopes such as 13C or 15N
into the sample. Heavy isotope labeled peptides are chemically equivalent to unlabeled
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’light’ peptides and differ only in their mass. Peptides with both labels behave identi-
cally in biochemical purification and fractionation procedures and thus enter the mass
spectrometer simultaneously. In the full MS scan, two precursor masses are detected
that represent the two peptide species. The ratio of the signal intensity of the peaks
corresponds to the relative abundance of the proteins in the input samples and allows
an accurate quantification [98].
Isotope-based quantitative proteomics relies on two different approaches to introduce
isotope labeling. In chemical labeling approaches such as isotope-coded affinity tag
(ICAT) [113] and isobaric tags for relative and absolute quantitation (iTRAQ) [280] the
reactive groups of peptides are used to couple them to an isotope containing tag. These
methods can be applied to all sample types including fixed tissues. Its disadvantages
are the labeling efficiency and experimental variability caused by the necessity to handle
samples seperately. In metabolic labeling strategies, the heavy isotopes are introduced
through the growth medium or food by replacing essential amino acids with heavy labeled
counterparts, a method known as stable isotope labeling by amino acids in cell culture
(SILAC) ([244], Figure 1.6.1).
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Figure 1.6.1: Stable isotope labeling by amino acids in cell culture (SILAC). Cells
grown in medium with normal amino acids (“light”, depicted in blue) are transferred to medium
containing arginine and lysine labeled with the stable isotopes 13C and 15N (“heavy”, depicted in
red). Protein turnover during growth leads to metabolic incorporation of the heavy amino acids
into the whole proteome. Digestion of the proteins with trypsin results in peptides with either a
13C-15N-arginine or a 13C-15N-lysine at the C-terminus. The presence of the heavy amino acid
leads to a residue specific mass shift of 10 or 8 Da for arginine or lysine, respectively, compared
to the light peptide (Figure adapted from [245]).
The most commonly used amino acids for metabolic labeling are arginine and lysine.
During growth, the protein turnover leads to metabolic incorporation of the heavy amino
acids into the whole proteome. The great advantage of metabolic labeling compared to
chemical methods is that the isotopic label is introduced before protein purification,
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Figure 1.6.2: SILAC based expression proteomics. Cells in two different states can be
labeled with light or heavy amino acids. The samples are then mixed in a 1:1 ratio and analyzed
together. For every peptide common for both states two isotope clusters, a so-called SILAC pair
can be detected in the mass spectrum. The mass difference between the SILAC pair corresponds
to the mass difference between the heavy and light amino acids. A ratio can be assigned to every
detected peptide pair. This ratio correlates to the relative abundance of the protein in the two
samples and indicates if a protein is unchanged, or up- or down regulated in the different states
(Figure adapted from [64]).
leading to a significant reduction of errors caused by sample handling. SILAC-based
quantitative proteomics can be applied to compare whole proteome changes between
different cellular states, for example upon stimulation [24] or between protein isoforms
([322], Figure 1.6.2). Pulsed SILAC has been established as a technique for the moni-
toring of dynamic changes [292] and this method has been successfully used to identify
miRNA targets [14, 297].
Protein-protein interactions and the underlying dynamics are of great importance for the
understanding of cellular processes. Different approaches such as the yeast two-hybrid
system [81] have been established for the identification of protein-protein interactions.
Great advances in the field of interaction proteomics came from the combination of
affinity purification and mass spectrometry (AP-MS). In this set-up, isolation of mul-
tiprotein complexes by affinity purification is followed by the identification of complex
components by MS. A great advantage of AP-MS is that it does not require pre-existing
knowledge of the protein complex to be analyzed. Another advantages of this approach
is that, unlike yeast two-hybrid screens that rely on expression and interaction of pro-
teins in the yeast nucleus, proteins are isolated from near physiological conditions and
post-translational modifications that are crucial for organization and activity of a protein
complex are not perturbed [98].
With the increasing sensitivity of modern mass spectrometers it is difficult to differentiate
background binders and contaminants from true interactors [1]. Immunoprecipitations
do not only contain the target protein itself and its specific interaction partners but con-
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Figure 1.6.3: SILAC-based interaction proteomics. In order to identify its interactors, the
protein of interest (“bait”) is purified from heavy labeled cells while a light labeled cell line without
the bait is used for the background control (forward experiment, left panel). The two samples
are combined after the enrichment and further processed and analyzed together. The experiment
is repeated with a label switch (reverse experiment, right panel). Both datasets are combined
and the ratios from the two experiments are plotted against each other on a logarithmic scale.
Specific interactors appear as outliers in the lower right quadrant (high ratios, green sphere)
while background binders cluster around zero (ratios 1:1, grey sphere) (Figure adapted from
[64]).
tain additional proteins non-specifically binding to the beads or the antibodies. Proteins
with cross-reactivity to the antibody are also detected. Applying a stringent purifica-
tion procedure, such as tandem affinity purification, can reduce the background binding.
However, it harbors the risk of loosing weak interactors and requires high amounts of
input sample. Quantitative proteomic approaches present a solution for these problems
[272]. These methods allow the direct distinction between background binders and true
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interaction partners based on the direct quantification between sample and control and
thus facilitate the high confidence identification of interaction partners from low strin-
gency and single step purifications [334]. In SILAC-based interaction proteomics the
protein of interest, the "bait" protein, is isolated from heavy labeled cells while a light
labeled cell line without the bait is used as background control. The ratios between
the SILAC pairs clearly distinguish specific interactors from background binders and
contaminants (Figure 1.6.3).
For the high confidence identification of interaction partners of endogenous proteins,
aquantitative immunoprecipitation combined with knockdown (QUICK) approach can
be used [296]. In this approach, the abundance of the protein of interest is reduced in one
of the SILAC labeled cell populations by RNAi. In affinity purifications followed by MS
analysis, the proteins of interest and its specific interaction partners show peptide ratios
whereas unspecific background binders show no ratio difference. Thereby the two groups
are easily distinguishable from each other. QUICK also harbors the advantage that
proteins cross-reacting with the antibody appear as background binders. The abundance
of the cross reactant is not affected by the knockdown, so equal amounts of both SILAC
states are bound by the antibody and no ratio differences are observed.
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1.7 Aim of the Thesis
Argonaute proteins are the key components of small RNA-mediated regulatory pathways.
They bind small regulatory RNAs and assemble with several other protein factors into
RNP complexes. The role of the small regulatory RNA bound into AGO is to guide
the RNP to a target RNA in a sequence specific manner. Depending on the nature of
the bound small regulatory RNA and on the protein composition of the RNPs, AGO
exerts various regulatory functions such as the regulation of transcription, translation
and mRNA decay.
To better understand the mechanisms of miRNA mediated regulation, it is necessary
to characterize the underlying structural features. One of the aims of this work was
to gather structural insights into RISC architecture by determining the structure of a
minimal RISC by electron microscopy. For this purpose, a purification strategy for the
isolation of a complex consisting of AGO2 and Dicer from cultured human cells had to
be established. In addition, the reconstruction of the structure of the methylosome core
complex, a protein complex involved in the post-translational modification of germ line
specific AGO proteins, was attempted.
So far, the identities of the accessory protein factors regulating the assembly and function
of AGO2-containing RNPs have been addressed by several semiquantitative proteomic
screens [127, 171, 220] but none of these studies allowed a direct comparison between
AGO2-containing RNPs under different cellular conditions. Therefore, it was aimed to
conduct a SILAC-based quantitative proteomic screen of murine AGO2-containing RNP
complexes in the absence or presence of mature miRNAs, allowing the definition and
comparison of the protein composition of the complexes under these two conditions. For
the studies on endogenous protein complexes, a highly specific antibody is a prerequisite.
Therefore, we aimed to establish an antibody highly specific for mouse AGO2 to be used
for the purification of endogenous AGO2-containing RNP complexes. As the quality
of affinity purifications of endogenous protein complexes are highly dependent on the
performance of the antibody, it was also an aim to establish MEF cell lines stably
overexpressing FLAG/HA-tagged AGO2 and to perform proteomic screens of AGO2-
containing RNPs isolated by this tag-based purification system.
29

2 Results
2.1 Structural Analysis of the AGO2 Complex I by Electron
Microscopy
The majority of structural insights on Argonaute and Dicer have come from crystal-
lization studies of full length prokaryotic homologues or from individual domains of the
eukaryotic proteins (see Section 1.3.3). These crystal structures reveal detailed informa-
tion about the individual proteins but they do not give insights into the architecture of
RISC. The AGO2 complex I described by Höck et al. has an approximate size of 232 kDa
and sediments at 11 S in sucrose gradients. It exhibits RISC and Dicer activity and the
components are associated in an RNA-independent manner [127]. Therefore, the AGO2
complex I was assumed to correspond to the RISC-loading complex. We established a
strategy to purify the AGO2 complex I from human cells and aimed to determine the
structure of the complex by electron microscopy (EM).
Our attempts to purify endogenous complexes were abandoned after initial experiments
(data not shown). When endogenous complexes were purified from cultured human
cells, the yield of the purification was very low so that the amount of protein after
the last purification step was not high enough to reach the concentration required for
grid preparation. Since we were mainly limited by the amount of input sample, we in-
creased the amount of input protein by simultaneous overexpression of FLAG/HA-tagged
AGO2 (F/H-AGO2) and cMyc-tagged Dicer in HEK 293T cells. AGO2-containing com-
plexes were separated by density centrifugation as described ([127], Figure 2.1.1A). Gra-
dient fractions containing the AGO2 complex I were combined and F/H-AGO2 was im-
munoprecipitated with FLAG-antibody coupled agarose beads. AGO2-containing com-
plexes were eluted from the antibody with competing peptide and further purified in
a GraFix gradient [150]. The GraFix sample preparation method applies a glycerol
gradient with an increasing concentration of a chemical fixation reagent. During the
centrifugation, protein complexes are separated by the density gradient and simulta-
neously chemically fixed. The fixation stabilizes the complexes, thereby leading to an
increased homogeneity and reduced aggregation and degradation of the sample [150]. In
the glycerol gradient used for the GraFix, AGO2 was distributed over fractions 7-23 and
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Figure 2.1.1: Purification of the AGO2 complex I from HEK293T cells in a Tris-
based buffer system. A) Lysate from HEK293T cells transiently transfected with F/H-AGO2
and cMyc-Dicer was separated by density centrifugation in a 15-55% sucrose gradient. The
individual fractions were analyzed by Western blotting against F/H-AGO2. B) F/H-AGO2-
containing protein complexes were immunoprecipitated from the combined fractions 3-8 with
FLAG-agarose. Bound protein was eluted with 3x FLAG peptide and separated by density
centrifugation in a 10-30% glycerol gradient. The distribution of F/H-AGO2 in the individual
fractions was analyzed by Western blot (upper panel) and silver stain (lower panel). Protein
bands were cut out and identified by mass spectrometry. Asterisks indicate protein degradation
products. C) Protein complexes were purified from untransfected HEK293T cells as described
in A and B and were analyzed by silver staining.
we visually distinguished three different protein complexes based on the protein band
pattern (Figure 2.1.1B). The individual proteins were identified by mass spectrometry.
Fractions 7-12 (corresponding to lanes 6-11 in Figure 2.1.1B) contained free AGO2 only.
In fractions 13-15, we saw clear bands for AGO2, full length Dicer and a Dicer degrada-
tion product. The protein band running at a size of 70 kDa was identified as the protein
methyltransferase 5. PRMT5 and its interaction partner MEP50 were highly abundant
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in fractions 16-19 together with the proteins found in fractions 13-15. The third reported
methylosome component pICln [87, 108, 261] was not detected. Fractions 19 and higher
contained only AGO2 and full length Dicer in low amounts.
PRMT5 and MEP50 have been identified in FLAG-purifications of AGO2 complexes
previously [221] and it is known that the PIWI proteins are substrates for the methy-
lase activity of PRMT5 [164]. It might be possible that AGO2 is also a substrate for
methylation and is therefore found in a stable complex with PRMT5. In order to demon-
strate that the methylosome components associate specifically with the AGO2 complex I,
we performed protein purification from untransfected HEK cells to define contaminating
proteins in our sample (Figure 2.1.1C). To our surprise, we obtained the PRMT5-MEP50
complex in fractions 16-19 with high purity. This implies that the methylosome compo-
nents do not specifically interact with the AGO2 complex I, but that their presence in
the sample is based on a non-specific association with the FLAG-antibody or the agarose
matrix.
It was our hope that the two unrelated complexes differ so significantly in their shape
or size that they can be clearly distinguished from each other. Therefore, we nega-
tively stained the particles in glutaraldehyde fixed fractions 17 and 20 from purifications
from untransfected HEK293T cells and from HEK293T cells transiently transfected with
F/H-AGO2 and cMyc-Dicer and compared the particles visible in the electron micro-
graphs (Figure 2.1.2). In fraction 17, which contains a mixture of the PRMT5-MEP50
and the AGO2 complex I or the PRMT5-MEP50 complex alone, we saw predominantly
distinct particles and only little aggregation in both samples. For the PRMT5-MEP50
complex, we observe a specific circular shape for a set of particles. A few particles with
this distinct shape were also visible in the mixed sample, but otherwise particles in both
samples looked very similar. Therefore, we were not able to distinguish the two com-
plexes from each other based on their shape and size in the electron micrograph of this
fraction. The methylosome sample contained almost no proteins in fraction 20. In the
AGO2 complex I purification, this fraction should therefore contain the AGO2-Dicer
complex only. We see an increased aggregation in this fraction compared to fraction
17. No ring shaped particles were observed in this sample but single particles were het-
erogenous and had a bigger size and aberrant shapes. Since the complexes in fraction
20 migrated further into the gradient they are expected to have a slightly higher mass
than the complexes in the previous fractions. This mass shift might be caused by ag-
gregation, which would explain size and heterogeneity of the particles. Because of this
heterogeneity the particles of the AGO2 complex I in fraction 20 were also not suitable
for single particle reconstruction. Consequently, it was necessary to further refine the
purification strategy.
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Figure 2.1.2: Representative electron micrographs of cross-linked, negatively stained
AGO2 complex I and PRMT5-MEP50 complex particles. Protein complexes were pu-
rified from HEK293T cells transiently transfected with F/H-AGO2 and cMyc-Dicer (panels 1-2)
or untransfected cells (panels 3-4). GraFix fractions 17 (panels 1 and 3) or 20 (panels 2 and 4)
were negatively stained and examined by EM. Yellow circles highlight aggregates and arrows
point at particles with a distinct circular shape.
We solved the problem of the PRMT5-MEP50 contamination by performing the pu-
rification in a different buffer system. All steps remained the same except that Tris
was exchanged for HEPES as buffer substance. As seen in Figure 2.1.3, the PRMT5-
MEP50 contamination was eliminated and we obtained only AGO2 and Dicer. Several
attempts to reduce the Dicer degradation were unsuccessful (data not shown). The spe-
cific degradation product with a size of 130 kDa was identified as the N-terminal part of
Dicer (Stephanie Schell, personal communication) and this fragment was also observed
in other purifications of Dicer protein [102].
Electron micrographs of negatively stained AGO2 complex I from this purification re-
vealed a very low number of heterogenous particles (Figure 2.1.4). To increase the con-
centration, the purification procedure was refined by introducing several elution steps
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Figure 2.1.3: Purification of the AGO2 complex I from HEK293T cells in a HEPES-
based buffer system. The AGO2 complex I was isolated in a HEPES-based buffer system
following the same purification procedure as described in Figure 2.1.1. Individual fractions of
the glycerol gradient were analyzed by SDS-PAGE and silver stain.
and an enrichment step (data not shown). These efforts proved to be futile as the pro-
tein amount on the grid increased only very slightly and the heterogeneity of particles
remained. The sample quality could not be increased to the standard necessary for de-
termination of a high-resolution structure and with the publication of the low resolution
EM structure of an in vitro reconstituted human RISC loading complex by Wang et al.
in 2009 [342] the project was discontinued.
Figure 2.1.4: Micrograph of the
formaldehyde fixed, negatively
stained AGO2 complex I. AGO2
complex I was isolated from HEK293T
cells in a HEPES-based buffer system and
fixed in a GraFix gradient before negative
stain and analysis by EM.
2.2 Structural Analysis of the PRMT5-MEP50 Complex by
Electron Microscopy
PRMT5 is a type II protein arginine methyltransferase that produces symmetric dimethy-
larginines [275]. Among its substrates are the Sm proteins [87, 218] and the PIWI pro-
teins of mouse, fly and X. laevi [164, 235, 326]. We have discovered a way to purify en-
dogenous PRMT5 in complex with its cofactor MEP50 from human cells (Figure 2.1.1C).
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Figure 2.2.1: Purification of the PRMT5-MEP50 complex from HEK293T cells.
A) Lysate from HEK293T cells was separated by density centrifugation in a sucrose gradient and
analyzed for PRMT5 by Western blot. B) PRMT5-MEP50 compleses were immunoprecipitated
from the combined fractions 4-9 with FLAG-agarose and eluted from the beads with 3x FLAG
peptide. Bound protein was eluted in three steps. Eluates were combined and concentrated
before loading on a glycerol gradient. The elution procedure was analyzed by Western blot
against PRMT5 (upper panel) and Coomassie stain (lower panel). C) The eluted proteins were
separated by density centrifugation in a 10-30% glycerol gradient. Individual fractions were
analyzed by Western blot against PRMT5 (upper panel) and silver stain (lower panel)
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Although the affinity of the FLAG-antibody for the PRMT5-MEP50 complex is as-
sumed to be unspecific, it was still strong enough to allow an efficient purification. This
purified PRMT5 complex could be used to determine its structure and to study the
methylation of human PIWI proteins. We improved the described purification strat-
egy by adding several elution and an enrichment step and obtained a PRMT5-MEP50
complex that appears highly pure in a silver stain (Figure 2.2.1). Electron micrographs
of the glutaraldehyde fixed, negatively stained complex (Figure 2.2.2) revealed a strong
heterogeneity of the particles. As expected, we observed the previously described ring
shaped particles. We saw additional particles that cannot be side views of the ring
shaped particles because of their size, which was a clear indication that we had at least
two different particle populations in the sample. PRMT5 forms homo-multimers un-
der cellular conditions [275], so it is quite possible that the sample contained different
complexes with varying multimers. In addition to particle heterogeneity, we had a low
amount of particles on the grids and sometimes observed non-uniform staining of the
particles.
Figure 2.2.2: Micrograph of the
formaldehyde fixed, negatively
stained PRMT5-MEP50 complex
PRMT5-MEP50 complexes were isolated
from HEK293T cells in a Tris-based buffer
system and fixed in a GraFix gradient
before negative stain and analysis by EM.
Particles were picked automatically and particles with positive staining or a flat appear-
ance as well as particles not discernible from background were sorted out manually. The
remaining 1700 particles were used for the generation of class averages. In the class
averages we see the typical ring shaped structure and additional particles of bigger size
without any distinguishable features. To separate the different particles, we used three
representative class averages of different sizes to subclassify the particles according to
their size and generated new class averages for the three groups (Figure 2.2.3, groups
A-C). Group A contains the 300 biggest particles without any distinct structural fea-
tures. 490 particles with the distinct circular shape were sorted into group B. Group C
consists of 747 particles. These particles are smaller than the ones in group B but also
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A
B
C
Figure 2.2.3: Class averages of the PRMT5-MEP50 complex. The particles were sepa-
rated into three groups (A-C) according to their size and 30 class averages per set were generated
from 300 (A), 490 (B) and 747 (C) particles. Arrows indicate additional densities on the circular
structure of the particles.
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show the distinctive circular shape without (boxes 2, 13 and 23) or with an additional
density (boxes 4, 6, 15 and 22) (Figure 2.2.3). Initial models were generated from the
class averages and we tried to refine the model by fifty rounds of refinement by projection
matching as shown in Figure 2.2.4A for the group of the smallest particles (group C). Al-
though some structural features such as an internal cavity and the previously mentioned
additional density seemed to become slightly more distinct, other densities grew and dis-
appeared between the refinement rounds. If a model converges into a three dimensional
map, the structural differences between the models of two consecutive refinement rounds
are very little and the curves in the Fourier Shell Correlation (FSC) plot (Figure 2.2.4B)
representing these structural variations show very similar shapes. In our case, the curves
in the plot did not overlap and thereby indicated strong differences between the mod-
els generated by each refinement round. An analysis of the Euler angles describing the
orientation of the particles revealed two problems (Figure 2.2.4C). First, we did not see
an isotropic angular distribution. This indicates a strong preferential orientation of the
particles on the grid, meaning that particles did not lie on the grid in all possible orien-
tations but tended to lie in a few preferred orientations. Thereby, the possible views of
the complex are not equally represented in our data, which makes the reconstruction of a
three dimensional structure difficult. Second, the class averages of the particles assigned
to a specific orientation often did not match to the corresponding projections. During
projection matching, the refinement method used for the reconstruction, projections of
different orientations are computed from the initial model. The images of the particles
are compared to the projections and are assigned to the projection they match best.
Next, a refined map is computed and the generation of projection and assignment of im-
ages is repeated. The wrong assignment of the images to projections in the refinement
of the PRMT5-MEP50 complex are an indication that some of the particles are lacking
sufficient structural details required for an assignment to a certain projection during
the refinement process. When we tried a similar 3D reconstruction with the particles
from the groups with higher particle sizes (groups A an B) the refinements also did not
converge (data not shown).
Taken together, these results show that with the present sample quality it is not possible
to reconstruct a three dimensional model. The project to gain structural insights on
the endogenous PRMT5-MEP50 complex was abandoned at this point but a second at-
tempt with an in vitro reconstituted complex has already been initiated (Nicholas Putz,
personal communication).
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Figure 2.2.4: Three dimensional reconstruction of the group C particles. A) Initial
model (left) and refined models after 30 (middle) and 50 (right) rounds of refinement are shown
in different orientations. B) Fourier Shell Correlation plot comparing individual models between
refinement rounds. C) Spheres showing the assigned Euler angles for the initial (left) and refined
models after 30 (middle) and 50 (right) rounds of refinement. Height and color of the cylinders
correspond to the number of particles assigned to each projection. Red indicate low numbers
and green corresponds to high numbers.
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2.3 Generation and Characterization of the Monoclonal
Mouse AGO2 Specific Antibody anti-AGO2(6F4)
Many of the studies on AGO complexes have been conducted with overexpressed, tagged
proteins due to the lack of highly specific and potent monoclonal antibodies against the
different AGO proteins. With the establishment of antibodies specific to human AGO
1-4 [20, 282, 349] it became possible to study the functions of endogenous AGO com-
plexes in human. However, antibodies against mouse AGO proteins were not available.
Since we aimed to analyze the function of endogenous RISCs in the murine system, we
established a monoclonal antibody specific for mouse AGO2.
A peptide spanning residues 13-26 of mouse AGO2, a region that is not conserved within
the mouse AGO proteins (Figure 2.3.1), was injected into rats for monoclonal antibody
production. The hybridoma clone 6F4 reacted strongly in the initial peptide coated
ELISA screen (data not shown) and was further analyzed by Western blotting (Fig-
ure 2.3.2A). Whole cell lysate from murine N2A cells and murine F/H-AGO2 purified
from HEK 293 cells were probed with the anti-AGO2(6F4) antibody. A signal at the
expected size of approximately 100 kDa was detected in both samples. This result indi-
cated that the antibody recognizes tagged and most likely endogenous AGO2. We next
tested if the anti-AGO2(6F4) immunoprecipitates endogenous AGO2 (Figure 2.3.2B).
The antibody was coupled to protein G sepharose beads and incubated with whole cell
lysate from N2A cells. Beads without antibody served as a control. The samples were
analyzed by Western blotting using the anti-AGO2(6F4). Signals were detected in the
lysate and supernatants of the immunoprecipitations (IPs). The signal in the IP with
the anti-AGO2(6F4) antibody was significantly enhanced, whereas no signal was ob-
served in the IP without antibody. Taken together, these findings indicate that the
anti-AGO2(6F4) immunoprecipitated AGO2.
mmuAgo2  NP_694818.3    1  MYSGAPGVLASPAPTTSPIPGYAFKPPPRP  30
mmuAgo1  NP_700456.1    1  MEAGPSGAAAGAYLPPLQQVFQAPRRPGIG  30
mmuAgo3  NP_700451.1    1  MEIGSAGPIGAQPLFIVPRRPGYGTMGKPI  30
mmuAgo4  NP_694817.2    1  MEALGPGPPASLLFQPPRRPGPGTVGKPIR  30
hsaAgo2  NP_036286.2    1  MYSGAGPALAPPAPPPPIQGYAFKPPPRPD  30
Figure 2.3.1: Amino acid alignment of the N-termini of mouse AGO 1-4 and human
AGO2. The peptide used for immunization and amino acid residues conserved between the
AGO proteins are depicted in red. mmu, Mus musculus; hsa, Homo sapiens.
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Figure 2.3.2: Specificity of the anti-AGO2(6F4) in Western blot and immunoprecip-
itation. A) To test the Western blot specificity, 30µg whole cell lysate from N2A cells (lane 1)
and purified F/H-AGO2 (lane 2) were probed with the anti-AGO(6F4) diluted 1:5000. B) Im-
munoprecipitations were performed from N2A whole cell lysate with the anti-AGO2(6F4) (lanes
4-5) or beads without antibody (w/o, lanes 2-3). 0,2% input (lane 1), 0,2% supernatants after
IP (lanes 2 and 4) and the 4% of the IPs (lanes 3 and 5) were analyzed by Western blot with
anti-AGO2(6F4). C) F/H-tagged mouse AGO 1-4 (mAGO1-4, lanes 1-8) and human AGO 1-4
(hAGO-1-4, lanes 9-16) were overexpressed in HEK293T and immunoprecipitated with FLAG
antibody (odd-numbered lanes) or the anti-AGO2(6F4) antibody (even numbered lanes). Pro-
teins were detected with anti-AGO2(6F4) (upper panel) or anti-HA (lower panel). D) For the
detection of endogenous AGO2 in different cell lines, whole cell lysates (30 µg, lanes 1-3) and
IPs with anti-AGO2(6F4) (lanes 4-6) from N2A, NIH 3T3 and a MEF cell line were analyzed
with the anti-AGO2(6F4) by Western blotting.
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In order to assess the specificity of the antibody for mouse AGO2, we overexpressed F/H-
tagged mouse and human AGO1-4 in HEK293T cells and immunoprecipitated proteins
either with anti-AGO2(6F4) or FLAG antibody (Figure 2.3.2C). Proteins were detected
with the anti-AGO2(6F4) or an antibody against the HA-tag. We observed strong signals
for all AGO proteins in the FLAG-IPs with the HA-antibody but the anti-AGO2(6F4)
detected only mouse AGO2.
This verifies that the antibody specifically recognizes mouse AGO2 in Western blot
analysis. The anti-AGO2(6F4) efficiently immunoprecipitated F/H-tagged AGO2 but
shows a cross reactivity with mouse AGO1 and a weak cross reactivity with human
AGO1 and AGO2 (Figure 2.3.2C, lower panel). Mass spectrometry analysis of murine
proteins immunoprecipitated with anti-AGO2(6F4) confirmed this cross reactivity with
mouse AGO1 and revealed additional cross reactivities, including an affinity for AGO3
(see Figure 2.3.6 and Section 2.4).
We next tested the ability of the antibody to detect endogenous AGO2 in whole cell
lysates from different mouse cell lines (Figure 2.3.2D) and observed strong signals at
the expected size in all cell lines. Several signals with lower molecular weights (65,
55 and 30 kDa) were also visible. Since these signals disappeared in the immunopre-
cipitations they were classified as background signals and not analyzed further. The
anti-AGO2(6F4) also specifically immunoprecipitated and detected rat AGO2 (Andrea
Rinck, personal communication).
Bound AGO2 protein can be eluted from the antibody matrix by addition of a peptide
encompassing the antibody epitope (Figure 2.3.3A). AGO2 was immunoprecipitated with
anti-AGO2(6F4) and incubated with the peptide used for immunization. A significant
amount of AGO2 was eluted from the antibody matrix but the bigger part remained
bound to the antibody. To increase elution efficiency, the concentration of the competing
peptide was varied but the efficiency of the elution was not influenced by the peptide
concentration (Figure 2.3.3B). However, it was significantly improved by performing
multiple elution steps (Figure 2.3.3C). The highest elution efficiency was reached with
eluting three times for 30 minutes. No protein was eluted when the competing peptide
was omitted from the reaction, a clear indication that AGO2 binding by the antibody
is strong and stable over time. The elution efficiency could be further increased by
raising the pH to 8.0 (Figure 2.3.3D). By using the commercially available antibody
anti-AGO2(C34C6) for the detection of AGO2 in the eluates (Figure 2.3.3C and D),
we validated the identity of the precipitated protein as AGO2 again. In summary, the
experiments showed that bound AGO2 protein can be efficiently eluted from the anti-
AGO2(6F4) with a competing peptide.
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Figure 2.3.3: Isolation of native RISC by peptide elution. A) AGO2 was immunoprecipi-
tated with anti-AGO2(6F4) from Hepa 1-6 whole cell lysate and eluted with 1mg/ml competing
peptide. Equal amounts of input (lane 1), supernatant after the IP (lane 2), eluate (lane 3)
and beads after elution were analyzed for AGO2 by Western blot with anti-AGO2(6F4). B)
F/H-tagged mouse AGO2 was overexpressed in HEK293T cells and immunoprecipitated with
anti-AGO2(6F4). Bound protein was eluted with 100 (lanes 1-2), 500 (lanes 3-4) or 1000 (lane
5-6) µg/ml peptide for 90min. Eluates and beads after elution were analyzed by Western blot
with an antibody against the HA-tag. C) AGO2-containing complexes were immunoprecipitated
with anti-AGO2(6F4) from wild type MEF whole cell lysate and eluted without (lanes 3-4) or
with 500 µg/ml peptide once for 90min (lanes 1-2) or three times for 10 (lanes 5-6), 20 (lane
7-8) or 30 (lanes 9-10) min. AGO2 amounts in eluates and beads after elution were detected
by Western blotting with the commercially available anti-AGO2(C34C6) antibody. D) AGO2
containing protein complexes were immunoprecipitated with anti-AGO2(6F4) from wild type
MEF whole cell lysate and eluted with 500 µg/ml peptide for 90min at pH 7.0 (lane 1), 7.5
(lane 2) or 8.0 (lane 3). Input sample was loaded in lane 4. Samples were analyzed by Western
blotting with anti-AGO2(C34C6).
Small RNAs bound to AGO proteins are essential for RISC function and of high in-
terest for functional studies. Therefore, we analyzed if the anti-AGO2(6F4) coimmuno-
precipitates miRNAs. RNAs were extracted from lysates and AGO2 immunoprecipita-
tions and were analyzed by Northern blotting using probes against miR-19b and miR-21
(Figure 2.3.4). We analyzed different cell lines including Dicer wild type MEFs (Dicer wt)
and Hepa 1-6 cells. As controls we used Dicer-depleted MEFs (Dicer ko) [101] and an
AGO2-depleted MEF cell line (AGO2 ko) [55]. The Dicer-depleted MEFs should not
contain mature miRNAs and therefore serve as negative control. The AGO2-depleted
MEFs contained mature miRNAs but because of the loss of AGO2 these should not be
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immunoprecipitated by the anti-AGO2(6F4). As expected, miRNAs were detected in
the lysates from all cell lines except the Dicer-depleted MEFs. An interesting observation
is that the abundance of miRNAs is significantly reduced in the AGO2-depleted MEFs.
In the IPs, both miRNAs were strongly enriched in the wild type MEFs and Hepa 1-6
cells but not in the AGO2-depleted cells.
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Figure 2.3.4: Coimmunoprecipitation
of miRNAs in AGO2-containing RNP
complexes isolated with the anti-
AGO2(6F4) antibody. RNAs were ex-
tracted from whole cell lysate (odd num-
bered lanes) or AGO2 immunoprecipita-
tions (even numbered lanes) with anti-
AGO2(6F4) from Dicer wild type MEFs
(Dicer wt, lanes 1-2), Dicer-depleted MEFs
(Dicer ko, lanes 3-4), AGO2-depleted MEFs
(AGO2 ko, lanes 5-6) or Hepa 1-6 (lanes
7-8). After size separation by denatur-
ing electrophoresis (upper panel) the RNAs
were transferred to membrane and probed
for miR-19b (2nd panel) and miR-21 (3rd
panel). U6 was used as a loading con-
trol (4th panel). AGO2 protein abundance
in the samples was monitored by West-
ern blotting with anti-AGO2(C34C6) (5th
panel). Tubulin was used as loading con-
trol for input protein (lower panel).
The amount of AGO2 protein was assessed byWestern blotting using anti-AGO2(C34C6).
As expected, no AGO2 was detected in lysate and IP from the AGO2-depleted cells.
AGO2 was present in the lysates and in the IPs from the other three cell lines. It
is noticeable that the AGO2 abundance in the Dicer-depleted MEFs was slightly de-
creased compared to the level in the wild type cells. Overall, the experiment demon-
strated that the anti-AGO2(6F4) antibody specifically coimmunoprecipitatesd AGO2
bound miRNAs.
In mammals, AGO2 is the only AGO protein that has slicer activity and target cleavage is
a sign for active and functional RISC. We performed in vitro cleavage assays to analyze
if the anti-AGO2(6F4) precipitates functional RISC from mouse cell lysates. AGO2-
containing protein complexes were immunoprecipitated from wild type Dicer, Dicer-
depleted or AGO2-depleted MEFs and from Hepa 1-6 cells (Figure 2.3.5A). The eluates
were incubated with a radiolabeled substrate RNA containing the fully complementary
target site for the endogenous miRNA 19b (Figure 2.3.5B, left panel). A specific cleavage
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Figure 2.3.5: RISC and Dicer activity of endogenous AGO2-containing RNP com-
plexes. A) Protein complexes were immunoprecipitated from Dicer wild type MEFs (lane 1
and 5), Dicer-depleted MEFs (lanes 2 and 6), AGO2-depleted MEFs (lanes 3 and 7) and Hepa
1-6 (lanes 4 and 8) whole cell lysates with the anti-AGO2(6F4) antibody (lanes 1-4). Bound
protein was eluted with competing peptide (lanes 5-8). The presence of AGO2 in the samples
was verified by Western blotting with the anti-AGO(C34C6) antibody. B) For RISC activity
assays, the eluates were incubated with a 32P cap-labeled substrate RNA containing a target
site for the endogenous miRNA-19b (left panel) or were preincubated with an exogenous single
stranded siRNA prior to cleavage reaction with a 32P cap-labeled substrate RNA containing a
target site for the exogenous siRNA (right panel). Cleavage products were separated by dena-
turing PAGE and visualized by autoradiography. In the experiment with the exogenous single
stranded siRNA, purified recombinant human AGO2 was used as a positive control (lane 2). C)
To test for Dicer activitiy, the IPs and eluates were incubated with an internally 32P-labeled
miR-27a precursor RNA. Cleavage products were analyzed by denaturing PAGE and autoradio-
graphy. 32P-end labeled RNAs with lengths of 16, 18 and 21 nt served as a size standard (lane
9) and recombinant human Dicer protein was used as a positive control (lane 2).
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product was observed for the wild type MEFs and the Hepa 1-6. As to be expected, we
saw no RISC activity in the Dicer-depleted and the AGO2-depleted MEFs. The RISC
activity can be reconstituted in vitro in the Dicer-depleted MEFs by loading AGO2 with
an exogenous single stranded siRNA (Figure 2.3.5B, right panel). After incubation with
the radiolabeled exogenous target RNA, specific degradation products were visible for
all samples except the AGO2-depleted MEFs. These results clearly show that the anti-
AGO2(6F4) precipitated active endogenous RISC and that the complex was not only
cleavage competent but was also able to load single stranded siRNAs into the AGO2
protein.
Earlier studies showed that Dicer associates stably with AGO2 [102, 221]. To test
whether Dicer is a component of the endogenous AGO2 complex that is precipitated
with the anti-AGO2(6F4), we analyzed Dicer activity in IPs and eluates from different
cell lines (Figure 2.3.5A and C). Immunoprecipitates and eluates were incubated with
an internally radiolabeled miR-27a precursor. Cleavage products were analyzed by de-
naturing PAGE and autoradiography (Figure 2.3.5C). Recombinant Dicer was used as
a positive control and gave a clear signal for the mature miRNA with the expected size
of 21 nt. We observed no Dicer activity in the IPs or the eluates. This result was quite
striking because the AGO-Dicer association is a well-studied and established interaction
[208, 289, 311]. From the presence of mature miRNAs in whole cell lysates (Figure 2.3.4)
we can assume that Dicer is present and active in the input samples. The lack of Dicer
activity indicated that Dicer is not stably associated with endogenous AGO2 in the
protein complex immunoprecipitated with anti-AGO2(6F4). The absence of Dicer in
the immunoprecipitated AGO2 complex was verified by mass spectrometry analysis at
a later point in time (see Section 2.4.1).
We aimed to get an overview about the proteins stably associated with AGO2 in our im-
munoprecipitations. For this purpose, we analyzed the band pattern of bound proteins
from stringently washed IPs by SDS-PAGE and silver staining (Figure 2.3.6A). A band
with the expected size for AGO2 was clearly visible and we also observe a strong band
with a molecular weight of about 120 kDa. Both bands were analyzed by mass spectrom-
etry. The 100 kDa band was identified as AGO2 and contained small contaminations of
AGO1 and 3. The 120 kDa band was identified as the coat protein complex II (COPII)
component protein SEC24C. The COPII machinery mediates the first step of the exo-
cytic pathway at the endoplasmatic reticulum and SEC24 is an adapter protein involved
in cargo recognition and selection. In mammalian cells, SEC24 has four isoforms (SEC24
A-D) [112]. Since components of the miRNA effector complex are enriched on multi-
vesicular bodies in the endocytic pathway [97], we investigated if SEC24C specifically
interacts with AGO2 and thereby connects it to the exocytic pathway. Because of the
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Figure 2.3.6: Cross reactivity of the
anti-AGO2(6F4) antibody with the
COPII component SEC24C. A) An anti-
AGO2(6F4) IP from N2A whole cell lysate
was washed stringently and analyzed by
SDS-PAGE and silver staining. Proteins of
interest were cut out and identified by mass
spectrometry. Antibody chains are indicated
by asterisks. B) Protein complexes were iso-
lated from HEK293T cells with either the
anti-AGO2(11A9) (lane 1) or a polyclonal
antibody against SEC24 (lane 2) and an-
alyzed for the presence of AGO2 (upper
panel) and SEC24 (lower panel) by Western
blotting.
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lack of suitable antibodies against mouse SEC24C, the specificity of the interaction was
tested in human cells (Figure 2.3.6B). We performed IPs from HEK 293 whole cell lysate
with either the anti-human AGO2(11A9) or an antibody specific for SEC24C and tested
the precipitates for the presence of the proteins by Western blotting. Both proteins were
only present in the IPs with their specific antibody and showed no interaction. Therefore,
the presence of SEC24C in the anti-AGO2(6F4) IPs was not a specific protein-protein
interaction but was most likely based on a cross reactivity of the antibody.
The cellular localization of proteins is of high interest for functional studies. With
an antibody specific against an endogenous protein the problems caused by tagging and
overexpressing, for example aggregation, can be avoided. We tested the anti-AGO2(6F4)
for its suitability for localization studies in immunofluorescence experiments using con-
focal microscopy (Figure 2.3.7). N2A cells or AGO2-depleted MEFs were fixed and
stained with anti-AGO2(6F4). Since the AGO2-depleted cell line contains no AGO2, we
expected no signal in these samples. Instead, we observed a diffuse cytoplasmic staining
in both cell lines. In order to rule out that this diffuse staining is background caused by
the secondary antibody, we omitted the anti-AGO2(6F4) antibody from the experiment.
In this setup, the background staining was clearly reduced. In summary, these results
imply that the anti-AGO2(6F4) is not specific for AGO2 but cross-reacted with other
proteins in immunofluorescence experiments. The antibody is therefore not suitable for
localization studies.
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Figure 2.3.7: Immunofluorescence experiments with the anti-AGO2(6F4) antibody.
A) N2A cells (panels 1-3) and AGO2-depleted MEFs (panels 4-6) were fixed and stained with
DAPI (panels 1 and 4) or anti-AGO2(6F4) (panels 2 and 5). Merged images are shown in panels
3 and 6. B) In a control experiment, both cell lines were stained with the secondary antibody
only.
We characterized the monoclonal antibody anti-AGO2(6F4). The antibody specifically
detected mouse AGO2 in Western blot analysis. It immunoprecipitated AGO2 and the
bound protein could be eluted from the antibody with a competing peptide encom-
passing the antibody epitope tag. MiRNAs were coimmunoprecipitated with AGO2
and the immunoprecipitated RISCs show cleavage activity and are able to load single
stranded siRNAs. The antibody is therefore suitable for miRNA profiling and RISC
activity studies. It is an interesting observation that Dicer is not present in the AGO2-
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containing complexes bound by the anti-AGO2(6F4) antibody. The antibody showed a
weak binding affinity for AGO1 and 3 and strongly cross-reacted with the COPII vesicle
component SEC24C. Due to this strong cross reactivity the antibody was not suitable
for localization studies by immunofluorescence under the tested conditions.
2.4 Identification of MicroRNA-Dependent AGO2
Interactors from Endogenous Ribonucleoprotein
Complexes
2.4.1 A Modified QUICK Approach for the Identification of Specific
AGO2 Interactors
Several studies [127, 171, 221] contributed to the present picture of the AGO2 interac-
tome. In these studies, tagged human AGO2 was overexpressed and RNPs were purified
via the affinity tag by several purification steps prior to semiquantitative proteomic
analysis. The anti-AGO2(6F4) antibody now provides a tool that allowed us to study
endogenous AGO2 complexes in mouse by AP-MS. For the high confidence identification
of interaction partners of endogenous proteins, quantitative immunoprecipitations can
be combined with knockdown in a so called QUICK approach ([296], see page 28). Since
we accounted frequent problems with the transfection and knockdown efficiency in the
MEF cell line (data not shown), we modified the QUICK approach. Instead of a knock-
down of AGO2 by RNAi, we used an AGO2-depleted MEF cell line [55] and applied
the method to identify specific interaction partners of endogenous AGO2 as depicted in
Figure 2.4.1.
Wild type and AGO2-depleted MEFs were SILAC labeled with light or heavy arginine
and lysine. The incorporation rate was above 95% and no arginine to proline conversion
was observed (data not shown). AGO2-containing protein complexes were immunopre-
cipitated with the anti-AGO2(6F4) antibody for each SILAC state separately to prevent
heavy to light exchange of specific interaction partners during the purification procedure
[231, 342]. After washing, the samples were combined for the elution with a compet-
ing peptide. The quality of the immunoprecipitations was analyzed by Western blot as
shown for the reverse experiment in Figure 2.4.2A. AGO2 was present in the wild type
cell line and enriched in the eluate but it was not detected in the AGO2-depleted cell
line. We worked with an excess of lysate and the significant amount of AGO2 remaining
in the supernatant after the IP (Figure 2.4.2A, lane 3) indicates that the amount of
AGO2 in the sample exceeded the AGO2 binding capacity of the antibody. The eluates
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Figure 2.4.1: Experimental setup of a modified QUICK approach to identify specific
AGO2 interactors. AGO2-containing complexes were immunoprecipitated from heavy labeled
wild type (wt) AGO2 and light labeled AGO2-depleted (ko) MEFs with the anti-AGO2(6F4)
antibody. Samples were washed and combined for elution with a competing peptide. Proteins
were separated by one-dimensional gel electrophoresis and in-gel digested with trypsin. Peptides
were analyzed by LC-MS/MS. For the reverse experiment the SILAC label was swapped between
the cell lines. Specific AGO2 interactors are expected to show high H/L ratios in the forward
and low ratios in the reverse experiment. Background binders show ratios around one in both
experiments. For data visualization the logarithmized, normalized ratios of the forward and
reverse experiments are plotted. Background binders are clustered around zero, as highlighted
by the grey sphere. Specific interactors can be found in the lower right quadrant as indicated
by the red sphere.
were separated by one-dimensional SDS-PAGE, stained with Coomassie (Figure 2.4.2B)
and in-gel digested with trypsin. Peptides were analyzed by LC-MS/MS on an LTQ
Orbitrap Velos.
We applied several filter criteria to the dataset to ensure a high quality of identification
and quantification of the reported proteins. The raw data contained 1385 protein iden-
tifications and was reduced to 1279 identified proteins after removing contaminants and
reverse identifications. We required two unique peptides and two quantification events
per protein for a valid identification. This reduced the number of identified proteins to
500. Figure 2.4.3 shows full scans and fragmentation spectra typical for the bait protein
or a background binder. In the full scans, the two SILAC pairs were clearly visible as
indicated by the arrows. For the AGO2 peptide (Figure 2.4.3A) the heavy peptide was
detected with a higher intensity in the forward experiment and in the reverse experiment
the light peptide had a higher intensity. These ratios are characteristic for the bait pro-
tein and specific interactors. Background binders show ratios close to one between the
SILAC pairs. In Figure 2.4.3B, a peptide from the protein DNAJ is shown. There were
no differences in the intensities between the SILAC states and the protein was classified
as a background binder.
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Figure 2.4.2: Representative immuno-
precipitation of the modified QUICK
approach. A) 1,25% input samples (lanes
1 and 2) or supernatant (lanes 3 and 4)
from the immunoprecipitations from light
labeled wild type (wt, lanes 1 and 3)
and heavy labeled AGO2-depleted cells (ko,
lanes 2 and 4) and 9% of the eluate (lane 5)
were loaded. AGO2 was detected by West-
ern blotting. B) The eluate was separated
by SDS-PAGE and stained with Coomassie
prior to in-gel digestion.
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AGO2 was detected with more than 30 unique peptides and more than 100 quantification
events both in the forward and the reverse experiment. The sequence coverage was
74%. Ratios of 14.6 and 0.06 in the forward and reverse experiments, respectively,
showed that AGO2 is specifically enriched in this experimental setup (Table 2.4.1). As
described previously (see Figure 2.3.6), the anti-AGO2 (6F4) strongly cross-reacts with
the COPII vesicle component SEC24C. This protein was detected with more than 40
unique peptides, more than 80 counts and a sequence coverage of 56%. It could be
clearly identified as a background binder by its ratios of 1.3 in the forward and 0.8
in the reverse experiment (Table 2.4.1). This demonstrated that the modified QUICK
approach successfully shifted antibody specific cross reactants into the background.
We visualized the data by ratio plots (Figure 2.4.4). As described in Figure 2.4.1,
the background binders are clustered around zero whereas specific interactors can be
found in the lower right quadrant. The data set did not display the ratio distribution
expected for a typical SILAC data set. Instead, we observed a wide scattering of the
background binders and a significant number of contaminants in the lower left quadrant.
A high number of proteins were located in the upper left quadrant. These are proteins
that were enriched in the IP in the absence of AGO2. This group includes the insulin
receptor substrate 1 (IRS1) but mainly comprises proteins involved in cell adhesion such
as laminins (LAMB2, LAMA5), glycoproteins (THBS1) and collagens (COL18A1). A set
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Figure 2.4.3: Full scans and fragmentation spectra for representative peptides. Full
scans and fragmentation spectra of a selected peptide are shown for the forward (upper row)
and the reverse experiment (lower row) for A) a peptide from the bait protein AGO2 and B) a
peptide from the background binder DNAJ.
53
2 Results
AGO1
AGO2
MSY1
AGO3
TNRC6B
SEC24C
TNRC6C
MOV10
TNRC6A
PABPC1
log(2)Ratio H/L normalized forward
lo
g(
2)
R
at
io
 H
/L
 n
or
m
al
iz
ed
 r
ev
er
se
−4 −2 0 2 4
−6
−4
−2
4
2
0
LAMA5
COL18A1
LAMB2
THBS1
IRS1
MYL9
IFIT1
P53
ACTC CORO1B
CFL2
Figure 2.4.4: Modified QUICK approach for the identification of AGO2 interactors.
Logarithmized normalized ratios of forward and reverse experiments are plotted as described in
Figure 2.4.1. Every dot represents an identified and quantified protein. Top outliers are labeled
and a selection of proteins reported to interact with AGO2 are indicated in color.
of proteins, among them AGO2 and the tumor suppressor p53, appeared as clear outliers
and were thereby defined as specific interactors. The top 30 outliers and a selection of
proteins reported to interact with AGO2 as well as the cross reactant SEC24C and
detected AGO proteins are summarized in Table 2.4.1. Dicer and its cofactor TARBP2
were not identified in the dataset. When analyzing the functions of the outliers (see
keywords in Table 2.4.1), the vast majority of these proteins were classified as cytoskeletal
proteins such as myosins (MYH9 and 10, MYO1b, 1c and 6), actin and actin binding
proteins (Cofilin 1 and 2, LIMA1 and Coronin 1B). We highlighted reported AGO2
interacting proteins including TNRC6 A-C, MOV10 and YB1 in the ratio plot and
these proteins were identified as background binders based on their ratios. Among the
background binders we also found the mRNA-binding proteins IGF2BP 1-3, HSP90 and
AGO1 and 3 (Table 2.4.1). It might be possible that the presence of these two AGO
proteins in the IP accounts for the background ratios of some of the reported AGO2
interactors. The majority of the established interactors we selected for analysis associate
with all AGO proteins [171] and therefore it is possible that we detected peptides from
these proteins in association with AGO1, 2 or 3 in our samples. A peptide from a protein
in complex with AGO2 had a high ratio, but since the same peptide from proteins in
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Protein Name Gene Name Uniprot ID Keywords forward reverse forward reverse
Bait
Protein argonaute-2 Eif2c2 Q8CJG0 RNA-mediated gene silencing 35 31 14,677 0,064
Cross reactivity
Sec24c protein Sec24c Q8R2V9 COPII vesicle coat component 46 41 1,301 0,828
Other AGO proteins
Protein argonaute-1 Eif2c1 Q8CJG1 RNA-mediated gene silencing
transcriptional gene silencing
19 7 1,087 1,046
Protein argonaute-3 Eif2c3 Q8CJF9 RNA-mediated gene silencing 23 16 0,930 1,352
Outliers
Interferon-induced protein with tetratricopeptide repeats 1 Iﬁt1 Q64282 unknown function 6 2 21,835 0,119
Myosin regulatory light polypeptide 9 Myl9 Q9CQ19 cytoscleletal protein 4 3 19,376 0,305
Cellular tumor antigen p53 Tp53 P02340 tumor suppressor 2 3 19,086 0,022
Coﬁlin-2 Cﬂ2 P45591 actin binding
cytoplasmic actin rods
5 10 11,080 0,120
LIM domain and actin-binding protein 1 Lima1 Q9ERG0 actin binding
LIM domain
8 7 10,132 0,133
Coronin-1B Coro1b Q9WUM3 actin binding
interacts with Arp2/3 complex
11 13 9,474 0,113
Coﬁlin-1 Cﬂ1 P18760 actin binding
cytoplasmic actin rods
6 9 8,378 0,156
Contactin associated protein 1 Cntnap1 O54991 contactin interactor
membrane protein
15 10 8,265 0,170
Coronin-1C Coro1c Q9WUM4 actin binding 21 29 8,112 0,185
MCG5400 2900073
G15Rik
Q6ZWQ9 unknown function
calcium binding
2 2 7,239 0,377
WD repeat-containing protein 1 Wdr1 O88342 actin binding 11 22 7,097 0,179
Myosin-14 Myh14 Q6URW6 myosin 2 4 6,941 0,882
Cysteine and glycine-rich protein 2 Csrp2 P97314 LIM domain protein
interacts with ATAC complex 
(histone acteylation)
3 2 6,832 0,146
Actin-related protein 2/3 complex subunit 4 Arpc4 P59999 actin binding
Arp2/3 complex
5 6 6,818 0,186
Twinﬁlin-1 Twf1 Q91YR1 actin binding 7 7 6,783 0,400
Tropomyosin beta chain Tpm2 P58774 actin binding 2 3 6,408 0,252
Calmodulin Calm1 P62204 calcium binding protein
stimulates kinases and 
phosphatases
3 5 6,051 0,266
Myosin-9 Myh9 Q8VDD5 myosin 88 111 6,030 1,029
Myosin-10 Myh10 Q61879 myosin 39 60 5,745 0,523
Ltbp2 protein Ltbp2 Q0VD84 unknown function
calcium binding
3 4 5,656 0,164
Actin-related protein 2 Actr2 P61161 ATP binding
Arp2/3 complex
(actin polymerization)
5 8 5,626 0,480
Tropomyosin alpha-4 chain Tpm4 Q6IRU2 actin binding 14 18 5,612 0,284
Myosin-Ic Myo1c Q9WTI7 myosin
isoform 3 required for 
transcription initiation
30 37 5,317 0,377
Myosin light chain 1 Myl3 P09542 myosin light chain 2 2 5,292 0,179
Histone H1.0 H1f0 P10922 histone 3 3 5,121 0,221
Filamin-B Flnb Q80X90 connects membrane to actin
cytoskeleton
88 103 5,045 0,267
Actin-related protein 3 Actr3 Q99JY9 ATP binding
Arp2/3 complex
9 12 4,862 0,199
Actin, alpha cardiac muscle 1 Actc1 P68033 actin 9 9 4,822 0,108
Dynactin subunit 4 Dctn4 Q8CBY8 Dynactin 2 7 4,791 0,164
selected reported AGO2 interactors
Trinucleotide repeat-containing gene 6A protein Tnrc6a Q3UHK8 RNA-mediated gene silencing 14 8 1,197 2,193
Trinucleotide repeat-containing gene 6B protein Tnrc6b Q8BKI2 RNA mediated gene silencing 62 51 1,058 3,213
Trinucleotide repeat-containing gene 6C protein Tnrc6c Q3UHC0 RNA-mediated gene silencing 7 3 0,438 5,058
Polyadenylate-binding protein 1 Pabpc1 P29341 poly(A) tail of mRNA binding 17 12 0,956 1,374
Poly(A) binding protein, cytoplasmic 4 Pabpc4 Q99LF8 RNA binding 16 8 0,559 0,873
Putative helicase MOV-10 Mov10 P23249 RNA-mediated gene silencing 40 29 1,376 0,582
Nuclease-sensitive element-binding protein 1 Ybx1 P62960 transcription
pre-mRNA splicing
mRNA processing
11 6 1,039 1,539
Insulin-like growth factor 2 mRNA-binding protein 1 Igf2bp1 O88477 mRNA 5'UTR  binding 14 3 0,551 2,943
Insulin-like growth factor 2 mRNA-binding protein 2 Igf2bp2 Q5SF07 mRNA translation
mRNA 5'UTR  binding
15 4 0,536 1,797
Insulin-like growth factor 2 mRNA-binding protein 3 Igf2bp3 Q9CPN8 RNA binding
mRNA translation and stabilty
13 4 0,801 1,932
Heat shock protein HSP 90-alpha Hsp90aa1 P07901 molecular chaperone
ATPase activity
18 14 0,347 1,561
Unique Peptides Ratio H/L
Table 2.4.1: List of selected proteins identified in the modified QUICK approach.
A subset of values is listed for the outliers, known cross reactants, AGO family proteins and a
selection of proteins reported to interact with AGO2. Keywords describing reported functions
were added. The data is visualized in Figure 2.4.4.
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Figure 2.4.5: Comparison of LIMA1 abundance in wild type and AGO2-depleted
MEF cell lines by Western blot analysis. Whole cell lysates were prepared from wild type
(wt) and AGO2-depleted (ko) MEFs (lanes 1 and 5). AGO2 was immunoprecipitated with the
anti-AGO2(6F4) antibody (lanes 2 and 6). As controls the RMC antibody (lanes 3 and 7) and
beads without antibody (w/o) was used (lanes 4 and 8). Proteins were detected antibodies
against AGO2 (upper panel) or LIMA1 (lower panel).
the AGO1 or 3 complexes was equally present in both SILAC states, the overall ratio
computed for the peptide was decreased to a background value and the protein appeared
as a background binder. As an alternative, the background binding behavior of the
reported interactors might also be caused by non-specific binding to the sepharose that
was used as matrix in the IP.
Wide scattering of the data points in ratio plots is an indication for differential back-
ground binding caused by significant differences in the whole proteome of the samples
used in the experiment. Both of the cell lines we used are mouse embryonic fibroblasts
but we observed a strong deviation of the cell shape of the AGO2-depleted cells from
other MEF cell lines (data not shown). The shape of the cell is based on the cytoskele-
ton, so cells with different appearance are likely to differ in the composition of their
cytoskeletal proteins. If this applies to this set of cell lines, it could account for the
high number of cytoskeletal proteins among the outliers. To test this hypothesis, we
analyzed the amount of the actin-binding protein LIMA1, one of the top outliers, in
the two cell lines by Western blotting (Figure 2.4.5). The experiment showed that the
LIMA1 expression level was higher in the wild type cell line than in the AGO-depleted
cells. LIMA1 did not specifically interact with AGO2 but bound non-specifically to the
antibody. Due to the different expression levels in the two cell lines it was only enriched
on the antibody in the wild type cell line and thus appeared as a false positive AGO2
interactor in the QUICK approach.
We were not able to identify specific AGO2 interactors with the modified QUICK ap-
proach despite the fact that cross reactants such as SEC24C were successfully shifted
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the to the background. Instead, this experimental setup demonstrated two aspects that
we needed to address with further experiments. One aspect was the cross reactivity
of the anti-AGO2(6F4) antibody with AGO1 and AGO3. The second aspect was the
influence of the whole proteome of the input samples on background binding in the
immunoprecipitation.
2.4.2 Comparison of Antibody Performance Between the anti-AGO2(6F4)
and the Commercially Available Argonaute2 (C34C6) Antibody
The anti-AGO2(6F4) antibody displayed a strong non-specific association with cytoskele-
tal proteins in the modified QUICK approach. To test if these reactivities are specific for
the anti-AGO2(6F4) antibody, we compared it to the commercially available monoclonal
Argonaute 2 (C34C6) antibody (anti-AGO2(C34C6)).
We immunoprecipitated AGO2-containing complexes from heavy labeled wild type MEFs
and light labeled AGO2-depleted MEFs with the anti-AGO2(C34C6). After the washing
steps the beads were combined and bound protein was non-specifically eluted from the
beads by the addition of denaturing sample buffer. Samples were processed further as
described before (Figure 2.4.1). The quality of the IP was checked in a Western blot and
Coomassie stain (Figure 2.4.6). As for the IPs with the anti-AGO2(6F4) (Figure 2.4.2A)
we worked with an excess of input sample and the amount of AGO2 in the sample sur-
passes the binding capacity of the anti-AGO2(C34C6) antibody as seen by the high
amount of AGO2 still present in the supernatant after the IP (Figure 2.4.6A). The satu-
ration of the binding capacity ensures that the amount of AGO2 bound is comparable in
all samples and allows for a reliable quantification independently of the AGO2 concen-
tration in the input samples. The protein profile in the Coomassie stain (Figure 2.4.6B)
showed no significant differences to the anti-AGO2(6F4) IP (Figure 2.4.2B) except for
stronger antibody chain bands caused by the unspecific elution with sample buffer. A
possibility to reduce the amount of antibody chains in unspecific elutions is covalent
coupling of the antibody. Direct coupling of the anti-AGO2(C34C6) resulted in a loss of
antibody binding activity (data not shown). Therefore, the method could not be applied
for the anti-AGO2(C34C6) antibody.
For data analysis the raw data from the forward experiment from the modified QUICK
approach was defined as forward experiment and the data from the IP with the anti-
AGO2(C34C6) antibody was defined as the reverse experiment. With the combination
of the two experiments into one dataset, we directly compare the ratios for the iden-
tified proteins between the two experiments instead of identifying outliers. After pro-
cessing, we filtered the dataset as described (Section 2.4.1) and obtained 446 identified
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Figure 2.4.6: Immunoprecipitation of
AGO2 complexes with the anti-
AGO2(C34C6) antibody. A) 1,28% of
input samples (lanes 1 and 2) or super-
natants of the immunoprecipitations (lanes
3 and 4) from heavy labeled wild type (lanes
1 and 3) and light labeled AGO2-depleted
cells (lanes 2 and 4) and 2% of the eluate
(lane 5) were loaded and probed with an
antibody against AGO2. Lane 6 shows a
longer exposure of the eluate. B) The eluate
was separated by SDS-PAGE and stained
with Coomassie.
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proteins. Selected values for proteins of interest are summarized in Table 2.4.2. The
anti-AGO2(6F4) precipitated more AGO2 then the anti-AGO2(C34C6), as can be seen
by the higher numbers of unique peptides and quantification events for AGO2. The ra-
tios in the anti-AGO2(C34C6) experiment are lower for all identified proteins, which we
attributed to a lower incorporation rate for the cells used in this experiment. The com-
parison of the values for the AGO proteins 1 and 3 and a selection of reported AGO2
interactors including the TNRC6 and IGF2BP protein families showed no significant
differences between the two antibodies in respect to unique peptides or quantification
events. We observed differences in the ratios for some proteins, especially for the AGO1
and 3 and the TNRC6 proteins, but all proteins clearly did not appear as specific in-
teractors in both experiments. Dicer and its interaction partners were not detected in
any of the experiments. SEC24C, the protein identified as a specific cross reactor for the
anti-AGO2(6F4) antibody, was also identified in the IP with the commercial antibody,
yet in a significantly lower amount. In both IPs, SEC24C was identified as a back-
ground binder. Overall, both antibodies showed very similar binding profiles in respect
to reported AGO2 interactors, cross reactivity with other AGO proteins and known
background binders. When comparing the proteins with the highest ratios, we also saw
a big overlap between the two experiments. In both cases the majority of these proteins
are cytoskeletal proteins (Table 2.4.2). Therefore, the high amount of cytoskeletal prote-
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Protein Names Gene Name Uniprot ID Keywords anti-AGO2
(6F4)
anti-AGO2
(C34C6)
anti-AGO2
(6F4)
anti-AGO2
(C34C6)
anti-AGO2
(6F4)
anti-AGO2
(C34C6)
Bait
Protein argonaute-2 Eif2c2 Q8CJG0 RNA-mediated gene silencing 36 26 14,497 9,156 154 69
Other AGO proteins
Protein argonaute-1 Eif2c1 Q8CJG1 RNA-mediated gene silencing
transcriptional gene silencing
18 18 1,085 0,363 40 37
Protein argonaute-3 Eif2c3 Q8CJF9 RNA-mediated gene silencing 22 17 0,904 0,396 31 30
Comparison of selected reported AGO2 interaction partners
Trinucleotide repeat-containing gene 6A protein Tnrc6a Q3UHK8 RNA-mediated gene silencing 14 16 1,506 0,024 18 20
Trinucleotide repeat-containing gene 6B protein Tnrc6b Q8BKI2 RNA-mediated gene silencing 62 56 0,841 0,226 139 118
Trinucleotide repeat-containing gene 6C protein Tnrc6c Q3UHC0 RNA-mediated gene silencing 7 16 0,600 0,048 7 22
Polyadenylate-binding protein 1 Pabpc1 P29341 poly(A) tail of mRNA binding 18 18 0,946 0,898 110 74
Poly(A) binding protein, cytoplasmic 4 Pabpc4 Q99LF8 RNA binding 15 12 0,560 0,512 30 20
Putative helicase MOV-10 Mov10 P23249 RNA-mediated gene silencing 36 33 1,367 1,321 43 37
Nuclease-sensitive element-binding protein 1 Ybx1 P62960 transcription
pre-mRNA splicing
mRNA processing
11 7 1,067 1,023 50 17
Insulin-like growth factor 2 mRNA-binding protein 1 Igf2bp1 O88477 mRNA 5'UTR  binding 14 16 0,561 0,630 25 19
Insulin-like growth factor 2 mRNA-binding protein 2 Igf2bp2 Q5SF07 mRNA translation
mRNA 5'UTR  binding
15 12 0,523 0,547 24 15
Insulin-like growth factor 2 mRNA-binding protein 3 Igf2bp3 Q9CPN8 RNA binding
mRNA translation and stabilty
15 13 0,784 0,788 22 17
Heat shock protein 84b Hsp90ab1 Q71LX8 molecular chaperone
ATPase activity
2 2 0,480 0,953 66 33
Heat shock protein HSP 90-alpha Hsp90aa1 P07901 molecular chaperone
ATPase activity
19 16 0,347 0,592 24 19
Comparison of selected contaminants
Sec24c protein Sec24c Q8R2V9 COPII vesicle coat component 45 19 1,276 1,172 83 20
Caseinolytic peptidase B protein homolog Clpb Q60649 ATPase
secretion/protein trafﬁcking
2 25 84,784 1,879 3 41
Myosin regulatory light polypeptide 9 Myl9 Q9CQ19 myosin
cytoscleletal protein
3 5 25,503 44,205 4 5
Interferon-induced protein with tetratricopeptide repeats 1 Iﬁt1 Q64282 unknown function 6 3 23,415 7,451 5 2
Cellular tumor antigen p53 Tp53 P02340 tumor suppressor 3 6 18,519 12,297 4 4
Coﬁlin-2 Cﬂ2 P45591 actin binding
cytoplasmic actin rods
5 5 10,977 20,324 7 5
Coronin-1B Coro1b Q9WUM3 actin bindin
interacts with Arp2/3 complex
11 7 9,731 25,584 13 12
Coronin-1C Coro1c Q9WUM4 actin binding 21 19 8,833 8,882 29 32
Tropomyosin beta chain Tpm2 P58774 actin binding 2 3 8,284 6,064 9 15
WD repeat-containing protein 1 Wdr1 O88342 actin binding 11 21 7,409 22,330 13 24
MCG5400 2900073 Q6ZWQ9 unknown function
calcium binding
2 4 7,139 14,765 22 87
Unique Peptides Ratio H/L Ratio H/L Count 
G15Rik
Table 2.4.2: List of proteins of interest identified in the anti-AGO2(6F4) and anti-
AGO2(C34C6) immunoprecipitations. Selected values are summarized for the identified
AGO proteins, reported AGO2 interactors and a set of contaminants and known cross reactants.
Keywords describing reported functions were added.
ins in the IPs was not based on the specific binding characteristic of the anti-AGO2(6F4)
antibody. Instead, it supported our previous observation that this background binding
of cytoskeletal proteins is a general problem caused by the significant differences of the
whole proteome between the two cell lines used in this experimental setup.
2.4.3 Identification of Specific AGO2 Interacting Proteins from Hepa 1-6
Cells
In the QUICK approach, the same antibody was used for IPs from different cell lines
which led to the strong differences in background binding (see Section 2.4.1). Further
experiments revealed that this binding behavior is not specific for the anti-AGO2(6F4)
antibody (see Section 2.4.2). In order to address the influence of the whole proteome of
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the input samples on the quality of the IP, we now went back to the classical approach
of using a control antibody to define background binding. This allowed the use of the
same cell line as input sample and should prevent the identification of proteome-based
false positives.
Hepa 1-6 cells were SILAC labeled and protein complexes were immunoprecipitated with
the anti-AGO2(6F4) or a control antibody from the different SILAC states separately.
As control antibody we used the anti-RmC(16D2), an antibody directed against mouse
complement C4 protein. Samples were combined at the elution step and further pro-
cessed for MS analysis as described previously. The quality of the IPs was assessed by
Western blot analysis and Coomassie stain of the eluates (Figure 2.4.7).
Figure 2.4.7: Immunoprecipitations
with the anti-AGO2(6F4) or the anti-
RMC antibody from Hepa 1-6 cells.
A) 1.2% of heavy (lane 1) or light labeled
(lane 2) input samples and supernatants
from IPs for the forward (lanes 3 and 4)
or the reverse (lanes 6 and 7) experiments
were loaded. 24% of the eluates from
the forward and reverse experiment were
loaded in lanes 5 and 8, respectively. B)
The eluate from the forward experiment
was separated by SDS-PAGE and stained
with Coomassie.
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Equal amounts of heavy or light labeled whole cell lysate were used for all IPs. The
amount of AGO2 remaining in the supernatant is unchanged in the control IPs with
the anti-RmC(16D2), suggesting that there is no unspecific AGO2 precipitation. As
with the anti-AGO2(6F4) IPs from MEF cells, AGO2 is strongly detected in the eluates.
First differences to the previous experiments became apparent in the Coomassie stain of
the eluate (Figure 2.4.7B). The band pattern of the proteins showed clear differences to
the band pattern in IPs from MEF cell lines (Figure 2.4.2B). The high molecular weight
bands above 191 kDa are either missing or very weak. Between the 97 and 64 kDa marker
the proteins bands are clearer and a distinct band appears at approximately 90 kDa.
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Figure 2.4.8: Immunoprecipitation of endogenous AGO2-containing RNP complexes
from Hepa 1-6 cells. Logarithmized, normalized ratios from the forward and reverse experi-
ments are plotted against each other. Every dot represents an identified and quantified protein.
Specific interactors appear in the lower right quadrant whereas background binder cluster around
zero. Selected proteins are indicated in colors.
In the LC-MS/MS analysis, 643 proteins were identified and 348 identifications passed
our filter criteria. AGO2 was identified with more than 40 unique peptides per experi-
ment and a high sequence coverage of 78% (Table 2.4.3). The ratios of 6.38 and 0.14 in
forward and reverse experiments were relatively low but still defined AGO2 as a clear
outlier. The cross reacting protein SEC24C was identified with more than 30 unique
peptides and was clearly defined as an outlier by the ratios of 17.09 and 0.04. No Dicer
petides were detected in the experiments. The data was visualized in a ratio plot (Fig-
ure 2.4.8). As for the modified QUICK approach, background binders cluster around
zero and outliers appear in the lower right quadrant.
The dataset showed a distribution typical for a high quality SILAC dataset. There was
almost no scattering and background binders were tightly clustered at the crossing of the
zero base lines of the forward and reverse experiments. In the lower left quadrant only
very few contaminants were visible. A set of proteins appeared as outliers in the lower
right quadrant and could be clearly distinguished from the background cloud. From the
ratio plot, we could conclude that the wide scattering of data points and the high amount
of outliers in the previous experiments was indeed caused by using cell lines showing dif-
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Protein Names Gene Names Uniprot ID Keywords forward reverse forward reverse
Bait
Protein argonaute-2 Eif2c2 Q8CJG0 RNA-mediated gene silencing 40 45 6,383 0,144
Outliers
Programmed cell death 6 interacting protein Pdcd6ip Q9WU78 multivesicular body protein 40 46 39,247 0,055
Insulin receptor substrate 1 Irs1 P35569 insulin receptor signaling pathway 43 47 19,529 0,064
Protein FAM110A Fam110a Q8R184 cytoskeleton
spindel pole organizer
5 5 18,503 0,031
Sec24c protein Sec24c Q8R2V9 COPII vesicle coat component 34 41 17,090 0,044
Peptidyl-prolyl cis-trans isomerase FKBP5 Fkbp5 Q64378 heteromeric cytoplasmic 
complex
with Hsp90 and Hsp70
8 7 15,199 0,167
Ras GTPase-activating protein 2 Rasa2 P58069 membrane, Ras c-AMP pathway 22 23 15,047 0,082
Contactin associated protein 1 Cntnap1 O54991 membrane protein 18 20 14,905 0,169
Protein transport protein Sec23A Sec23a Q01405 COPII vesicle coat component 24 27 13,940 0,058
Syntenin-1 Sdcbp O08992 membrane protein 8 6 11,337 0,097
Protein transport protein Sec23B Sec23b Q9D662 COPII vesicle coat component 31 32 10,988 0,086
Glutamine and serine rich 1 Qser1 A2BIE1 unknown function 14 14 10,895 0,091
Latent-transforming growth factor beta-binding protein 3 Ltbp3 Q61810 TGF beta1 signalling pathway 3 6 7,903 0,110
Ubiquitin carboxyl-terminal hydrolase 19 Usp19 Q3UJD6 deubiquitination 7 12 7,563 0,255
Phosphate carrier protein, mitochondrial Slc25a3 Q8VEM8 phosphate group transport
cytosol-mitrochondrial matrix
10 10 7,174 0,113
Heat shock protein HSP 90-alpha Hsp90aa1 P07901 molecular chaperone
ATPase activity
11 14 7,126 0,133
Heat shock protein 84b Hsp90ab1 Q71LX8 molecular chaperone,
ATPase activity
2 2 6,898 0,107
Ubiquitin-associated protein 2 Ubap2 Q91VX2 unknown function 7 8 5,912 0,103
SUN domain containing protein1 Sun1 Q9D666 nucleoskeleton/cytoskeleton 6 4 5,841 0,103
Heterogeneous nuclear ribonucleoprotein H1 Hnrnph1 O35737 pre mRNA alternative splicing
RNA binding
10 11 4,639 0,236
Heterogeneous nuclear ribonucleoprotein H2 Hnrnph2 P70333 hnRNP complex
RNA binding
8 8 4,350 0,220
Protein argonaute-3 Eif2c3 Q8CJF9 RNA-mediated gene silencing 5 5 4,274 0,325
Annexin A2 Anxa2 P07356 calcium binding
sectreted
3 3 3,279 0,450
Protein argonaute-1 Eif2c1 Q8CJG1 RNA-mediated gene silencing
transcriptional gene silencing
11 15 3,123 0,313
Ythdc1 protein Ythdc1 Q8R5E6 unknown function 9 8 2,867 0,289
Ubiquitin-40S ribosomal protein S27a Rps27a P62983 cleaved into Ubiquitin and
40S ribosomal protein27a,
modiﬁcation
translation
5 4 2,848 0,223
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Atp2a2 O55143 ATP-dependent Ca2+ transport
cytosol-sarcoplasmatic reticulum
2 2 2,750 0,270
Myoferlin Myof Q69ZN7 Calcium binding
transmembrane protein
5 8 2,736 0,340
Trinucleotide repeat-containing gene 6C protein Tnrc6c Q3UHC0 RNA-mediated gene silencing 9 9 2,644 0,339
Trinucleotide repeat-containing gene 6B protein Tnrc6b Q8BKI2 RNA-mediated gene silencing 23 25 2,630 0,366
14-3-3 protein epsilon Ywhae P62259 Signaling
recognizes phosphoserine and 
phosphothreonines
6 7 2,476 0,384
Trinucleotide repeat-containing gene 6A protein Tnrc6a Q3UHK8 RNA-mediated gene silencing 13 15 2,471 0,322
Selected reported AGO2 interactors
Fragile X mental retardation syndrome-related protein 1 Fxr1 Q61584 RNA binding 15 13 1,945 0,407
Fragile X mental retardation protein 1 homolog Fmr1 P35922 RNA binding
RNA transport 
translation
11 10 1,927 0,411
Polyadenylate-binding protein 1 Pabpc1 P29341 poly(A) tail of mRNA binding 20 21 1,140 0,769
Poly(A) binding protein, cytoplasmic 4 Pabpc4 Q99LF8 RNA binding 19 19 1,230 0,760
Putative helicase MOV-10 Mov10 P23249 RNA-mediated gene silencing 42 40 1,352 0,766
Nuclease-sensitive element-binding protein 1 Ybx1 P62960 transcription
pre-mRNA splicing
mRNA processing
9 8 1,148 0,776
Insulin-like growth factor 2 mRNA-binding protein 1 Igf2bp1 O88477 mRNA 5'UTR  binding 14 13 1,109 0,839
Insulin-like growth factor 2 mRNA-binding protein 2 Igf2bp2 Q5SF07 mRNA translation
mRNA 5'UTR  binding
14 14 1,113 0,808
Insulin-like growth factor 2 mRNA-binding protein 3 Igf2bp3 Q9CPN8 RNA binding
mRNA translation and stabilty
17 19 1,301 0,762
Regulator of nonsense transcripts 1 Upf1 Q9EPU0 nonsense mediated mRNA decay 47 48 1,452 0,648
Unique Peptides Ratio H/L
Table 2.4.3: List of selected values for proteins of interest identified in AGO2-
containing RNP complexes from Hepa 1-6 cells. A subset of values is given for the top 40
outliers and reported AGO2 interactors. Keywords describing protein functions are added.
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ferences in their proteome as input samples and that this problem can be circumvented
by working with samples from identical or at least very similar cell lines.
The antibody specific cross reactant SEC24C and other vesicle components such as
PDCD6IP and SEC23A and B are the top outliers together with membrane proteins
such as RASA2, CNTNAP1 and SDCBP. The TNRC6 proteins and AGO1 and 3 also
appear as clear outliers (Figure 2.4.8). In combination with the background ratios in the
QUICK approach (see Section 2.4.1), the high ratios for AGO1 and 3 clearly identify the
latter two proteins as cross reactants of the anti-AGO2(6F4) antibody. HSP90, FXR1
and FMR are proteins that have been reported to interact with AGO2 [144, 255] and
these proteins were identified as specifically interacting proteins in this dataset. Another
set of reported interactors including MOV10, YB1, PABPC1, the IGF2BP proteins 1-3
and UPF1 appeared as background binders (Table 2.4.3). An association with AGO1
and 3 cannot explain this binding behavior because, unlike in the QUICK approach,
AGO1 and 3 were detected with high ratios in this experimental setup. Therefore, the
background binding of these established AGO2 interactors was not caused by binding
to other AGO proteins as previously suggested (see Section 2.4.1) but is more probably
based on non-specific interactions with the control antibody or the sepharose matrix.
To investigate this possibility, we analyzed the binding behavior of YB1 and UPF1 by
Western blot analysis (Figure 2.4.9). Proteins were immunoprecipitated from whole cell
lysate of MEF cells with either the anti-AGO2(6F4) or the anti-RmC(16D2) antibody
and the IPs were tested for the presence of AGO2, YB1 and UPF1. AGO2 was present
only in the IP with the anti-AGO2(6F4) antibody but YB1 and UPF were present in
the control IP with the anti-RmC(16D2) antibody as well. Therefore the background
binding behavior of YB1 and UPF1 was based on non-specific binding to the control
antibody or the sepharose matrix.
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Figure 2.4.9: Cross reactivity of the
anti-RMC(16D2) antibody with the
reported AGO2 interacting proteins
YB1 and UPF1. Protein complexes
were immunoprecipitated from wild type
MEFs with the anti-AGO2(6F4) (lane 1)
or the anti-RMC(16D2) antibody (lane 2).
Eluates were analyzed for the presence of
AGO2 (upper panel), YB1 (middle panel)
and UPF1 (lower panel) by Western blot-
ting.
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Taken together, our results on the analysis of endogenous AGO2 complexes (see Sec-
tions 2.4.1, 2.4.2 and 2.4.3) it becomes apparent that our current experimental approach
does not allow a confident identification of the endogenous AGO2 complex components.
Further changes to the experimental setup might enable us to reduce the non-specific
binding of reported AGO2 interactors to the control antibody or the sepharose matrix
and to diminish the influence of the whole proteome on the binding profile. But since the
cross reactivity of the anti-AGO2(6F4) antibody with other AGO proteins is a problem
that cannot be solved without significant time and effort, the project was discontinued.
2.4.4 Characterization of the MicroRNA Dependency of AGO2-Specific
Interactors
Quantitative proteomics cannot only be used for the identification of specific interaction
partners but can be applied to monitor stimulus-specific changes of complex composi-
tion. As described previously, several proteins specifically interacting with AGO2 also
bind non-specifically to the affinity matrix and thereby appear as background binders
(see Sections 2.4.1 and 2.4.3). In addition, the cross reactivity of the anti-AGO2(6F4)
antibody with AGO1 and 3 renders it impossible to define the composition of the basal
AGO2 protein complex since proteins associating with all three AGO proteins can not be
distinguished from those only interacting with AGO2 in the MS analysis. Nevertheless,
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Figure 2.4.10: Experimental setup for the identification of the miRNA-dependency
of AGO2 interactions. AGO2-containing complexes were immunoprecipitated from SILAC
labeled Dicer wild type and Dicer-depleted MEFs with the anti-AGO2(6F4) antibody. Samples
were combined at the elution step and analyzed by MS. Proteins interacting with AGO2 in the
presence of Dicer and miRNAs are expected to show high ratios in the forward and are located in
the lower right quadrant (red area) in a ratio plot. Background binders and Dicer and miRNA-
independent interactors show ratios around one in both experiments and cluster around zero
(green area). Proteins with low forward and high reverse ratios bind to AGO2 preferentially in
the absence of Dicer and miRNAs and appear in the upper left quadrant (yellow area).
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we should theoretically be able to monitor changes of specific AGO interactors in similar
cell lines under different cellular conditions. Performing immunoprecipitations with the
anti-AGO2(6F4) in Dicer wild type and Dicer-depleted MEFs provides a system that
enabled us to study the influence of the presence or absence of Dicer and miRNAs on
the protein composition of endogenous AGO2-containing RNPs.
We carried out AGO2 IPs with the anti-AGO2(6F4) from SILAC-labeled Dicer wild
type and Dicer-depleted cells as depicted in Figure 2.4.10. The quality of the IPs was
checked by Western blotting and Coomassie staining of the eluates (Figure 2.4.11). As
the cellular concentration of AGO2 is decreased in the Dicer-depleted cells, we worked
with an excess of input sample to reach full saturation of the antibody binding capacity
and to facilitate quantitative analysis between the samples. The eluates (Figure 2.4.11B)
showed the typical protein band pattern previously observed for MEFs (see Figure 2.4.2)
and were further processed for MS analysis as described earlier (Section 2.4.1).
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Figure 2.4.11: Immunoprecipitations for the identification of miRNA-dependent
AGO2 interaction partners. A) 0,6% input samples (lanes 1, 3, 6 and 8), supernatants
after IPs (sub. IP, lanes 2, 4, 7 and 9) and 10% eluates (lanes 5 and 10) for forward (lanes
1-5) and reverse (lanes 6-10) experiments were probed for AGO2 (upper panel) and tubulin as
loading control (lower panel) by Western blot. B) Eluates from the forward (lanes 1-2) and
the reverse (lanes 3-4) experiments were separated by one dimensional PAGE and stained with
Coomassie.
With only 374 identified proteins after filtering, this was the smallest dataset we obtained
so far. This can be partly attributed to the fact that the data was measured on a LTQ
Orbitrap, a mass spectrometer which is less sensitive than the LTQ Orbitrap Velos,
which was used for the previous measurements. In this experimental setup AGO2 was
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Figure 2.4.12: Identification of miRNA-dependent interactors in endogenous AGO2-
containing RNPs. Logarithmized normalized ratios from forward and reverse experiments are
plotted. Every dot represents an identified and quantified protein. A selection of proteins of
interest are indicated in color.
precipitated in both IPs and this was reflected by the high sequence coverage of 82%
and around 50 unique peptides per experiment. Dicer was not detected (Table 2.4.4).
We visualized the data in a ratio plot (Figure 2.4.12) and observed a very wide scattering
of the data points. There was no clearly defined background cloud and it was therefore
not possible to define a cut off for the numerous outliers. We observed a mixture of
cytoskeletal, membrane and mitochondrial proteins as outliers in the forward experiment
(Table 2.4.4). Among the background binders we found AGO1 and 3, PABPC, IGF2BP1
and SEC24C. In the reverse experiment, the reported AGO2 interactors HSP90, MOV10,
TNRC6A and B as well as IGF2BP3 were identified as outliers. We also saw mRNA
binding proteins (DHX9 and HNRNPD), the two SEC proteins 16A and 23 and several
membrane proteins in this group. The identification of reported AGO2 interacting and
mRNA binding proteins among the outliers was promising, but the quality of the data,
as indicated by the low number of identified proteins, was too poor to draw reliable
conclusions. Apparently the loss of Dicer and miRNAs changed the whole proteome
significantly and led to the wide scattering of the data points that prevented a separation
of outliers from the background cloud. This was a problem inherent to the experimental
setup and can not be overcome by measuring on an instrument with higher sensitivity.
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Protein Names Gene Names Uniprot ID Keywords forward reverse forward reverse
Bait
Protein argonaute-2 Eif2c2 Q8CJG0 RNA-mediated gene silencing 50 51 1,296 1,769
Cross reactivity
Sec24c protein Sec24c Q8R2V9 COPII vesicle coat component 49 48 1,139 4,835
Top 20 outliers Dicer wild type 
Ltbp2 protein Ltbp2 Q0VD84 unknown function
calcium binding
2 3 19,421 0,085
Caldesmon 1 Cald1 Q8VCQ8 unknown function
actin binding
11 21 16,194 0,068
Phostensin 2310014
H01Rik
Q8BQ30 targets phosphatase 1 to F-actin 2 6 10,197 0,083
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 Plod2 Q9R0B9 collagen modiﬁcation 2 5 9,211 0,155
Filamin-B Flnb Q80X90 connects cell membrane to actin 60 91 8,184 0,258
Cytoskeletal protein Utrn O08614 actin binding 7 37 7,206 0,471
Serine hydroxymethyltransferase Shmt2 Q3TFD0 carbon metabolism 4 4 6,890 0,128
Galectin-1 Lgals1 P16045 beta-galactoside binding
secreted
2 6 6,181 0,250
Cytospin-A Cytsa Q2KN98 cytokinesis
spindle organization
30 49 6,119 0,120
Latent-transforming growth factor beta-binding protein 3 Ltbp3 Q61810-1 TGF signalling, secreted 34 31 5,711 0,701
Transforming growth factor beta-3 Tgfb3 P17125 cell differentiation
secreted
4 4 5,470 0,413
Regulator of nonsense transcripts 1 Upf1 Q9EPU0 nonsense mediated mRNA decay 36 36 5,053 0,640
Ankycorbin Rai14 Q9EP71 cytoskeletal protein 14 25 4,978 0,123
Calreticulin Calr P14211 calcium binding
ER
Trim21 interactor
4 4 4,921 0,303
Nidogen-1 Nid1 P10493 extracellular matrix
lamin associated
3 2 4,645 0,409
Phenylalanine--tRNA ligase alpha chain Farsa Q8C0C7 Aminoacyl-tRNA synthetase 13 10 4,602 0,349
ADP/ATP translocase 2 Slc25a5 P51881 ADP/ATP translocase
mitochondrial
6 7 4,570 0,352
ADP/ATP translocase 1 Slc25a4 P48962 ADP/ATP translocase
mitochondrial
8 8 4,535 0,478
Glypican-4 Gpc4 P51655 cell surface proteglycan 5 6 4,530 0,100
Peptidyl-prolyl cis-trans isomerase A Ppia P17742 protein folding 2 4 4,450 0,533
Top 20 outliers Dicer depleted
Peptidyl-prolyl cis-trans isomerase FKBP5 Fkbp5 Q64378 heteromultimeric cytoplasmic 
complex with HSP90 and HSP70
22 22 0,157 14,289
Heat shock protein HSP 90-alpha Hsp90aa1 P07901 molecular chaperone
ATPase activity
19 21 0,225 11,782
Low-density lipoprotein receptor-related protein 2 Lrp2 A2ARV4 high density lipoprotein
endocytosis
4 5 0,122 10,806
Neurobeachin Nbea Q9EPN1 anchors protein kinase A
to membrane
71 67 0,646 10,233
Prostaglandin E synthase 3 Ptges3 Q9R0Q7 molecular chaperone 3 5 0,258 10,179
Trinucleotide repeat-containing gene 6B protein Tnrc6b Q8BKI2 RNA-mediated gene silencing 57 49 0,631 8,698
Heterogeneous nuclear ribonucleoprotein D0 Hnrnpd Q60668 3'UTR ARE binding 4 4 0,910 8,604
EMILIN-1 Emilin1 Q99K41 cell adhesion, secreted 6 4 0,708 8,353
Sec16a protein Sec16a Q8K000 unknown function
human protein deﬁnes ER exit 
sites
and ER-Golgi trafﬁcking
11 9 0,993 7,453
Heat shock protein 84b Hsp90ab1 Q71LX8 molecular chaperone
ATPase activity
2 2 0,352 6,891
Laminin subunit alpha-5 Lama5 Q61001 cell adhesion, secreted 5 3 0,246 6,416
Histone H3 H3 P68433
P84228
P84244
chromatin 4 4 0,041 6,126
Heterogeneous nuclear ribonucleoprotein A/B Hnrnpab Q99020 transcriptional repressor 6 7 0,918 5,948
E3 ubiquitin-protein ligase TRIM21 Trim21 Q62191 ubiquitin ligase 2 2 0,261 5,338
Trinucleotide repeat-containing gene 6A protein Tnrc6a Q3UHK8 RNA-mediated gene silencing 11 10 0,547 5,241
Histone H4 H4 P62806 chromatin 6 6 0,101 5,199
Protein transport protein Sec23B Sec23b Q9D662 COPII vesicle coat component 33 36 0,724 5,186
Insulin-like growth factor 2 mRNA-binding protein 1 Igf2bp1 O88477 mRNA 5'UTR  binding 4 4 0,230 5,174
Putative helicase MOV-10 Mov10 P23249 RNA-mediated gene silencing 28 24 0,929 4,501
ATP-dependent RNA helicase A Dhx9 O70133 CRD-mediated complex
transcriptional activator
32 35 1,709 4,392
Other AGO proteins
Protein argonaute-1 Eif2c1 Q8CJG1 RNA-mediated gene silencing
transcriptional gene silencing
12 10 4,936 0,283
Protein argonaute-3 Eif2c3 Q8CJF9 RNA-mediated gene silencing 6 6 2,827 0,529
selected reported AGO2 interactors in background
Insulin-like growth factor 2 mRNA-binding protein 3 Igf2bp3 Q9CPN8 RNA binding
mRNA translation and stabilty
4 4 0,546 2,414
Polyadenylate-binding protein 1 Pabpc1 P29341 poly(A) tail of mRNA binding 7 7 2,501 0,762
Poly(A) binding protein, cytoplasmic 4 Pabpc4 Q99LF8 RNA binding 6 5 2,681 0,697
Unique Peptides Ratio H/L 
Table 2.4.4: List of proteins identified in the AGO2 IPs for the identification of
miRNA-dependent interactors from endogenous AGO2-containing RNPs. Selected
values are given for the top 20 outliers, a set of reported AGO2 interactors, identified AGO
proteins and the cross reactant SEC24C. Keywords describing protein functions are added.
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2.5 Identification of AGO2 Interactors from Tagged Protein
Complexes and Characterization of the RNA
Dependency of the Interactions
2.5.1 Establishment of Stable FLAG-HA-tagged AGO2 Expressing MEF
Cell Lines
Our approaches to identify AGO2 specific interaction partners from endogenous protein
complexes revealed the influence of the whole cell proteome on background binding as
one of the major factor preventing a high confidence analysis of AGO2 protein complexes.
A second factor is the cross reactivity of the endogenous antibodies with other proteins
of the AGO family. One solution to address the latter aspect is to work in a tag-
based system. The combination of a FLAG- and HA-tag (F/H-tag) is an established
system for the purification and analysis of AGO-containing ribonucleoprotein complexes
[127, 171, 221, 349].
We established a set of Dicer wild type or Dicer-depleted mouse embryonic fibroblasts
that stably overexpress AGO2 with a FLAG/HA-tag at the N-terminus by using retro-
viral transfection (Figure 2.5.1). Two sets of constructs were used. One contained the
F/H-AGO2 and IRES-GFP as a transfection marker and the other, the control construct,
contained only IRES-GFP. The cells were tested for the stability of the Dicer depletion
during culturing (Figure 2.5.1A). The expression level of F/H-AGO2 was higher in the
Dicer wild type cells than in the Dicer-depleted cells and thereby follows the same trend
as the endogenous AGO2 protein levels (Figure 2.5.1B, middle panel). Tagged protein
could be immunoprecipitated with the FLAG-antibody and AGO2 could be eluted by
incubation with FLAG-peptide (Figure 2.5.1C). The GFP expressing cell lines served
as negative controls for all experiments (Figure 2.5.1A-C). The amount of miRNAs was
not affected by the expression of F/H-AGO2 in the Dicer wild type cells (Figure 2.5.1D)
and an enrichment of miRNAs in the FLAG-IP is only observed for the F/H-AGO2 ex-
pressing Dicer wild type cells. Mature miRNAs were not detected in the Dicer-depleted
MEFs (Figure 2.5.1D). Some small RNA species are independent of Dicer processing,
for example miR-451 [40, 45]. Although miR-451 is not detectable in the MEFs (Anne
Dueck, personal communication) it can not be excluded that other Dicer-independent
small RNAs species are present in the Dicer-depleted cell lines.
This set of cell lines now enabled us to identify AGO2 interaction partners and to study
the Dicer and miRNA requirement of the interactions. By using the FLAG-tag for pu-
rification, we avoided the problem of cross reactivity with other AGO proteins. Since
the F/H-AGO2 expressing cell lines differ from their respective GFP expressing con-
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trol cell lines only in respect to the AGO2 overexpression, the differences in the whole
cell proteome between the cell lines should be only minor and the problems caused by
differently expressed background binders should be significantly reduced.
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Figure 2.5.1: Characterization of the FLAG/HA-tagged AGO2 expressing MEF cell
lines. Wild type (wt) and Dicer-depleted (ko) MEF cells were transduced with retrovirus
carrying FLAG/HA-tagged AGO2 (F/H-AGO2) and GFP or GFP (GFP) alone. A) Cultured
MEFs were genotyped to verify Dicer depletion. Genomic DNA was isolated from cells three
weeks after transduction and amplified by PCR with primers flanking the deleted region in the
Dicer gene. PCR products were visualized by ethidiumbromide stain after size separation in an
agarose gel. B) The expression of F/H-AGO2 was analyzed by Western blot. 30 µg total cell
lysates were probed with anti-HA or anti-AGO2 antibody for detection of F/H-AGO2 (upper
panel) or endogenous AGO2 (middle panel). Tubulin was used as a loading control (lower panel).
C) F/H-AGO2 was immunoprecipitated from total lysate with anti-FLAG agarose beads and
analyzed by Western blot with an anti-HA-antibody. D) RNAs were isolated from lysate or
immunoprecipitated F/H-AGO2-containing RNP complexes and probed for miR-19b (upper
panel). The membrane was stripped and reprobed for U6 to control equal loading of input RNA
(lower panel).
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2.5.2 Characterization of the Protein Composition of AGO2-Containing
Ribonucleoprotein Complexes and Analysis of the miRNA
Dependency of the Interactions
In a first set of experiments, we aimed to define the protein composition of the AGO2
complex. By comparing FLAG-based purifications from the F/H-AGO2 expressing cell
line against the corresponding control cell line, we were able to identify specific in-
teractors with high confidence and to define the protein composition of basal AGO2-
containing RNPs (Figure 2.5.2A). Protein complexes were immunoprecipitated with the
FLAG-antibody from total lysates from SILAC labeled F/H-AGO2 expressing Dicer wild
type MEFs (wt F/H-AGO2) and the control MEF cell line transduced with empty virus
(wt GFP). Samples were combined at the elution step and analyzed by LC-MS/MS
on an LTQ Orbitrap. The experiment was also carried out with the Dicer-depleted
(ko F/H-AGO2 and ko GFP) cell lines. In the next step, we performed experiments
designed to analyze the Dicer and miRNA dependency of the AGO2 interactions. For
this purpose, AGO-containing RNPs from the F/H-AGO2 expressing Dicer wild type
and the Dicer-depleted cells were directly compared against each other analogous to the
approach carried out for the endogenous protein complexes (Figure 2.5.2B). In contrast
to the endogenous approach (see Section 2.4.4), we were looking at a complex with a
known protein composition as our first set of experiments (Figure 2.5.2A) predefined
the composition of the basal AGO2-containing RNP complex. Thus, the proteins which
interact independently of Dicer and miRNAs and therefore show no significant ratios
could be tracked among the background binders.
We identified between 1050 and 1350 proteins per experiment. Between 47 and 60%
passed the filter criteria of at least two unique peptides and two quantification events
per protein. We obtained datasets containing 758, 617 and 641 proteins for the wt F/H-
AGO2 versus wt GFP, ko F/H-AGO2 versus ko GFP and the wt F/H-AGO2 versus ko
F/H-AGO2 experiments, respectively. AGO2 was identified with more than 37 unique
peptides and sequence coverages over 72% in all measurements. Dicer was detected with
at least 25 unique peptides and 22% sequence coverage in the wt F/H-AGO2 versus wt
GFP and the wt F/H-AGO2 versus ko F/H-AGO2 data, indicating that Dicer stably
associates with overexpressed F/H-AGO2. We visualized the data by ratio plots (Fig-
ure 2.5.3) and cluster analysis (Figure 2.5.4). For the cluster analysis, the logarithmized
normalized ratios of proteins identified as specific AGO2 interactors were hierarchically
clustered and the result was displayed as a heat map.
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Figure 2.5.2: Experimental setup for the identification of specific AGO2 interactors
and analysis of the miRNA requirement of the interaction. A) FLAG-antibody was
used for immunoprecipitations of protein complexes from total cell lysates from heavy SILAC
labeled F/H-AGO2 expressing Dicer wild type MEFs (wt F/H-AGO2) and a light labeled control
MEF cell line transduced with GFP only (wt GFP). Immunoprecipitations were carried out for
each SILAC state separately and the beads were combined for elution with 3x FLAG-peptide.
Eluates were separated by SDS-PAGE, digested with trypsin and analyzed by LC-MS/MS. For
the reverse experiment the SILAC label was swapped between the cell lines. The experiments
were also carried out using the F/H-AGO2 expressing Dicer-depleted MEFs (ko F/H-AGO2)
and its corresponding control cell line (ko GFP). In the ratio plot, background binders are
clustered around zero, as highlighted by the grey area. Specific interactors can be found in
the lower right quadrant as indicated by the red area. B) AGO2-containing RNP complexes
were immunoprecipitated with the FLAG-antibody from heavy labeled F/H-AGO2 expressing
Dicer wild type MEFs and light labeled F/H-AGO2 expressing Dicer-depleted MEFs separately.
For the elution with 3xFLAG peptides, the samples were combined and eluates were further
processed as described in A. The reverse experiment with swapped labels was also carried out.
In a ratio plot, interactions that are independent of the presence or absence of miRNAs and
Dicer cluster around zero together with background binders (green sphere). Proteins interacting
preferentially in the presence of miRNAs and Dicer appear in the lower right quadrant (red
sphere) and proteins preferentially interacting with AGO2 in the absence of miRNAs and Dicer
are located in the upper left quadrant (yellow sphere).
More than 90% of the identified proteins could directly be classified as background
binders based on their SILAC ratios around 1, among them the methylosome compo-
nents PRMT5, MEP50 and pICLn. 53 proteins appeared as outliers and were thereby
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Figure 2.5.3: Identification of AGO2-associated proteins and the miRNA-
requirement of the interaction. Logarithmized normalized ratios of forward and reverse
experiments for F/H-AGO2 immunoprecipitations from Dicer wild type (wt), Dicer-depleted
(ko) and Dicer wild type versus Dicer-depleted MEFs are plotted as described in Figure 2.5.2.
Selected proteins binding to AGO2 A) independently of Dicer and miRNAs B) preferentially in
the presence of Dicer and miRNAs and C) preferentially in the absence of Dicer and miRNAs
are indicated in color.
suggested to be specific interactors (Tables 2.5.1, 2.5.2 and 2.5.3). Among the specific in-
teractors more than 85% are RNA binding proteins or are involved in mRNA processing
or degradation, translation or RNA-mediated gene silencing.
We compared our data set to two semiquantitative proteomic data sets for human
F/H-AGO2-containing RNP complexes published by Höck and colleagues [127] and by
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Figure 2.5.4: Hierachical clustering of AGO2-associated proteins and the miRNA
requirement of the interaction. Logarithmized normalized ratios of proteins identified as
AGO2 interactors either in the presence or absence of Dicer and miRNAs were used for clustering.
Proteins included in the cluster analysis were required to have ratios above the cut off manually
deduced from ratio distributions for each individual dataset and had to be identified in at least
four out of the six measurements. Grey squares indicate that the protein was not quantified in an
experiment whereas colors represent the values for the ratios. Red indicates values above, blue
below and white around zero. The forward and reverse ratios for an outlier are characterized
by a red-blue pair in columns one and two or three and four. Dicer- or miRNA-independent
binders show ratios close to zero in the comparative experiment (column 5 and 6). Dicer- or
miRNA-dependent interactors show a red-blue pair in these columns, whereas proteins binding
preferentially in the absence of Dicer or miRNAs show a blue-red pair.
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Figure 2.5.5: Comparison between the SILAC data for mouse and semiquantitative
datasets for human F/H-AGO2-containing RNP complexes. The complete data set
(purple) or outliers (yellow) of the SILAC data for mouse F/H-AGO2-containing RNP complexes
were compared to data published by Höck and colleagues (red) [127] and by Landthaler and
colleagues (blue) [171] for human F/H-AGO2-containing RNP complexes.
Landthaler et al. [171] (Figure 2.5.5). The datasets for human F/H-AGO2 contained
around 30 proteins each and showed an overlap of 33%. When comparing the homo-
logues murine proteins identified in at least two out of three of our SILAC datasets with
both data sets for the human F/H-AGO2 complexes, we saw that our data covered 90%
of the reported interactors from the human datasets. 42% of the proteins reported as
AGO2 interactors in human were identified as outliers and therefore as specific inter-
actors in the SILAC data for mouse AGO2 complexes as well. The other 48% of the
interactors reported by Höck and Landthaler were classified as background binders in
our SILAC approach. Among the outliers identified in our SILAC data, 28% have not
been described as specific interactors of AGO2 so far.
We grouped the specific interactors according to the miRNA and Dicer dependency of
their binding behavior. Among the proteins binding to AGO2 independently of the
presence or absence of Dicer and thus mature miRNAs (Figure 2.5.3A, Table 2.5.1),
we identified the heat shock proteins HSP90-alpha and HSP90-beta and their cochap-
erones FKBP5 and PTGES. HSP90 is involved in loading small RNAs into RISC in
mammals and plants [134, 138, 148] and it regulates AGO2 localization [255]. The
cochaperones FKBP5 and PTGES have not been described in AGO2 complexes before.
Another protein showing miRNA-independent binding behavior is the putative helicase
MOV 10 whose Drosophila homologue Armitage is involved in RISC formation [318].
Other proteins in this group are the mRNA binding proteins IGF2BP 1-3, PUM2, HN-
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Protein Name Gene Name Uniprot ID Keywords
Ratio H/L
forward
Ratio H/L
reverse
Ratio H/L
forward
Ratio H/L
reverse
Ratio H/L
forward
Ratio H/L
reverse
Bait
Protein argonaute-2 Eif2c2 Q8CJG0 RNA-mediated gene silencing 31,401 0,017 35,089 0,021 1,288 0,952
Proteins binding independently of the presence or absence of miRNAs and Dicer
Peptidyl-prolyl cis-trans isomerase FKBP5 Fkbp5 Q64378 heteromultimeric cytoplasmic 
complex with HSP90 and HSP70
55,043 0,016 63,056 0,016 1,377 1,017
Heat shock protein HSP 90-alpha Hsp90aa1 P07901 molecular chaperone
ATPase activity
33,307 0,008 22,783 0,026 0,903 2,010
Heat shock protein 84b Hsp90ab1 Q71LX8 molecular chaperone
ATPase activity
33,102 0,015 16,950 0,044 1,401 1,066
Trinucleotide repeat-containing gene 6A protein Tnrc6a Q3UHK8 RNA mediated gene silencing 29,605 0,027 37,910 0,012 0,878 1,995
Prostaglandin E synthase 3 Ptges3 Q9R0Q7 molecular chaperone 27,236 0,015 36,365 0,017 1,270 1,301
Trinucleotide repeat-containing gene 6B protein Tnrc6b Q8BKI2 RNA-mediated gene silencing 17,280 0,032 9,537 0,075 1,665 1,106
Insulin-like growth factor 2 mRNA-binding protein 1 Igf2bp1 O88477 RNA binding
mRNA translation and stabilty
13,611 0,064 2,622 0,537 0,571 2,068
Putative helicase MOV-10 Mov10 P23249 RNA-mediated gene silencing 12,604 0,053 4,575 0,229 0,645 1,757
Insulin-like growth factor 2 mRNA-binding protein 3 Igf2bp3 Q9CPN8 RNA binding
mRNA translation and stabilty
11,289 0,064 3,601 0,372 1,002 1,452
Enhancer of mRNA-decapping protein 4 Edc4 QQ3UJB9 mRNA decapping no value no value 8,772 0,108 1,043 0,785
Probable ATP-dependent RNA helicase DDX6 Ddx6 P54823 mRNA degradation
mRNA decapping
no value no value 7,152 0,129 1,803 1,118
Pumilio homolog 2 Pum2 Q80U58 mRNA translation and stabilty
mRNA 3'UTR  binding
8,727 0,084 no value no value 1,910 0,635
Insulin-like growth factor 2 mRNA-binding protein 2 Igf2bp2 Q5SF07 mRNA translation
mRNA 5'UTR  binding
6,983 0,112 3,477 0,406 1,023 1,330
Probable ATP-dependent RNA helicase DHX36 Dhx36 Q8VHK9 mRNA degradation 
mRNA deadenylation
6,003 0,125 2,961 0,379 1,165 0,585
Putative ATP-dependent RNA helicase DHX30 Dhx30 Q99PU8 RNA binding
ATP dependent helicase
5,459 0,166 2,308 0,483 1,623 0,454
YTH domain family 2 Ythdf2 Q8K325 unknown function 4,820 0,175 3,732 0,350 no value no value
40S ribosomal protein S14 Rps14 P62264 ribosomal protein 4,387 0,280 4,217 0,298 1,435 0,685
Heterogeneous nuclear ribonucleoprotein L Hnrnpl Q8R081 pre-mRNA binding 4,080 0,198 2,338 0,780 no value no value
Eukaryotic initiation factor 4A-III Eif4a3 Q91VC3 ATP dependent RNA helicase
exon junction complex
4,077 0,319 1,841 1,053 1,350 1,025
Serine-threonine kinase receptor-associated protein Strap Q9Z1Z2 SMN complex 3,996 0,187 1,702 0,836 no value no value
Cold shock domain-containing protein E1 Csde1 Q91W50 RNA binding 3,965 0,208 2,190 0,493 1,179 0,423
40S ribosomal protein S5 Rps5 P97461 ribosomal protein 3,951 0,299 4,169 0,273 1,337 0,740
40S ribosomal protein S19 Rps19 Q9CZX8 ribosomal protein 3,558 0,369 4,152 0,287 1,305 0,827
40S ribosomal protein S3a Rps3a P97351 ribosomal protein 3,337 0,362 4,435 0,294 1,370 0,776
Heterochromatin protein 1-binding protein 3 Hp1bp3 Q3TEA8 unknown function 2,229 0,248 5,788 0,297 0,815 1,439
wt F/H-AGO2
vs.
wt GFP
ko F/H-AGO2
vs.
wt GFP
wt F/H-AGO2
vs.
ko F/H-AGO2
Table 2.5.1: Specific interactors associating with AGO2 independently of the pres-
ence or absence of Dicer and miRNAs. Selected values are summarized for proteins
identified to interact with AGO independently of the presence or absence of Dicer and miRNAs.
Keywords describing reported functions were added.
RNPL, DHX30, several ribosomal proteins (RPS 19, 14, 5 and 3a) and the ARE binding
protein DHX36/RHAU. We also found proteins involved in mRNA decay such as the
decapping complex proteins EDC4 and DDX6/RCK. The AGO2-associated proteins
TNRC6A and TNRC6B also showed a Dicer- and miRNA-independent binding behav-
ior. We characterized several of the newly identified interactors as miRNA-independent
interactors by their ratios, among them the uncharacterized protein YTHDFH2 and
the heterochromatin binding protein HB1BP3. EIF4A3 also belongs to this group. This
ATP-dependent RNA helicase is part of the Exon Junction Complex [38] that is required
for the degradation of aberrant mRNAs through UPF1-mediated NMD [92, 93]. The
two novel AGO2 interacting proteins STRAP/UNRIP [104] and CSDE1/UNR interact
with poly-A binding proteins and are involved in translational repression in Drosophila
[60, 61].
In Figure 2.5.3B and Table 2.5.2, we highlight proteins that bound to AGO2 preferen-
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Protein Name Gene Name Uniprot ID Keywords
Ratio H/L
forward
Ratio H/L
reverse
Ratio H/L
forward
Ratio H/L
reverse
Ratio H/L
forward
Ratio H/L
reverse
Bait
Protein argonaute-2 Eif2c2 Q8CJG0 RNA-mediated gene silencing 31,401 0,017 35,089 0,021 1,288 0,952
Proteins preferentially binding in the presence of miRNAs and Dicer
Trinucleotide repeat-containing gene 6C protein Tnrc6c Q3UHC0 RNA-mediated gene silencing 23,986 0,050 no value no value 13,655 0,161
Endoribonuclease Dicer Dicer Q8R418 RNA-mediated gene silencing 16,371 0,037 no value no value 11,599 0,115
Regulator of nonsense transcripts 1 Upf1 Q9EPU0 nonsense mediated mRNA decay 10,406 0,085 2,786 0,411 2,350 0,294
Matrin-3 Matr3 Q8K310 RNA binding
nuclear matrix
7,601 0,081 no value no value 1,867 0,378
RISC-loading complex subunit TARBP2 Tarbp2 P97473 RNA-mediated gene silencing 7,550 0,066 no value no value 5,522 0,403
Nuclease-sensitive element-binding protein 1 Ybx1 P62960 transcription
pre-mRNA splicing
mRNA processing
7,006 0,158 3,917 0,348 4,475 0,300
Polyadenylate-binding protein 1 Pabpc1 P29341 poly(A) tail of mRNA binding 6,248 0,142 2,471 0,549 2,908 0,408
Constitutive coactivator of PPAR-gamma-like protein 1 FAM120A Q6A0A9 RNA binding
oxidative stress
6,071 0,129 2,512 0,516 1,861 0,385
ELAV-like protein 1 Elavl1 P70372 AU-rich element binding 5,352 0,204 2,716 0,530 4,400 0,325
Cold shock domain-containing protein A Csda Q9JKB3 mRNA binding
translational repression
transcription
5,349 0,144 no value no value 2,444 0,229
Poly(A) binding protein, cytoplasmic 4 Pabpc4 Q99LF8 RNA binding 5,161 0,178 2,166 0,651 3,487 0,311
Heterogeneous nuclear ribonucleoproteins C1/C2 Hnrnpc Q9Z204 pre-mRNA binding
mRNA binding
5,136 0,093 1,691 0,919 2,079 0,446
ATP-dependent RNA helicase A Dhx9 O70133 transcription
RNA binding
helicase
4,962 0,099 1,676 0,764 2,539 0,685
La-related protein 1 Larp1 Q6ZQ58 RNA binding 4,932 0,169 1,718 0,581 2,564 0,464
Fragile X mental retardation syndrome-related protein 1 Fxr1 Q61584 RNA binding 4,897 0,191 2,945 0,386 2,713 0,469
Fragile X mental retardation syndrome-related protein 2 Fxr2 Q9WVR4 RNA binding 4,806 0,190 2,855 0,360 no value no value
Heterogeneous nuclear ribonucleoprotein U-like protein 1 Hnrnpul1 Q8VDM6 transcription
mRNA processing and transport
4,388 0,161 no value no value 2,087 0,438
Gem-associated protein 5 Gemin5 Q8BX17 RNA binding
SMN complex
4,279 0,251 1,407 0,744 5,662 0,232
Heterogeneous nuclear ribonucleoprotein D Hnrnpd Q60668 3'UTR ARE binding 4,199 0,235 no value no value 3,539 0,489
Gem (Nuclear organelle) associated protein 4 Gemin4 Q8K1K1 RNA binding
SMN complex
3,916 0,257 no value no value 2,172 0,267
Fragile X mental retardation protein 1 homolog Fmr1 P35922 RNA binding
RNA transport 
translation
3,849 0,232 2,270 0,527 5,165 0,231
Polypyrimidine tract binding protein 1 Ptbp1 P17225 pre-mRNA splicing 3,812 0,236 no value no value 2,834 0,306
wt F/H-AGO2
vs.
wt GFP
ko F/H-AGO2
vs.
wt GFP
wt F/H-AGO2
vs.
ko F/H-AGO2
Table 2.5.2: Specific interactors preferentially associating with AGO2 in the absence
of Dicer and miRNAs. Selected values are summarized for proteins identified as specific
AGO2 interactors and keywords describing reported functions were added.
tially in the presence of Dicer and miRNAs. As expected, we found Dicer and its cofac-
tor TARBP2 [43, 114] in this group, but we did not identify the reported Dicer cofactor
PACT [167, 178] in any of the datasets. In contrast to the binding behavior of its paralogs
TNRC6A and B, the interaction between TNRC6C and AGO2 seemed to be Dicer- and
miRNA- dependent. The RNA helicase A/DHX9 has been implicated in siRNA load-
ing [278] and is the only protein involved in RISC assembly that showed miRNA or
Dicer dependency. A number of RNA binding proteins including YB1, Gemin 4 and 5,
HNRNPC and HNRNPUL were found in this group along with the ARE binding proteins
HNRNPD/AUF1 and ELAVL1/HuR, the cytoplasmic poly-A binding proteins 1 and 4,
the mitochondrial protein Matrin3 as well as UPF1. The latter is involved in nonsense
mediated mRNA decay and has been reported to function in the miRNA pathway [143].
The fragile X mental retardation protein and its paralog FXR2 have been reported to
associate with AGO [37, 136] and Dicer activity [144] and the paralog FXR1 is involved
in miRNA-regulated upregulation of translation [331, 332]. We also identified these
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Protein Name Gene Name Uniprot ID Keywords
Ratio H/L
forward
Ratio H/L
reverse
Ratio H/L
forward
Ratio H/L
reverse
Ratio H/L
forward
Ratio H/L
reverse
Bait
Protein argonaute-2 Eif2c2 Q8CJG0 RNA-mediated gene silencing 31,401 0,017 35,089 0,021 1,288 0,952
Proteins preferentially binding in the absence of miRNAs and Dicer
Putative uncharacterized protein Herc6 Q3UEA7 E3 ubiquitin-protein ligase
ISGylation
1,690 0,040 28,888 0,022 0,109 1,732
Protein argonaute-3 Eif2c3 Q8CJF9 RNA-mediated gene silencing 2,976 0,176 13,360 0,129 no value no value
Clathrin heavy chain 1 Cltc Q68FD5 vesicel coating 1,537 0,507 10,934 0,068 0,360 2,680
60 kDa SS-A/Ro ribonucleoprotein RoRNP O08848 RNA binding protein no value no value 8,421 0,153 0,512 1,990
Zinc ﬁnger protein 521 Znf521 Q6KAS7 transcription factor 0,923 1,034 3,739 0,261 0,484 3,891
wt F/H-AGO2
vs.
wt GFP
ko F/H-AGO2
vs.
wt GFP
wt F/H-AGO2
vs.
ko F/H-AGO2
Table 2.5.3: Specific interactors preferentially associating with AGO2 in the pres-
ence of Dicer and miRNAs. Selected values are summarized for proteins identified as specific
AGO2 interactors. Keywords describing reported functions were added.
proteins as Dicer- and miRNA-dependent AGO2 interactors. Among the newly iden-
tified AGO2 interacting proteins, we observed a preference for binding in the presence
of miRNAs for the PABPC1-binding protein LARP1 [34], the mRNA binding protein
FAM120A/Ossa, the YB1-associating protein PTBP1 [46] and for CSDA, a protein that
shares cellular functions with YB1 [201].
The third group contains proteins that preferentially interacted with AGO2 in the ab-
sence of Dicer or miRNAs (Figure 2.5.3C, Table 2.5.3) and which are hereby described
for the first time. In this group we found the RNA binding protein RoRNP [21], the zinc
finger protein ZNF521 [28] and the vesicle coat protein Clathrin (CLTC). It was very
interesting to see that AGO3 showed an increased association with AGO2 in the absence
of Dicer and miRNAs. We also identified HERC6, a HECT-type E3 protein ligase that
mediates conjugation of ISG15 to target proteins in human [351] in this group.
2.5.3 AGO2 Associates with Large RNAs Independently of the Presence
or Absence of Dicer and Mature miRNAs
Our data revealed a high number of RNA binding proteins in complex with AGO2. The
RNA binding proteins PUM2, IGF2BP1-3 and TNRC6A-C have been studied in respect
to their bound mRNAs [115] recently and the role of the TNRC6 proteins in miRNA-
dependent gene silencing is well established [324]. An analysis of PUM2-RNA target sites
showed that these are enriched around predicted miRNA binding sites, which suggests a
link between PUM2 and the miRNA pathway [91]. To our surprise, we noticed that these
and other RNA binding proteins show a miRNA-independent binding behavior. If these
proteins associate with AGO2 in an RNA-dependent manner as it has been reported for
IGF2BP1 and 3 [127], this strongly suggests that AGO2 associates with large RNAs in
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Figure 2.5.6: RNA-binding behavior of AGO2 in Dicer wild type and Dicer-depleted
MEFs. A) AGO2-containing RNP complexes were precipitated from equal amounts of whole cell
lysate from Dicer wild type (lanes 2-4) and Dicer-depleted (lanes 8-10) F/H-AGO2 expressing
MEFs or from the corresponding GFP-expressing control cell lines (lanes 5-7 and 11-13) with
(lanes 4, 7, 10 and 13) or without (lanes 3, 6, 9 and 12) RNase A treatment. RNA was
isolated from immunoprecipitates and lysates and visualized by ethidiumbromide staining after
size separation in an agarose gel (upper panel). The presence of AGO2 in the samples was
analyzed by Western blot (middle panel). Tubulin was used as a loading control in the Western
blot analysis (lower panel). B) A fraction of the extracted RNA samples were reverse transcribed
into DNA using an oligo-(dT) primer. The first strand cDNA was separated according to size
in an agarose gel and visualized by staining with ethidiumbromide.
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the absence of Dicer and mature miRNAs. To test this hypothesis, we immunoprecipi-
tated F/H-AGO2-containing RNP complexes from the F/H-AGO2 expressing Dicer wild
type and Dicer-depleted MEF cell lines and extracted the bound RNAs (Figure 2.5.6A).
To be able to distinguish specifically bound RNAs from background, we used two dif-
ferent controls. First, we used the GFP expressing control cell lines and second, IPs
were treated with RNase A to completely degrade all contained RNAs. The RNAs were
analyzed in an agarose gel stained with ethidiumbromide (upper panel) and the AGO2
amount was assesed by Western blot analysis (middle panel). It is clearly visible that a
significant amount of large RNAs is bound to AGO2 in the Dicer depleted cells (lane 9),
suggesting that AGO2 may stably associate with large RNAs in the absence of miRNAs.
To analyze whether the large RNAs coprecipitating with AGO2 are polyadenylated, the
extracted RNAs were reverse transcribed into cDNA with oligo-d(T) primers and ana-
lyzed in an agarose gel stained with ethidiumbromide (Figure 2.5.6B). The detection of
oligo-d(T) primed cDNAs in the untreated IPs from the Dicer-wild type as well as the
Dicer-depleted cells suggests that the large RNAs associated with AGO2 in the absence
of Dicer and miRNAs contain polyadenylated RNAs.
2.5.4 The large RNA and MicroRNA Dependency of AGO2 Interactions
Is Not Coupled
The observation that RNA binding proteins might associate with AGO2 through larger
RNAs bound independently of miRNAs sheds a new light on the role of large RNAs on the
protein composition of AGO2-containing RNPs. To be able to analyze the dependency
of the specific AGO2 interactors on the presence of large RNAs without disturbing the
influence of miRNAs on the binding behavior, it was necessary to establish conditions
under which large RNAs are completely degraded and miRNAs are still intact.
F/H-AGO2-containing RNPs were isolated from Dicer wild type or Dicer-depleted MEFs
and treated with RNAse A for either 20min or 4 h at 4°C prior to the washing steps.
RNAs were isolated and analyzed by Northern Blotting (Figure 2.5.7). After RNAse A
treatments, no miRNAs were detected in the supernatants of the IPs. For the RNAse A
treated IPs, we saw a strong influence of the duration of the treatment on miRNA
stability. After a short treatment, the amount of miRNAs was only slightly reduced
compared to the untreated sample whereas a long treatment led to a strong reduction
of miRNAs. However, longer RNA species were effectively degraded with both the long
and the short RNAse A treatment. This experiment established a 20min long treatment
with 100µg/ml RNase A at 4°C as suitable conditions for the analysis of the large RNA
requirement without interfering with miRNA binding and stability.
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Figure 2.5.7: Analysis of large RNA and miRNA degradation by RNase A treat-
ment. AGO2-containing RNP complexes were precipitated from whole cell lysate from Dicer
wild type (lanes 1-5 and 11-15) or Dicer-depleted (lanes 6-10 and 16-20) F/H-AGO2 expressing
MEFs with (lanes 3, 5, 8, 10 and 13, 15, 18 and 19) or without (lanes 2, 4, 7, 9 and 12, 14, 17
and 20) treatment with 100µg/ml RNase A for 20min (left panel) or 4 h (right panel) at 4°C.
RNA was isolated from lysate or immunoprecipitated F/H-AGO2, separated by 12% denaturing
PAGE and visualized by ethidiumbromide staining (upper panel). The RNA was then blotted
and probed for miR-19b (second panel). The membrane was stripped and reprobed with U6 to
control equal loading of input RNA (third panel). The presence of AGO2 in the samples was
analyzed by Western blot (fourth panel). Tubulin was used as a loading control in the Western
blot analysis (lowest panel).
As observed previously (Figure 2.5.1B), the expression level of F/H-AGO2 was lower in
the Dicer-depleted cells, which was compensated by increasing the amount of input sam-
ple to achieve full saturation of the binding capacity of the antibody for all experiments.
The short RNase A treatment did not influence the amount of AGO2 protein in the IP
but after the long treatment less AGO2 was present in the eluates. This observation is
another indication for the importance of miRNA abundance on AGO2 stability.
We modified our SILAC based experimental set up for the analysis of the large RNA
dependency of the interactions as shown in Figure 2.5.8. Immunoprecipitations for the
isolation of AGO2-containing mRNPs were carried out from SILAC labeled F/H-AGO2
expressing Dicer wild type MEFs for each SILAC label separately as described before.
To be able to see a large RNA dependency of the interaction, we degraded the RNA in
the IP from the light labeled cells by treatment with RNase A for 20min at 4°C directly
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Figure 2.5.8: Experimental setup for the analysis of large RNA-dependent binding
behavior of AGO2 interactors. The experimental setup shown in Figure 2.5.2 was adapted
to analyze the large RNA dependency of the AGO2 interaction. F/H-AGO2-containing RNP
complexes were immunoprecipitated from total cell lysates from SILAC labeled, F/H-AGO2-
expressing Dicer wild type (wt F/H-AGO2) MEFs. One sample was treated with RNase A
and beads were combined for elution after washing. For the reverse experiment, the label of
the RNAse A treated sample was swapped. The large RNA-dependent AGO2 interactors are
expected to show high H/L ratios in the forward and low ratios in the reverse experiment.
Background binders show ratios around one in both experiments. The experiments were also
carried out using the F/H-AGO2 expressing Dicer-depleted MEFs.
before the washing steps. The heavy labeled sample was not treated with RNase A
and contained intact large RNAs. For the reverse experiments the heavy labeled sample
was treated with RNAse A. The experiment was also carried out with the F/H-AGO2
expressing Dicer-depleted MEF cell line.
With 985 identifications the number of identified proteins in the Dicer-depleted cell line
(ko F/H-AGO2, 20min RNAse A treated) was lower then in the Dicer wild type cell
lines (wt F/H-AGO2, 20min RNAse A treated, 1074 identified proteins) as it was also
the case for the previous experiments. We obtained 681 identifications in the Dicer wild
type and 520 in the Dicer-depleted cell lines after filtering. We focused the analysis on
those proteins already identified as potential interactors in previous experiments (see
Section 2.5.2). The identification and quantification for the interactors was better in
the data from the Dicer wild type cells than in the data set from the Dicer-depleted
and reflects the higher number of identifications (Table 2.5.4). Seven interactors (EDC4,
DDX6, FXR2, TARBP2, RoRNP, HERC6 and PUM2) either did not pass the filter
criteria or were not identified at all in the datasets. All of these proteins had either
low peptide numbers or were not identified in all of the measurements for the miRNA
dependency experiment.
For the identified specific interactors, the data was visualized in ratio plots (Figure 2.5.9)
and a heat map (Figure 2.5.10). In the heat map no cut off was set but only interactors
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Protein Name Gene Name Uniprot ID
Ratio H/L 
forward
Ratio H/L
 reverse
Ratio H/L
forward
Ratio H/L
reverse
Bait
Protein argonaute-2 Eif2c2 Q8CJG0 0,964 1,077 0,988 1,030
large RNA dependent interactors
ELAV-like protein 1 Elavl1 P70372 23,522 0,075 no value 0,047
Heterogeneous nuclear ribonucleoprotein L Hnrnpl Q8R081 18,787 0,039 11,405 0,040
Putative helicase MOV-10 Mov10 P23249 17,880 0,026 15,032 0,084
Nuclease-sensitive element-binding protein 1 Ybx1 P62960 16,441 0,042 8,083 0,115
Insulin-like growth factor 2 mRNA-binding protein 1 Igf2bp1 O88477 16,224 0,028 13,345 0,043
Heterochromatin protein 1-binding protein 3 Hp1bp3 Q3TEA8 15,491 0,091 8,570 0,114
Insulin-like growth factor 2 mRNA-binding protein 3 Igf2bp3 Q9CPN8 15,403 0,040 10,633 0,058
Cold shock domain-containing protein A Csda Q9JKB3 14,131 0,035 no value no value
Insulin-like growth factor 2 mRNA-binding protein 2 Igf2bp2 Q5SF07 13,066 0,046 10,980 0,064
Probable ATP-dependent RNA helicase DHX36 Dhx36 Q8VHK9 12,600 0,042 6,981 0,117
Poly(A) binding protein, cytoplasmic 4 Pabpc4 Q99LF8 11,727 0,071 6,775 0,117
Polyadenylate-binding protein 1 Pabpc1 P29341 10,879 0,071 5,477 0,118
Regulator of nonsense transcripts 1 Upf1 Q9EPU0 9,236 0,081 6,314 0,133
Heterogeneous nuclear ribonucleoprotein U-like protein 1 Hnrnpul1 Q8VDM6 9,222 0,088 no value no value
Heterogeneous nuclear ribonucleoproteins C1/C2 Hnrnpc Q9Z204 7,047 0,112 no value no value
La-related protein 1 Larp1 Q6ZQ58 6,910 0,107 4,889 0,189
40S ribosomal protein S14 Rps14 P62264 6,142 0,161 5,439 0,170
Polypyrimidine tract binding protein 1 Ptbp1 P17225 4,806 0,224 no value no value
Constitutive coactivator of PPAR-gamma-like protein 1 FAM120A Q6A0A9 4,762 0,186 2,808 0,299
ATP-dependent RNA helicase A Dhx9 O70133 4,561 0,233 1,856 0,498
Eukaryotic initiation factor 4A-III Eif4a3 Q91VC3 4,505 0,202 1,350 0,583
Putative ATP-dependent RNA helicase DHX30 Dhx30 Q99PU8 4,105 0,219 no value no value
Fragile X mental retardation protein 1 homolog Fmr1 P35922 3,847 0,245 no value 0,430
Matrin-3 Matr3 Q8K310 3,789 0,201 2,140 0,331
Proteins binding preferntially in the presence of large RNAs
40S ribosomal protein S19 Rps19 Q9CZX8 3,604 0,319 3,291 0,332
Fragile X mental retardation syndrome-related protein 1 Fxr1 Q61584 3,208 0,276 1,885 0,601
40S ribosomal protein S5 Rps5 P97461 3,115 0,356 2,764 0,374
Gem-associated protein 5 Gemin5 Q8BX17 2,181 0,383 0,792 1,100
Heterogeneous nuclear ribonucleoprotein D Hnrnpd Q60668 2,139 0,397 no value no value
Gem (Nuclear organelle) associated protein 4 Gemin4 Q8K1K1 1,918 0,462 0,756 1,205
YTH domain family 2 Ythdf2 Q8K325 1,915 0,329 no value 0,326
Serine-threonine kinase receptor-associated protein Strap Q9Z1Z2 1,591 0,458 no value no value
Cold shock domain-containing protein E1 Csde1 Q91W50 1,569 0,437 1,512 0,648
direct interactors
Clathrin heavy chain 1 Cltc Q68FD5 1,152 0,991 0,911 1,024
Zinc ﬁnger protein 521 Znf521 Q6KAS7 1,027 0,864 0,810 0,785
Heat shock protein HSP 90-alpha Hsp90aa1 P07901 1,005 1,096 1,007 1,055
Heat shock protein 84b Hsp90ab1 Q71LX8 1,003 1,118 1,018 1,084
Endoribonuclease Dicer Dicer Q8R418 0,992 0,843 no value no value
Protein argonaute-3 Eif2c3 Q8CJF9 0,990 1,059 no value no value
Peptidyl-prolyl cis-trans isomerase FKBP5 Fkbp5 Q64378 0,973 1,147 0,980 0,968
Prostaglandin E synthase 3 Ptges3 Q9R0Q7 0,960 1,345 0,861 1,242
Trinucleotide repeat-containing gene 6C protein Tnrc6c Q3UHC0 0,916 1,101 no value no value
Trinucleotide repeat-containing gene 6B protein Tnrc6b Q8BKI2 0,894 1,080 0,784 1,073
Trinucleotide repeat-containing gene 6A protein Tnrc6a Q3UHK8 0,865 0,975 0,836 0,896
wt F/H-AGO2
20 min RNAse A treated
ko F/H-AGO2
20 min RNAse A treated
Table 2.5.4: Large RNA dependency of specific AGO2 interaction partners. Selected
values are listed for proteins previously identified as specific AGO2 interactors. The data was
visualized by ratio plots (Figure 2.5.9) and a heat map (Figure 2.5.10).
identified in at least two out of the four measurements were included. Proteins were
not clustered but displayed in the heat map according to the ratios of the forward ex-
periment ratios in the Dicer wild type cells. Interactors associating with AGO2 in a
large RNA-dependent way appeared as outliers in the lower right quadrant in ratio plots
and showed intensively colored red-blue ratio pairs in the heat map. The binding of the
interactors that bind to AGO2 via protein-protein interactions was not affected by the
RNase A treatment and therefore these proteins appeared together with the background
binders in the ratio plots and showed white or weak coloring in the heat map.
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Figure 2.5.9: Ratio plots for the large RNA requirement of AGO2 interacting pro-
teins. Normalized H/L ratios were plotted as described in Figure 2.5.8. Every dot represents
an identified and quantified protein. Selected proteins are indicated in color.
We saw a high number of proteins that associate with AGO2 in a strongly large RNA-
dependent manner. In this group we found many RNA binding proteins including
IGF2BP1-3, RHAU/DHX36, PUM2, DHX30, HNRNPL, HNRNPUL and the riboso-
mal proteins RPS14 and RPS3a. Other large RNA-dependent binders were MOV10
and HP1BP3. All these proteins showed a miRNA-independent binding behavior and
therefore associated with AGO2 via large RNAs bound to AGO2 independently of the
presence or absence of miRNAs.
Among the Dicer- and miRNA-dependent interactors, UPF1, FAM120A, PTBP1, YB1,
CSDA, FMR, HNRNPD/AUF1, ELAVL1/HuR, Matrin3, HNRNPC and LARP1 exhib-
ited a strong large RNA requirement for their association with AGO2. PABPC1 and 4
also associated with AGO2 in a large RNA-dependent way. This binding behavior in-
dicates that they associated with AGO2 via large RNAs bound to AGO2 only in the
presence of miRNAs and Dicer.
A group of proteins showed a preference for binding to AGO2 when large RNAs were
present. Here, we saw members of the group of miRNA-independent binders (RPS19
and 5, YTHDF2, STRAP and CSDE1) and the miRNA-dependent interactors FXR1,
HNRNPD/AUF1 as well as Gemin 4 and 5. This subgroup appeared to be enriched
on large RNAs specifically bound by AGO2 in the presence of miRNAs and Dicer but
could also be found on large RNAs associated with AGO2 in the absence of miRNAs
and Dicer.
A set of proteins associated with AGO2 in a large RNA-independent manner. This
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Figure 2.5.10: Heat map analysis of the large RNA requirement of AGO2 interac-
tions. The normalized H/L ratios are displayed in form of a heat map. Red indicates values
above, blue below and white around zero. Grey squares indicate that the protein was not quanti-
fied in the experiment. The color intensity indicates the strength of the large RNA dependency.
Proteins were not clustered but sorted according to the ratio in the forward experiment for the
Dicer-wild type sample.
includes the TNRC6 proteins that directly interact with AGO2 via their N-terminal
GW-repeat containing region [324]. This direct interaction did not require Dicer and
miRNAs for TNRC6A and B. TNRC6C on the other hand showed a strong dependency
on Dicer and miRNAs. Dicer and AGO2 interact directly via the AGO PIWI-box and
the RNase III domain of Dicer [311], so this interaction is also clearly RNA-independent.
Other Dicer- and miRNA-independent interactors directly associating with AGO2 in an
RNA independent manner were the HSP90 alpha and beta proteins with their cochap-
erones PTGES and FKBP5. Among the interactors preferentially binding to AGO2 in
the absence of Dicer and miRNAs, only AGO3, CLTC and ZNF521 were identified in
the datasets and they all showed a direct protein-protein binding behavior.
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Figure 2.5.11: Ratio plots for the large RNA requirement of AGO2 interacting pro-
teins after long RNase A treatment. H/L ratios were plotted as described in Figure 2.5.8.
Selected proteins are indicated in color.
For the two proteins DHX9 and eIF4AIII the ratios between the data sets from wild
type and Dicer-depleted cells showed an inconsistency, making it impossible to clearly
define their binding behavior. According to the ratios they are strongly RNA-dependent
binders in the wild type cells but in the Dicer-depleted cells they showed only weak
large RNA dependency (Table 2.5.4 and Figure 2.5.10). This could be attributed to
the quality differences of the data sets or it might indicate that the two proteins have
different functions in the presence and absence of mature miRNAs and Dicer.
To be able to compare the influence of the duration of the RNase A treatment on the
stability of the AGO2-containing RNPs, we measured samples treated with RNase A for
4 h in the same setup as for the samples treated for 20min only. The datasets were of
comparable size (1169 and 1202 identifications for the Dicer wild type (F/H-AGO2 wt,
4 h RNAse A treated) and Dicer-depleted (F/H-AGO2 ko, 4 h RNAse A treated) cell
lines, respectively) and over 50% of identified proteins passed the filter criteria. Final
datasets contained 679 proteins in the Dicer wild type and 647 proteins in the Dicer-
depleted experiments. In the visualization of the data as ratio plots (Figure 2.5.11),
we observed scattering of the datapoints and tailing into the upper left quadrant. This
tailing is very strong for the experiment in the Dicer wild type cells and is an indication
for significant changes in protein composition in the sample upon degradation of miRNAs
and large RNAs.
Despite comparable or even higher numbers of proteins in the datasets, the number
of previously identified AGO2 interactors was lower than in the samples treated with
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Protein Name Gene Name Uniprot ID
Ratio H/L 
forward
Ratio H/L
 reverse
Ratio H/L
forward
Ratio H/L
reverse
Bait
Protein argonaute-2 Eif2c2 Q8CJG0 0,980 1,011 0,964 0,999
large RNA dependent interactors
ELAV-like protein 1 Elavl1 P70372 28,757 0,029 17,041 0,049
Heterogeneous nuclear ribonucleoprotein L Hnrnpl Q8R081 10,390 0,117 11,460 0,047
Putative helicase MOV-10 Mov10 P23249 10,340 0,104 14,660 0,051
Nuclease-sensitive element-binding protein 1 Ybx1 P62960 5,079 0,375 9,116 0,057
Insulin-like growth factor 2 mRNA-binding protein 1 Igf2bp1 O88477 14,699 0,058 13,349 0,035
Heterochromatin protein 1-binding protein 3 Hp1bp3 Q3TEA8 2,749 1,396 6,877 0,092
Insulin-like growth factor 2 mRNA-binding protein 3 Igf2bp3 Q9CPN8 10,409 0,104 8,999 0,058
Cold shock domain-containing protein A Csda Q9JKB3 no value no value no value no value
Insulin-like growth factor 2 mRNA-binding protein 2 Igf2bp2 Q5SF07 10,365 0,123 7,982 0,068
Probable ATP-dependent RNA helicase DHX36 Dhx36 Q8VHK9 4,757 0,312 4,804 0,122
Poly(A) binding protein, cytoplasmic 4 Pabpc4 Q99LF8 10,490 0,083 7,738 0,074
Polyadenylate-binding protein 1 Pabpc1 P29341 9,887 0,089 6,968 0,093
Regulator of nonsense transcripts 1 Upf1 Q9EPU0 12,494 0,069 7,344 0,081
Heterogeneous nuclear ribonucleoprotein U-like protein 1 Hnrnpul1 Q8VDM6 3,317 0,350 no value no value
Heterogeneous nuclear ribonucleoproteins C1/C2 Hnrnpc Q9Z204 1,542 1,226 no value no value
La-related protein 1 Larp1 Q6ZQ58 6,205 0,182 5,786 0,123
40S ribosomal protein S14 Rps14 P62264 0,512 2,412 1,451 0,423
Polypyrimidine tract binding protein 1 Ptbp1 P17225 3,630 0,321 no value no value
Constitutive coactivator of PPAR-gamma-like protein 1 FAM120A Q6A0A9 2,223 0,458 no value no value
ATP-dependent RNA helicase A Dhx9 O70133 0,376 4,483 1,066 0,729
Eukaryotic initiation factor 4A-III Eif4a3 Q91VC3 1,471 1,181 0,860 0,833
Putative ATP-dependent RNA helicase DHX30 Dhx30 Q99PU8 0,277 5,592 0,535 0,713
Fragile X mental retardation protein 1 homolog Fmr1 P35922 no value no value no value no value
Matrin-3 Matr3 Q8K310 4,743 0,226 2,637 0,231
Proteins binding preferntially in the presence of large RNAs
40S ribosomal protein S19 Rps19 Q9CZX8 0,866 3,072 1,744 0,343
Fragile X mental retardation syndrome-related protein 1 Fxr1 Q61584 0,139 9,027 0,277 1,670
40S ribosomal protein S5 Rps5 P97461 0,812 3,183 1,685 0,339
Gem-associated protein 5 Gemin5 Q8BX17 1,132 0,822 0,685 1,100
Heterogeneous nuclear ribonucleoprotein D Hnrnpd Q60668 1,627 0,685 no value no value
Gem (Nuclear organelle) associated protein 4 Gemin4 Q8K1K1 no value no value 0,551 1,320
YTH domain family 2 Ythdf2 Q8K325 1,668 0,581 no value no value
Serine-threonine kinase receptor-associated protein Strap Q9Z1Z2 no value no value no value no value
Cold shock domain-containing protein E1 Csde1 Q91W50 0,463 3,007 no value no value
direct interactors
Clathrin heavy chain 1 Cltc Q68FD5 0,569 2,627 0,693 1,192
Zinc ﬁnger protein 521 Znf521 Q6KAS7 no value no value 0,753 0,882
Heat shock protein HSP 90-alpha Hsp90aa1 P07901 1,051 0,968 0,936 0,990
Heat shock protein 84b Hsp90ab1 Q71LX8 1,020 0,978 0,966 1,030
Endoribonuclease Dicer Dicer Q8R418 1,836 0,470 no value no value
Protein argonaute-3 Eif2c3 Q8CJF9 no value no value no value no value
Peptidyl-prolyl cis-trans isomerase FKBP5 Fkbp5 Q64378 1,021 0,927 0,965 1,157
Prostaglandin E synthase 3 Ptges3 Q9R0Q7 1,839 0,505 0,974 1,097
Trinucleotide repeat-containing gene 6C protein Tnrc6c Q3UHC0 0,812 1,095 no value no value
Trinucleotide repeat-containing gene 6B protein Tnrc6b Q8BKI2 0,875 1,050 0,779 1,062
Trinucleotide repeat-containing gene 6A protein Tnrc6a Q3UHK8 0,905 0,704 0,905 0,704
wt F/H-AGO2
4 h RNAse A treated
ko F/H-AGO2
4 h RNAse A treated
Table 2.5.5: Large RNA requirement of specific AGO2 interaction partners after
long RNase A treatment. Selected values are listed for proteins previously analyzed in
Table 2.5.4. The data was visualized in the ratio plots in Figure 2.5.11.
RNAse A for only 20min (Table 2.5.5). The majority of the identified specific AGO2 in-
teractors showed the same large RNA dependency as in the samples with the short RNase
treatment, for example PABPC1, MOV10 and YB1 (strong large RNA dependency) and
TNRC6A (direct protein-protein interaction). However, in the group of proteins classi-
fied to bind preferentially in the presence of large RNAs, the deviation of the binding
behavior between the short and the long RNAse A treatment is quite strong. One ex-
ample is the protein FXR1, which was shown to bind to AGO2 preferentially in the
presence of Dicer and miRNAs in our previous experiments. FXR1 was shifted into the
upper left quadrant in the long RNase A treated samples, which is an indication for an
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increased binding to AGO2 in the absence of large RNAs and the decreased abundance
of miRNAs. In the short RNase A treated samples, FXR1 appeared in the lower right
quadrant and was classified to bind preferentially in the presence of large RNAs (see
Figure 2.5.9 and Table 2.5.4). RPS5, a protein associating with AGO2 independently
of the presence of absence of miRNAs and Dicer, showed a weak large RNA-dependent
binding behavior in the short RNase A treated samples as well as in the long RNAse
A treated samples from the Dicer-depleted cells. Contrary to the similar behavior in
those three samples, RPS5 was shifted into the upper left quadrant in the long RNAse A
treated Dicer wild type sample. Taken together, these observations suggested that the
long treatment with RNase A leading to the degradation of miRNAs within the AGO2
protein did not only lead to the destabilization of Dicer- and miRNA-dependent interac-
tions and a reduced stability of AGO2 itself (see Figure 2.5.7) but might also destabilize
miRNA-independent interactions. It is possible that, as indicated by the low number of
reported interactors identified in this experiment, the AGO2-containing RNPs dissoci-
ated upon the degradation of large RNAs and AGO2-bound miRNAs. As a consequence
of the reduced size of the specifically bound AGO2-containing RNP complexes, more
surface of the agarose matrix becomes available for non-specific binding and the amount
of background binders increases, as indicated by the strong tailing observed in the ratio
plots (Figure 2.5.11).
2.5.5 Verification of Interactions and Their RNA Dependency by Western
Blot Analysis
In general, the identification of proteins by mass spectrometry is very reliable when
stringent filter criteria are applied. The great progress in the field of quantitative pro-
teomics now even allows a reliable quantitation of proteins by mass spectrometry and
facilitates the confidential identification of interaction partners by AP-MS. Nevertheless,
for our data a false discovery rate of 1% remains and it is necessary to verify the data
using a second, independent method. Therefore, we performed Western Blot analysis
of a subset of identified AGO2 interactors (Figure 2.5.12). F/H-AGO2-containing RNP
complexes were immunoprecipitated from the F/H-AGO2-expressing cell lines. To test
the RNA dependency of the interactors, a set of samples was treated with RNase A for
4 h. IPs from the GFP expressing control cell lines served as background control. Equal
amounts of AGO2 were loaded for the analysis to allow for a direct comparison of protein
amounts. We selected twelve antibodies specific against various of the interactors and
tested the F/H-AGO2 immunoprecipitation for the presence of these proteins by Western
blotting. Of the twelve antibodies, only four showed no or only low background signals
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Figure 2.5.12: Western Blot analysis
of identified AGO2 interactors. F/H-
AGO2-containing RNP complexes were im-
munoprecipitated from the MEF cell lines as
described before (lanes 1, 2, 5 and 6). To an-
alyze the large RNA dependency of the inter-
action, the samples were treated with RNase
A for 4h at 4°C (lanes 3 and 4). IPs from
the GFP-expressing cell lines were used as
controls for background binding (lanes 5 and
6). Proteins were separated by SDS-PAGE,
transferred to membrane and probed with
antibodies against the endogenous proteins
or the HA-tag. Arrows indicate signals spe-
cific for the target protein, asterisks indicate
background signals.
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and detectable signals at the expected size. The others either showed no signals at all,
no signal at the size expected for their target protein or a vast number of additional,
strong and non-specific bands that greatly reduced our confidence in the specificity of
the antibody.
YB1 and UPF1 were both found to be miRNA- and large RNA-dependent interactors in
our mass spectrometry approach. In the Western blot analysis, we saw a strong signal
in the Dicer wild type sample and a reduced signal in the Dicer-depleted cells for these
two proteins. This validated the miRNA dependency of the interaction. The large RNA
requirement of the interaction was confirmed by the disappearance of the signal after
RNAse A treatment. The Western blot signals were specific as can be seen by the absence
of signals in the control samples. ZNF521 is a protein that directly interacts with AGO2
in the absence of miRNAs and Dicer. As predicted based on the mass spectrometry
data, we saw signals in the samples from the Dicer-depleted cells only and the signal
intensity was not affected by the RNAse treatment. The lowest panel shows the Western
blot analysis of eIF4AIII. This protein is a Dicer- and miRNA-independent interactor
and bound equally in the Dicer wild type and Dicer-depleted cells according to our mass
spectrometry data. The ratios for the large RNA dependency differed between the two
cell lines. In the Dicer wild type cell lines, the interaction showed a strong large RNA
dependency and we also observed that there was no signal in the western blot for the
RNase A treated Dicer wild type sample. In the Dicer-depleted cells, the large RNA
requirement seemed to be reduced and in accordance with the mass spectrometry data,
we still observed a very weak signal in the RNAse A treated sample.
In summary, the results of the Western blot analysis were in good agreement with the
mass spectrometry data and supported our results.
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3.1 Single-Particle Electron Microscopy Analysis of the
AGO2 Complex I and Methylosome Components
Our current knowledge of the architecture of AGO and Dicer derives from crystallization
studies of full length homologous proteins from archaea or unicellular eukaryotes [207,
258, 344, 345]. For eukaryotic AGO and Dicer, structural insights are only available
for individual domains or truncated proteins [26, 27, 59, 85, 206, 305, 312]. These
crystal structures reveal detailed information about the individual proteins and their
catalytic functions, but they do not give insights into the structural details underlying
the interaction between the RISC components. Therefore, we aimed to analyze the
structure of the human RISC loading complex by electron microscopy to gain insights
into RISC architecture and the mechanism of RISC loading.
The human RISC loading complex consists of AGO2, Dicer and TRBP [102, 208, 212].
We assumed that the AGO2 complex I described by Höck et al. [127] corresponds to the
RISC loading complex and we refined the purification strategy to isolate this complex
from HEK cells. In the last purification step, a GraFix gradient designed to gradually
cross-link protein complexes while simultaneously separating them according to their
size, the AGO2 complex I subdivided into free AGO2 and a heterodimeric complex con-
sisting of AGO2 and Dicer. TRBP was not copurified with the AGO2-Dicer complex
in this experimental set up. RISC assembly in Drosophila involves two intermediate
complexes [318] and it is possible that the free AGO2 and the AGO2-Dicer heterodimer
represent similar intermediate complexes in human. Micrographs of negatively stained
GraFix fractions containing the AGO2-Dicer complex revealed a low number of particles
with a strong heterogeneity that were not suitable for 3D reconstruction. This hetero-
geneity is very likely caused by dissociation of the complex during sample preparation.
In 2009, Wang et al. [342] presented a low resolution structure of a reconstituted hu-
man RISC loading complex reconstructed by single particle EM analysis. They reported
similar problems with complex stability at the dilute conditions applied during sample
preparation for the negative stain EM analysis. In their hands, the AGO2-Dicer complex
dissociated completely during grid preparation. This instability of the complex reflects
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a very low affinity among the RLC components. The complex is stabilized by the ad-
dition of TRBP, probably by enhancing the affinity of Dicer for AGO2 [43]. However,
we did see a rather stable AGO2-Dicer complex without TRBP until the grid prepara-
tion. In the hands of Wang et al., GraFix stabilized ternary RLC particles appeared
mono-dispersed in EM and facilitated the reconstruction of the RLC structure with a
resolution of 33 Å [342]. Dicer has a distinct L-shape in which the base branch is con-
stituted by the DEXH/D domain. AGO2 binds in a way that it connects with the top
and the base branch of Dicer, giving the complex an overall triangular structure. TRBP
binds to the Dicer DEXH/D domain [114, 167] and additional densities observed at the
base branch of Dicer might correspond to TRBP in this study [342]. A simultaneously
published study presented the EM structure of the Dicer-TRBP complex with the mod-
erate resolution of 18 Å [173]. In this study Dicer likewise has an L-shape structure and
the higher resolution reveals a surface trench for dsRNA binding. The dimeric TRBP-
Dicer complex is very stable and sample preparation for EM analysis did not require
cross-linking. This is a clear indication that the affinity of Dicer to its cofactor TRBP
is significantly higher than its affinity for AGO2 and is in support of the theory that
TRBP enhances the affinity between AGO2 and Dicer. For further insights into the
RLC structure, for example the identification of individual proteins and domains, it is
necessary to improve quality and resolution of the structure. One approach is to use
cryo-EM since it is possible that the RLC is more stable during vitrification than during
grid preparation for negative stain. This approach requires highly concentrated, pure
RLC and an input sample with this quality is more likely to be provided by an in vitro
reconstitution approach than by the purification of the complex from human cells.
During our efforts to establish a purification strategy for the AGO2 complex I, we fre-
quently copurified the methylosome core components PRMT5 and MEP50. PRMT5
symmetrically dimethylates the PIWI proteins in mouse, fly and X. laevi and these
posttranslational modifications are required for the interaction of PIWI proteins with
TDRD proteins [304]. The methylosome stably associates with murine and fly PIWI
proteins and has been observed in FLAG-based purification procedures for AGO2 [221].
We showed that the copurification of this protein complex is not based on a specific in-
teraction between the methylosome and AGO2. It has been previously observed that the
methylosome components are contained in FLAG immunoprecipitations [23]. We now
established it as a cross-reactivity of the FLAG agarose matrix used for the immuno-
precipitation. We utilized this unspecific affinity to isolate endogenous PRMT5-MEP50
complex from HEK cells. With this highly pure sample of the PRMT5-MEP50 complex
at hand, we aimed to reconstruct the methylosome core structure by single particle EM
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analysis. Electron micrographs of the GraFix cross linked, negatively stained complex
showed that the sample contains particles with varying sizes and structural features. We
tried to reconstruct the structure but the refinement of an initial model failed despite our
efforts to reduce sample heterogeneity by sub-classifying the particles according to their
size. Endogenous PRMT5 forms homo-oligomeric complexes and is mostly present as
tetramers [275]. Our purified endogenous PRMT5-MEP50 complex had an approximate
size of 300 kDa, which corresponds to the size of a PRMT5 tetramer in association with
one MEP50 protein. It is suggested that large endogenous PRMT5 homo-oligomeric
complexes are very unstable and dissociate into smaller, more stable complexes during
the purification procedure [275]. Therefore, it is possible that our sample contained
oligomeric complexes that dissociated into smaller complexes during grid preparation.
This theory is supported by the fact that non-cross-linked PRMT5-MEP50 particles
showed an even stronger heterogeneity after negative staining. PRMT5 has an indis-
criminate activity towards a variety of substrates and depends on the association with
adapter proteins for substrate specificity [108, 261]. The best characterized of these
adapter proteins is pICln, a methylosome component that stimulates the methylation of
Sm proteins through PRMT5 [87, 218]. It enhances the solubility and activity of recom-
binant PRMT5 [261], an observation which indicates that the adapter proteins might be
important for methylosome stability. We do not detect adapter proteins or substrates
in our sample preparations and it might be possible that the absence of these proteins
further contributes to the instability of the methylosome core complex.
So far the molecular mechanism underlying the association of PRMT5 to the PIWI
proteins remains unknown. Future projects such as the recently initiated reconstruction
of an in vitro reconstituted methylosome in combination with a PIWI protein as substrate
will give insights into methylosome architecture and substrate binding and will provide
a better understanding of PRMT5 function.
3.2 The Mouse AGO2 Specific Rat Monoclonal
anti-AGO2(6F4) Antibody
AGO-containing RNPs have been purified using different biochemical approaches ranging
from the reconstruction of RISC on tagged RNAs and density centrifugation to affinity
chromatography of tagged AGO proteins [127, 171, 214, 221]. Aside from giving insights
into the proteomic composition of AGO-containing RNPs, these approaches also facili-
tated the cloning and deep sequencing of small RNAs associated with AGO proteins and
greatly advanced the knowledge of small RNA profiles and enabled miRNA target iden-
91
3 Discussion
tification [20, 63, 115]. The majority of these studies employed overexpressed, tagged
AGO proteins because of the lack of suitable antibodies against the endogenous proteins.
Overexpression of proteins can cause artificial protein-protein interactions and the added
affinity tag can interfere with protein function. In addition, these approaches can only be
implemented in transfectable cell lines and thereby exclude tissues samples and primary
cells. Although an N-terminal FLAG/HA-tag does not interfere with the activity of
AGO2, the impact of AGO2 overexpression on protein interactions remains elusive. The
establishment of highly specific monoclonal antibodies against the human AGO proteins
[20, 282, 349] greatly advanced the analysis of endogenous AGO complexes in the hu-
man system. We have generated a monoclonal antibody specific for mouse AGO2. The
anti-AGO2(6F4) detected and immunoprecipitated catalytically active AGO2 with its
associated small RNAs from various murine cell lines. Bound proteins could be eluted
from the antibody matrix with a competing peptide, a property especially useful for
interaction studies since it allows to circumvent denaturing elution conditions that often
result in the elution of contaminating proteins. The anti-AGO2(6F4) had weak affinities
for AGO1 and 3 and a strong cross-reactivity for the COP II vesicle component SEC24C.
These additional affinities complicate the utilization of the antibody for proteomic stud-
ies (see Section 2.4), localization studies and the profiling of AGO2 associated RNAs.
Despite the cross-reactivities, the affinity of the antibody for AGO2 is very high and
bound miRNAs were coimmunoprecipitated with high reliability. Therefore, the anti-
body is well suited for the verification of novel miRNAs as recently demonstrated by
Zhu et al. [365].
3.3 Quantitative Proteomic Analysis of Endogenous
AGO2-containing Ribonucleoprotein Complexes
MiRNA-guided gene silencing is important for almost all cellular processes and miRNA
function is therefore heavily regulated at many different steps. AGO proteins are em-
bedded into large protein-RNA structures containing si- and miRNAs as well as trans-
lationally repressed mRNAs [127, 171, 349]. It is becoming more and more apparent
that the proteins associating with AGO in the RNPs have a strong regulatory effect
on AGO activity and function. Several large scale semiquantitative proteomic studies
of tagged AGO protein complexes contributed to our current knowledge of the protein
composition of AGO-containing RNPs [95, 127, 171, 221, 349]. However, many of the
interactions have not been further classified or validated and little is known about how
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well these observations apply to the endogenous complexes. In order to investigate the
protein composition of endogenous murine AGO2-containing RNPs, we used a SILAC-
based quantitative proteomic approach to identify specific AGO2 interactors and aimed
to characterize the miRNA-dependency of the associations. In a modified QUICK ap-
proach, we used the anti-AGO2(6F4) antibody to isolate AGO2-containing RNPs from
SILAC-labeled AGO2 wild type and AGO2-depleted MEFs. Although AGO2 was iden-
tified with a high sequence coverage and clear ratios, and known cross reactants were
identified as background binders, this approach did not allow us to define AGO2 inter-
acting proteins with high confidence. The group of outliers contained predominantly
highly abundant cytoskeletal proteins. Actins and Myosins, amongst others, often bind
non-specifically to sepharose and are frequently found in immunoprecipitations carried
out with sepharose as an affinity matrix [323]. In quantitative AP-MS approaches, such
contaminants usually appear as background binders and are only occasionally identified
as outliers due to variabilities inherent to sample handling and quantification. Subse-
quent analysis showed that the cytoskeletal proteins were differently expressed in the
two cell lines used in our modified QUICK approach. Consequently, non-specific bind-
ing of these proteins was stronger in one of the samples and generated high ratios for
these proteins. Similar differential background binding also prevented the analysis of the
miRNA dependency of AGO2 interactions. This observation highlighted the influence
of the whole proteome on interaction proteomics. Upon cellular stimuli, not only the
composition of individual protein complexes might be altered but the whole cell pro-
teome can undergo significant changes that might have severe effects on the composition
of the non-specific background binders associated with the affinity matrix and lead to
the identification of false positive interactors.
Many previously reported AGO2 interacting proteins, in part with established functions
in miRNA-mediated gene silencing, were identified as background binders in the mod-
ified QUICK approach. It is not likely that anti-AGO2(6F4) binding interferes with
complex formation or that the antibody recognizes a sub-complex lacking these inter-
actors because a commercially available antibody with a different epitope produced a
very similar protein profile. Both antibodies precipitated AGO1 and AGO3 in significant
amounts. This could reflect a specific interaction between the different AGO proteins.
AGO1 and 2 interact with each other in vivo [298, 359]. Different AGO proteins were
identified in the same complex in AGO 1-4 immunoprecipitations [171] but the non-bait
AGO proteins were identified with low sequence coverages and only one unique peptide
each, thus the identification is not very reliable. In addition, the murine AGO proteins
share a high sequence homology, so it is probable that the presence of AGO1 and 3 in the
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immunoprecipitations were based on a cross-reactivity of the antibodies. This theory is
supported by the observation that AGO1 and 3 showed background ratios in the QUICK
approach but appear as specific interactors in an approach with a control antibody. All
four human AGO proteins associate with highly similar sets of proteins and the majority
of the analyzed reported AGO2 interactors in our data set interact with all four AGO
proteins. This interaction with cross reacting AGO proteins could cause a shift of the
ratios below the threshold for specific interactors. But since AGO 1, 2 and 3 all show
high ratios in the approach with a control antibody and the reported interactors retain
their background ratios, it is necessary to consider non-specific associations with the
affinity matrix for this set of proteins. As described by Trinkle-Mulcahy et al., for some
cases, especially for low abundance proteins, the SILAC ratios alone are not sufficient to
define specificity and it is necessary to apply special filters for the identification of such
interactors [323].
Dicer and its cofactors TRBP/TARBP2 and PACT/PRKRA were not identified in any
of the immunoprecipitations of endogenous AGO2-containing RNPs. As our experiments
showed, the lack of Dicer and TRBP in these complexes was not cell line or antibody
specific. The absence of Dicer in endogenous AGO2-containing RNPs is an interesting
observation since the association between Dicer and AGO is well studied at the molec-
ular level [208, 311]. RISCs undergo several intermediates during their formation and
protein composition is likely to vary considerably depending on the current function
of an individual RISC. A Dicer-free AGO2 complex was identified in human cells after
fractionation of tagged-AGO2 complexes [127] but we did not apply comparable frac-
tionation to our samples. As discussed above (see Section 3.1) the AGO2-Dicer complex
appears to be rather unstable, which reflects a low affinity between the two proteins. In
vitro reconstitution of the human RLC complex indicates that AGO2 dissociates from
the RLC after miRNA loading [208]. Once loaded with a small RNA, AGO2 does not
necessarily have to be associated with Dicer for its function in target RNA degrada-
tion and translational repression. Thus, Dicer is possibly not a part of active RISCs.
This hypothesis is strengthened by two observations. First, although Dicer coimmuno-
precipitates with AGO, immunoprecipitations of Dicer do not contain the majority of
AGO interactors and second, Dicer-associated mRNAs share no sequence similarity with
AGO-associated miRNA targeted mRNAs [171]. However, Dicer is frequently observed
in immunoprecipitations of overexpressed, tagged AGO proteins. Is the association be-
tween AGO and Dicer concentration dependent? Does a higher abundance of AGO
trigger a more stable association? If yes, how does this influence the association with
other protein components and AGO function? These and other questions concerning the
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presence and function of Dicer in RISCs need to be carefully addressed in future studies
on endogenous AGO2-containing RNP complexes.
3.4 Identification of Differential AGO2 Interactions by
SILAC-based Quantitative Proteomics
Several semiquantitative proteomic studies and various genetic or RNAi-based screens
have been performed in plants and animals leading to the identification of proteins that
are involved in the different aspects of small RNA-guided gene silencing. However, none
of these studies were aimed at the discrimination of protein-protein or protein-RNA
interactions within AGO-containing RNPs but mostly focused on the identification of
AGO interaction partners. We used affinity purification of FLAG/HA-tagged AGO2-
containing RNPs in combination with SILAC-based quantitative proteomics to provide
a comprehensive list of proteins associating with AGO2 either through protein-protein
interactions or by indirect binding via RNAs. We identified 94% of the AGO2 interaction
partners previously identified by proteomic studies [127, 171] and the high sensitivity
of our measurements facilitated the identification of additional, so far unreported po-
tential AGO2 interaction partners. The quantitative aspect of our analysis allowed us
to discriminate between background binders and specific interactions and several pre-
viously reported interaction partners, for example the methylosome components [221],
were classified as non-specific binders.
In order to analyze the miRNA dependency of AGO2 interactions, we used MEF cell
lines in which Dicer has been genetically inactivated [101]. As a consequence, miRNA
precursors are not processed into mature miRNAs in these cells. AGO2 complexes in
these MEFs are most likely free of miRNAs as miR-451, the only known miRNA pro-
cessed by AGO2 independently of Dicer [40, 45], is not expressed in these cells.
We hypothesized that unloaded, miRNA-free AGO2 associates with different proteins
than miRNA-loaded AGO2. To test this hypothesis, we compared AGO2-containing
RNPs from Dicer wild type and Dicer-deficient MEFs. Indeed, we found a number
of proteins that interacted with AGO2 specifically in the presence or absence of Dicer
and miRNAs, while other proteins associated with AGO2 under both conditions (Fig-
ure 3.4.1). Among the specific interactions not affected by the miRNA loading status
of the AGO2 protein, we identified a high number of RBPs reported to associate with
mRNAs. MiRNAs are generally regarded as sequence-specific guides that target AGO
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protein complexes to distinct sites on mRNAs with partial sequence complementary to
the miRNA [82]. Following this assumption, we presumed that AGO proteins would
not interact with mRNAs in the absence of Dicer and mature miRNAs. The miRNA-
independent binding behavior of the RBPs with AGO2 now lead us to hypothesize that
AGO2 binds large RNAs with its associated RBPs irrespective of miRNAs. We showed
that AGO2 stably associates with large RNAs in the absence of miRNAs and that large
RNA binding strongly influences the protein composition of AGO2 containing RNPs
(Figure 3.4.1). Our proteomic based observation of miRNA-independent large RNA
binding is confirmed by deep-sequencing studies. Chi and colleagues [44] described so
called "orphan cluster" mRNAs that have no predicted seed matches with known miR-
NAs but nevertheless associate with AGO2. Leung et al. observed that a G-rich motif
containing mRNAs associate with AGO2 in an miRNA independent manner. They spec-
ulate that the presence of a G-rich motif in the close proximity of a miRNA binding site
strengthens the affinity of the AGO-miRNA complex for the binding site and increases
the probability for miRNA-mediated repression [183]. It might also be possible that
miRNA-independent mRNA binding is the basis for a so far unknown regulatory mech-
anism in which mRNA target recognition and binding is mediated by RBPs and AGO2
only serves as a scaffold protein for the recruitment of factors involved in translational
repression and mRNA degradation. With our current knowledge, the exact mechanism
and function of non-miRNA-guided mRNA binding remains elusive and needs to be in-
vestigated in future studies.
A current model of the mechanism of miRNA-guided gene silencing is that AGO pro-
teins interact with a member of the GW128 protein family, which in turn interacts with
the PABP bound to the poly(A)-tail of the mRNA. This interaction interferes with
PABP function and inhibits translation or induces deadenylation. Drosophila GW182
predominantly binds to the RRMs of PABP through its N- and C-terminal domains,
whereas human TNRC6C and PABP interact via binding between the PAM2 motif and
the Mlle domain. It is hypothesized that the different modes of interaction cause funda-
mental differences in the silencing mechanism [324]. Our finding that TNRC6C binds to
AGO2 only in the presence of miRNAs and Dicer, while TNRC6A and B show a Dicer
and miRNA-independent binding behavior, supports this theory of differential silencing
mechanisms of the TNRC6 proteins.
Messenger RNA destabilization has emerged as a widespread effect of miRNA mediated
regulation. The interactions of miRNPs with the deadenlyase complex has been charac-
terized in molecular detail [79, 363], yet not much is known about functional interactions
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Figure 3.4.1: AGO2 Interaction Network. The proteomic data was combined into an in-
teraction network. Proteins were grouped according to their biological functions and reported
interactions between the AGO2-associated proteins were added. AGO2 is depicted in red. Pro-
teins interacting with AGO2 independently of Dicer and the miRNA loading status of AGO2 are
shown in green. Interactors binding to AGO2 only in the presence or absence of miRNAs and
Dicer are indicated in yellow and blue, respectively. The style of the connecting lines represents
the large RNA dependency. Solid lines indicate protein-protein interactions. Short dashed lines
represent a strong large RNA dependency of the interactions. A weak influence of large RNA
presence on the binding behavior is depicted by long dashed lines. Broken dashed lines indicate
differential large RNA dependencies in the presence of absence of miRNAs and Dicer. Proteins
not identified in the large RNA dependency screen are connected to AGO2 by dotted lines.
with the decapping machinery. DDX6, a DEAD box helicase more widely referred to as
RCK, is involved in translational regulation and associates with AGO1 and 2 in human
cells [359]. RCK and the decapping enhancer Ge-1 are required for miRNA-guided gene
silencing in flies [75]. Based on our observation that AGO2 interacts with DDX6/RCK
and the Ge-1 homologue EDC4, it is tempting to suggest a model in which AGO2
does not only stimulate deadenylation via the GW182 proteins but also triggers sub-
sequent decapping and efficient mRNA decay by recruiting the decapping factors RCK
and EDC4. Other proteins identified as interactors in our proteomic screen might also
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connect AGO2 and the miRNA machinery to mRNA decay. The RNA helicase UPF1
is a miRNA- and large RNA-dependent AGO2 interactor and is known to interact with
decapping, deadenylation and exosome components. RISC bound mRNAs accumulate
due to inefficient degradation in the absence of UPF1, so one might speculate that UPF
mediates the interaction between RISC and mRNA decay factors [143]. In addition,
UPF1 and the exon junction complex component eIF4A3 are involved in NMD and
represent a possible connection between this degradation process and miRNA-mediated
repression [92, 93]. Another helicase, DHX36/RHAU, is involved in deadenylation of
AU-rich mRNAs and might link AGO2 to ARE-mediated messenger RNA decay. A con-
nection between miRNA-mediated repression and ARE-mediated translation regulation
is suggested by our data by the miRNA- and large RNA-dependent AGO2 interactor
HuR and its cofactor AUF1 [39].
Aside from various RBPs and mRNA decay factors, we identified components involved
in RISC assembly and maturation. Dicer and AGO interact through their RNase III
and PIWI domains [311]. This direct protein-protein interaction is reflected by an RNA-
independent binding behavior in our data. TRBP seems to have no affinity for AGO
in the absence of miRNAs and Dicer, and its presence in the RNP complex appears
to be coupled to its association with Dicer. HSP90 regulates AGO localization and its
ATPase activity is required for the conformational changes of the AGO protein during the
process of small RNA loading [134, 138, 255]. Together with its cochaperones, HSP90
associated with AGO2 in an RNA-independent manner, suggesting a stable protein-
protein interaction that could have additional functions besides small RNA loading.
The only RISC loading factor binding in a miRNA-dependent manner is the RNA heli-
case A (RHA/DHX9). This is in good agreement with its proposed function of promoting
the interaction between Dicer products and AGO [278]. It is puzzling that RHA bind-
ing to AGO2 displayed differently strong large RNA dependencies in the presence and
absence of Dicer and miRNAs and it could be worthwhile to elucidate the function un-
derlying this binding behavior. Another protein involved in RISC maturation is the
putative helicase MOV10 [221, 318]. Among the identified RISC assembly components,
MOV10 is the only factor showing a large RNA-dependent association with AGO. This
binding behavior suggests a function downstream of RISC loading, possibly at the step
of large RNA binding by the RISC.
We identified a number of proteins that specifically associated with AGO2 preferentially
in the absence of miRNAs. These proteins bind to AGO2 through protein-protein inter-
actions. It is interesting that one of these proteins is AGO3. AGO1 and 2 are known
98
3 Discussion
to interact with each other [298, 359], but why and with which functional consequences
AGO3 associates specifically with unloaded AGO2 can only be speculated. ZNF521 is a
nuclear factor suggested to be involved in transcription regulation [28] and its discovery
in RNA-free AGO2 complexes points towards a possible miRNA-independent nuclear
function for AGO2. We observed that AGO2 abundance is significantly lower in the
Dicer-deficient cells compared to the wild type cells, not only at endogenous levels but
also when AGO2 was overexpressed. This lower abundance seems to be caused by an
instability of AGO2 in the absence of miRNAs. In addition, large RNA binding also
seemed to have a stabilizing effect on AGO2 since AGO2 stability decreased upon long
RNase treatment (Figure 2.5.7). Is AGO2 targeted for degradation when it can not
execute its function in the absence of miRNAs? Murine AGO2 turnover is regulated by
ubiquitinylation [283] and we identified the HECT-type E3 ligase HERC6 in association
with RNA-free AGO2. HERC6 mediates the conjugation of ISG15 to target proteins in
human [351]. ISG15 functions as a ubiquitin homolog and it is therefore tempting to
speculate that RNA-free AGO2 might be subjected to this specific form of post transla-
tional modification in the absence of mature miRNAs.
We combined our proteomic data into an interaction network that presents an overview
of the protein components of AGO2-containing RNPs and displays the miRNA and Dicer
as well as the large RNA requirements of the interactions (Figure 3.4.1). Reported inter-
actions between the AGO2-associated proteins were included into the network to point
out possible regulatory pathways and AGO2-independent interactions between the RNP
components. Our experimental set up does not discriminate between proteins present
in the RNPs with a clear AGO2-related function and RBPs without related functions
that "hitchhike" to the RNPs on the associated large RNAs. One transcript is bound
and regulated by multiple RBPs and a single RBP can bind to up to 30% of the RNA
transcripts in human cells [115]. In the end it is the combination of the associated factors
that determines the regulatory outcome. It is suggested that RBPs and miRNAs medi-
ate each others activities by competition or complementation for target RNA binding.
Indeed, there seems to be a strong interplay between RBPs and miRNAs, which is repre-
sented by several proteins in our data set. One example is FMR, a protein that facilitates
the assembly of miRNAs on specific targets [266]. Another example is the ARE-binding
protein HuR. Its binding sites are found in close proximity to miRNA binding sites [175]
and HuR mediates translation either by acting cooperatively with miRNAs in RISC
recruitment or by relieving miRNA-mediated repression [23, 39, 159]. Target sites for
the mRNA binding protein PUM2 are also enriched around predicted miRNA binding
sites and it is suggested that PUM proteins recruit the miRNA machinery to regulate
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their targets [91]. RBP-mediated regulation of miRNA activity is also dependent on
cellular conditions, as seen for FXR1 that relieves miRNA-mediated repression during
cell cycle arrest [331, 332]. Our proteomic data does not reveal the composition of such
highly individual RNPs but gives an average of protein complexes and binding partners
associated with AGO2. It would therefore be interesting to refine our present interaction
network by further separating the different RNPs to allow for a more detailed analysis
of the proteomic composition of the individual RNPs with a special focus on how the
associated proteins influence AGO2 function under varying cellular conditions.
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4.1 Material
4.1.1 Chemicals, Enzymes, Peptides and Oligonucleotides
All chemicals were, unless stated otherwise, purchased from one of the following com-
panys: Amersham Bioscience (Buckinghamshire, UK), Biorad (Hercules, USA), Merck
(Darmstadt, Germany), Qiagen (Hilden, Germany), Roche (Basel, Switzerland), Roth
(Karlsruhe, Germany) and Sigma-Aldrich (Munich, Germany). Radiochemicals were
provided by Perkin Elmer (Waltham, USA). Enzymes were purchased from New Eng-
land Biolabs (Ipswich, USA) or Fermentas (Burlington, Canada). Unless specified oth-
erwise, peptides were synthesized by the Peptide Service of the Core Facility at the Max
Planck Institute of Biochemistry (Martinsried, Germany). DNA oligonucleotides were
synthesized by Metabion (Martinsried, Germany).
4.1.2 Plasmids
pVP5: This mammalian expression vector has been kindly provided by the Bob Roeder
laboratory. It is based on the pIRES1neo expression vector (Clontech, Mountain View,
USA) but contains a Kozak Sequence followed by a FLAG- and an HA-tag, which has
been inserted between the EcoRV and NheI restriction site in the multiple cloning site.
The pVP5 is used in this work for the overexpression of FLAG/HA-tagged (F/H-tagged)
proteins in mammalian cells.
pDest26cMyc: This mammalian expression vector is based on the pDest26 vector
(Invitrogen, Carlsbad, USA) and has been engineered to contain an N-terminal cMyc-
tag instead of a 6xHis-tag. In this work the vector is used for the overexpression of
cMyc-tagged Dicer in HEK293T cells.
4.1.3 Antibodies
- anti-AGO1(4B8): rat monoclonal, hybridoma supernatant [20]
- anti-human AGO2(11A9): rat monoclonal, hybridoma supernatant [282]
101
4 Material and Methods
- anti-human AGO3(5A3): rat monoclonal, hybridoma supernatant [349]
- anti-AGO4(6C10): rat monoclonal, hybridoma supernatant [349]
- anti-RmC(16D2): rat monoclonal, hybridoma supernatant
- anti-mouse AGO2(6F4): rat monoclonal, hybridoma supernatant
- anti-human SEC24C: rabbit polyclonal [248]
- anti-HA: mouse monoclonal 16B12 (Covance, Berkely, USA)
- anti-β-tubulin: mouse monoclonal DM1A (Sigma, St. Louis, USA)
- anti-β-actin: mouse monoclonal AC15 (Abcam, Cambridge, UK)
- anti-AGO2(C34C6): rabbit monoclonal C34C6 (Cell Signaling, Danvers, USA)
- anti-mouse IgG: rabbit, peroxidase conjugated (Sigma, St. Louis, USA)
- anti-rat IgG: goat, peroxidase conjugated (Jackson Laboratory, West Grove, USA)
- anti-rabbit IgG: goat, peroxidase conjugated (Jackson Laboratory, West Grove, USA)
- fuorescein anti-rat IgG: rabbit, fluorescein conjugated (Vector Laboratories, Burlin-
game, USA)
4.1.4 Bacterial Strains and Cell Lines
Bacterial strains
- E. coli XL1 blue
Mammalian cell lines
- human embryonic kidney 293 T cells (HEK293T)
- AGO2 (-/-) mouse embryonic fibroblasts [55]
- Dicer (+/+) mouse embryonic fibroblasts (1C1) [101]
- Dicer (-/-) mouse embryonic fibroblasts (2G4) [101]
- Dicer (+/+) FLAG/HA expressing AGO2 embryonic fibroblasts (1C1)
- Dicer (-/-) FLAG/HA AGO2 expressing embryonic fibroblasts (2G4)
- mouse hepatoma cells (Hepa 1-6)
- mouse neuroblastoma cells (N2A)
- mouse fibroblast cells (NIH 3T3)
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4.1.5 Media
Bacteria media
Lysogeny broth media (LB) 1% (w/v) Trypton
1% (w/v) NaCl
0.5% (w/v) Yeast extract
Cell culture media
Normal DMEM: DMEM with high glucose (PAA, Pasching, Austria) with 10% fe-
tal bovine serum (Biochrom, Berlin, Germany) and 10% Penicillin/Streptomycin (PAA,
Pasching, Austria.)
SILAC media: DMEM with high glucose devoid of arginine and lysine (PAA, Pasching,
Austria) supplemented with 10% dialyzed FBS (Invitrogen, Carlsbad USA), 10% Peni-
cillin/Streptomycin (PAA, Pasching, Austria), 2 nM stable glutamine (PAA, Pasching,
Austria) and either with normal lysine and arginine or the heavy counterparts (13C615N4-
L-arginine, 13C615N2-lysine, Sigma-Aldrich, Munich, Germany) at a concentration of
42mg/l and 72mg/l, respectively.
4.1.6 Buffers and Solutions
General Buffers
Phosphate buffered saline (PBS) 135mM NaCl
1.3mM KCl
3.2mM Na2HPO4
0.5mM NaH2PO4, pH 7.4
TBE buffer 89mM Tris-HCl, pH 8.3
89mM boric acid
2.5 mM EDTA
HEPES (2x) 274mM NaCl
54.6mM HEPES
1.5mM Na2HPO4
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MOPS buffer (50x) 1M MOPS, pH 7.0
SDS-PAGE
Protein sample buffer (5x) 400mM Tris-HCl, pH 6.8
5mM EDTA
0.01% (w/v) bromphenol blue
50% (w/v) glycerol
1% (w/v) SDS
5% stacking gel 5% (v/v) acrylamide (37%, 5:1)
75mM Tris-HCl, pH 6.8
0.1% (w/v) SDS
0.1 % (w/v) APS
4 µM TEMED
10% separation gel 10% (v/v) acrylamide (37%, 5:1
400mM Tris HCl, pH 8.0
0.1% (w/v) SDS
0.1% (w/v) APS
4 µM TEMED
SDS running buffer 200mM glycerol
25mM Tris-HCl, pH 7.5
25mM SDS
Coomassie Staining
Coomassie solution 0.25% (w/v) Coomassie R250
50% (v/v) methanol
10 % (v/v) acetic acid
Destaining solution 30% (v/v) methanol
10% (v/v) acetic acid
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Colloidal Coomassie staining 0.08% (w/v) Coomassie G250
solution 1.6% (v/v) H3HPO4
8.0% (w/v) (NH4)2SO4
20% (v/v) methanol
Silver Staining Solutions
Fixing solution 50% (v/v) methanol
12% (v/v) acetic acid
0.5ml/l 37% formaldehyde
Washing solution 30% (v/v) ethanol
Sodium thiosulfate solution 0.2 g/l NaS2O3 x 5 H2O
Silver nitrate solution 2 g/l AgNO3
0.75ml/l 37% formaldehyde
Developer 60 g/l NaCO3
0.5ml/l 37% formaldehyde
Stopping solution 50% (v/v) methanol
12 % (v/v) acetic acid
Buffers for Western Blotting
TBS-T 137mM NaCl
20mM Tris-HCl, pH 7.6
0.1% (v/v) Tween-20
Towbin buffer 192mM glycin
25mM Tris-HCl, pH 8.3
20% (v/v) methanol
0,037% (w/v) SDS
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Transfer buffer 25mM Tris HCl
192mM glycine
20% (v/v) methanol
Western blot wash buffer 300mM Tris-HCl, pH 7.5
150mM NaCl
0.25% (v/v) Tween-20
Chemiluminescence detection 100mM Tris-HCl, pH 8.5
1.2mM Luminol
0.68% p-coumaric acid
0.02% H2O2
Buffers for Immunofluorescence
Fixing Solution 130mM NaCl
774mM Na2HPO4, pH 7.4
226mM NaH2PO4
3.7% (w/v) formaldehyde
Stopping solution 130mM NaCl
774mM Na2HPO4, pH 7.4
226mM NaH2PO4
0.2% (w/v) Triton 100
3% (w/v) Albumin fraction V
Wash buffer 130mM NaCl
774mM Na2HPO4, pH 7.4
226mM NaH2PO4
0.1% (w/v) Tween 20
0.2% (w/v) Albumin fraction V
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Buffers for RNA Isolation and Northern Blotting
Protease K buffer (2x) 300mM NaCl
200mM Tris-HCl, pH 7.5
25mM EDTA
2%(w/v) SDS
RNA loading dye (1x) 89mM Tris-HCl, pH 8.3
89mM boric acid
2.5mM EDTA
90% (v/v) formamide
0.025% (w/v) xylene cyanol
0.025% (w/v) bromophenol blue
Denaturing polyacrylamide gels 25.2 g urea
for RNA 18ml acrylamide (40%; 19:1)
1.2ml 1 M MOPS-NaOH, pH 7.0
360µl APS
21µl TEMED
Cross-link solution 0.13M 1-methylimidazole, pH 8.0
0.16M 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide
SSC (20x) 3M NaCl
0.3M sodium citrate, pH 7.1
Denhardt’s solution (50x)
1% (w/v) Albumin fraction V
1% (v/v) Polyvinylpyrrolidon K30
1%v(v/v) Ficoll 400
Hybridization solution 5x SSC
7% (w/v) SDS
20mM Na2HPO4, pH 7.2
1x Denhardt’s solution
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Wash buffer I 5x SSC
1% (w/v) SDS
Wash buffer II 1x SSC
1% (w/v) SDS
Buffers for In Vitro RISC Activity Assays
in vitro transcription buffer 1x T7 RNA polymerase buffer
1mM ATP
1mM CTP
1.6mM GTP
0.4mM UTP
5mM DTT
RNA elution buffer 300mM NaCl
2mM EDTA, pH. 8.0
GT buffer 40mM Tris-HCl, pH 8.0
60mM MgCl2
10mM DTT
2mM spermidine
Reaction buffer 1mM ATP
0.2mM GTP
10U/ml RNasin (Promega, Madison, USA)
100mM KCl
1.5mM MgCl2
0.5mM DTT
T1 digestion buffer 1mM ATP
10mM urea
1.5mM EDTA
0.05% (w/v) bromphenol blue
0.05% (w/v) xylene cyanol
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Buffers for In Vitro Dicer Activity Assays
in vitro transcription buffer 1x T7 RNA polymerase buffer
1mM ATP
1mM CTP
1.6mM GTP
20 µM UTP
5mM DTT
Reaction buffer 135mM NaCl
1.3mM KCl
3.2mM Na2HPO4, pH 7.4
0.5mM NaH2PO4
5mM ATP
7.5mM MgCl2
Buffers for AGO2 Complex I Purification from HEK293T Cells
Cell lysis buffer 150mM KCl
25mM HEPES-KOH, pH 7.4
2mM EDTA
1mM NaF
0.5% (v/v) NP-40
5% (v/v) glycerol
5mM DTT
1mM AEBSF
Sucrose gradient buffer 150mM KCl
25mM HEPES-KOH, pH 7.4
15 or 55% (w/v) sucrose
IP wash buffer 150mM KCl
50mM HEPES-KOH, pH 7.4
5mM MgCl2
0.01% (v/v) NP-40
5% (v/v) glycerol
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Elution buffer 150mM KCl
25mM HEPES-KOH, pH 7.4
5mM MgCl2
5% (v/v) glycerol
Buffers for PRMT5-MEP50 Complex Purification from HEK293T Cells
Cell lysis buffer 150mM KCl
25mM Tris-HCl, pH 7.4
2mM EDTA
1mM NaF
0.5% (v/v) NP-40
5% (v/v) glycerol
5mM DTT
1mM AEBSF
Sucrose gradient buffer 150mM KCl
25mM Tris-HCl, pH 7.5, pH 7.4
15 or 55% (w/v) sucrose
IP wash buffer 150mM KCl
50mM Tris-HCl, pH 7.5, pH 7.4
5mM MgCl2
0.01% (v/v) NP-40
5% (v/v) glycerol
Elution buffer 150mM KCl
25mM Tris-HCl, pH 7.5, pH 7.4
5mM MgCl2
5% (v/v) glycerol
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Buffers for Glycerol Gradients
Glycerol gradient buffer 150mM KCl
25mM HEPES-KOH, pH 7.4
10 or 30% (v/v) glycerol
Buffers for Immunoprecipitation of AGO2-Containing RNP Complexes for Mass
Spectrometry Analysis
Cell lysis buffer 150mM KCl
25mM Tris-HCl, pH 7.5
2mM EDTA
1mM NaF
0.5% (v/v) NP-40
5mM DTT
5%(v/v) glycerol
1x complete protease inhibitor cocktail
(Roche, Basel, Switzerland)
IP wash buffer 300mM NaCl
(for FLAG-IPs) 50mM Tris-HCl, pH 7.5
5mM MgCl2
0.01% (v/v) NP-40
5% (v/v) glycerol
IP wash buffer 150mM NaCl
(for anti-AGO2(6F4) 50mM Tris-HCl, pH 7.5
and anti-AGO2(C34C6) IPs) 5mM MgCl2
0.01% (v/v) NP-40
5% (v/v) glycerol
Elution buffer 150mM NaCl
25mM Tris-HCl, pH 7.4
5mM MgCl2
5% (v/v) glycerol
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Buffers Peptide Extraction, Stage Tipping and Mass Spectrometry Analysis
Buffer A* 2% (v/v) acetonitrile
0.1% (v/v) trifluoroacetic acid
Buffer A 0.5% (v/v) acetic acid
Buffer B 0.5% (v/v) acetic acid
80% (v/v) acetonitrile
4.2 Methods
4.2.1 General Methods
General Molecular Biological Methods
Standard molecular biology methods, for example DNA gelelectrophoresis, extraction
and precipitation of nucleic acids and transformation of E.coli with plasmid DNA were
performed as described by Sambrook et al. [288].
Cloning of Murine Argonaute Genes
The murine Argonaute genes 1-4 (AGO1-4) were cloned into pVP5 using the templates,
primers and restriction sites indicated in Table 4.2.1. Genes were amplified from tem-
plate DNA with PhusionTM DNA Polymerase (Finnzymes, Espoo, Finnland) and PCR
Products were isolated from agarose gels with the NucleoSpin-Kit (Macherey Nagel,
Düren, Germany). Vector DNA and PCR products were digested with the respective
restriction enzymes, ligated using T4 DNA Ligase (Fermentas, Burlington, Canada) and
transformed into E. coli XL1 blue. Isolation of plasmid DNA from E. coli was carried
out using the NucleoBond® XtraMini or the NucleoBond® XtraMidi Kit (Macherey
Nagel, Düren, Germany). All kits and enzymes were used according to the manufacturers
instructions.
Whole Cell Lysate Preparation
Cells were cultured to 80-90% density, washed three times with PBS, scraped off and
pelleted at 200 g for 10min at RT. The cell pellets were flash frozen in liquid nitrogen
and stored at -80°C. For lysate preparation, the cells were thawed on ice, suspended in
lysis buffer freshly supplemented with DTT and protease inhibitor by pipetting up and
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AGO1
template IMAGE clone 40111808 (RZPD, Berlin, Germany)
forward primer 5’-CGCTGCGGCCGCATGGAAGCGGGACCCTCGGG-3’
reverse primer 5’-CGCTGAATTCTCAAGCGAAGTACATGGTGCGT-3’
restriction sites NotI/EcoRI
AGO2
template IMAGE clone 40111875 (Geneservice, Cambridge, UK)
forward primer 5’-CGCTGCGGCCGCATGGACTCGGGAGCCGGCCC-3’
reverse primer 5’-CGCTGAATTCTCAAGCAAAGTACATGGTGCGC-3’
restriction sites NotI/EcoRI
AGO3
template cDNA clone (Alexa Dittmer, Research Group Klaus Förstemann)
forward primer 5’-CGCTGCGGCCGCATGGAAATCGGCTCCGCAGG-3’
reverse primer 5’-CGCTCAATTGTTAAGCGAAGTACATTGTGCGT-3’
restriction sites NotI/MfeI
AGO4
template IMAGE clone 30607807 (RZPD, Berlin, Germany)
forward primer 5’-CGCTGCGGCCGCATGGAGGCGGTGGGACCCGG-3’
reverse primer 5’-CGCTCAATTGTCAGGCAAAATACATAGTGTGC-3’
restriction sites NotI/MfeI
Table 4.2.1: Templates, primers and restriction sites used for cloning of murine
Argonaute genes into the vector pVP5.
down and incubated on ice for 20 min. The cell debris was pelleted by centrifugation
(17 000 g, 10min, 4°C) and the supernatant transferred to a fresh reaction tube. The
total protein concentration was either determined by measurement of the A280 or by
Bradford Protein Assay (Biorad, Hercules, USA).
Antibody Matrix Preparation
Protein G Sepharose beads (GE Healthcare, Fairfield, USA) were washed twice with PBS.
Hybridoma supernatant was cleared of precipitated protein by centrifugation (5min,
17 000 g, 4°C) and 20 fold the volume of beads was added to the prepared beads. For
purified antibodies, 1 µg of antibody was used per µl of beads. PBS buffer was added
until the desired volume and the mixture was incubated over night at 4°C with slow
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rotation. The beads were then washed twice with PBS and resuspended in a small
volume of buffer.
SDS-PAGE, Coomassie Staining and Silver Staining
Proteins from lysates or IPs were separated on polyacrylamide gels with 5% and 10%
acrylamide in stacking and separation gel, respectively, or NuPAGE 4-12 % Bis-Tris
Gels (Invitrogen, Carlsbad, USA). For Coomassie staining and destaining of separated
proteins either Coomassie R-250 and destaining solution or Coomassie G-250 and water
were used. NuPAGE gels were stained using the Novex Colloidal Blue Stain Kit (Invit-
rogen, Carlsbad, USA). For silver staining of separated proteins, gels were fixed in fixing
solution for 1 h and washed with washing solution 3x for 20min. Sodium thiosulfate
solution was applied for 1min followed by rinsing with water for 3x 20 sec. The gel was
then soaked with silver nitrate for 20min and rinsed with water for 2x 20 sec. Developer
was applied until the desired stain intensity was reached and the reaction was stopped
by discarding the developer followed by rinsing with water. The gel was then incubated
in stopping solution for 10min and transferred into water.
Western Blotting
Proteins were separated by SDS-PAGE and transferred to Amersham Hybond ECL
membrane (GE Healthcare, Fairfield, USA) by semi dry electroblotting in Towbin buffer.
Proteins run in NuPAGE gels were transferred to nitrocellulose membrane (Whatmann,
Maidstone, UK) by wet blotting in transfer buffer. The membranes were blocked in West-
ern blot wash buffer or TBS-T with 10% (w/v) dry milk. Rat hybridoma supernatants
or purified monoclonal primary antibodies were diluted with Western blot wash buffer.
Commercially available primary antibodies were used according to the manufacturer’s
instruction. Secondary antibodies were used in the same buffer as the corresponding pri-
mary antibody with the addition of 5% (w/v) dry milk. Dilution factors for secondary
antibodies were as indicated by the manufacturer.
Immunofluorescence
Cells were grown on cover slips to 50% confluency, the medium was aspirated and the
cells were fixed in fixing buffer at 4°C for 15min. The reaction was stopped by incubation
of the cells in stopping buffer for 5min at 4°C. After incubation in blocking buffer for
10min at 4°C the cells were washed three times with wash buffer. The primary antibody
anti-AGO2(6F4) was diluted 1:50 in wash buffer and incubated with the cells for 1 h at
RT followed by five washing steps with wash buffer. The fluorescein coupled anti-rat
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secondary antibody was diluted 1:100 with wash buffer. After incubation for 1 h at RT
in the dark, the antibody solution was aspirated. The cells were incubated in wash
buffer containing 0.1mg/ml DAPI for 5min at RT and washed five times with wash
buffer. The cover slips were then mounted on object holders with Hard Set Mounting
Medium (Vector Laboratories, Burlingame, USA). Confocal images were recorded on a
TCS SP2 confocal laser microscope (Leica Microsystems, Wetzlar, Germany).
RNA Isolation
Total RNA was extracted from cultured cells using the PrepEaseTM RNA Spin Kit (USB,
Cleaveland, USA) according to the manufacturer’s instructions. For the isolation of RNA
from IPs and input samples, the beads or lysates were mixed with Protease K buffer
containing 40µg/ml Proteinase K and incubated for 15min at 65°C. RNA was extracted
with phenol/chlorophorm/isoamylalkohol (25:24:1) and precipitated in ethanol at -20°C
over night. After pelleting by centrifugation (30min, 17 000 g, 4°C) the isolated RNA
was dried at room temperature and dissolved in an appropriate volume of water.
Northern Blotting
Isolated RNAs were separated on denaturing 12% polyacrylamide gels by electrophore-
sis and the gels were stained with ethidium bromide to control RNA quality. RNAs
were transferred to Hybond-N membrane (Amersham Biosciences, Buckinghamshire,
UK) by semidry electroblotting in water at 20V for 30min and crosslinked to the mem-
brane with 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride [252] at 50°C
for 1 h. After crosslinking the membrane was rinsed with water, dried and incubated
in hybridization solution at 50°C for 1h. Northern blot probes were prepared by radi-
olabeling 10 pmol of DNA oligonucleotides with T4 polynucleotide kinase (Fermentas,
Burlington, Canada) in the presence of 32P-ATP according to the manufactures’ instruc-
tion. The labeled probe was purified using MicroSpin G-25 columns (GE Healthcare,
Fairfield, USA) as described by the manufacturer and the purified probe was added into
the hybridization solution and incubated with the membrane over night at 50°C. The
membrane was then washed twice with Northern blot wash buffer I for 10min at 50°C
and once with Northern blot wash buffer II for 10min at 50°C. Signals were detected by
audioradiography with MS film and an intensifying screen (Kodak, Stuttgart, Germany)
at -80°C. The probes used in this work are summarized in Table 4.2.2.
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mmu-miR-19b 5’-TCAGTTTTGCATGGATTTGCACA-3’
mmu-miR-21 5’-TCAACATCAGTCTGATAAGCTA-3’
lysin-tRNA 5’-CTGATGCTCTACCGACTGAGCTATCCGGGC-3’
U6-snRNA 5’-CTGATGCTCTACCGACTGAGCTATCCGGGC-3’
Table 4.2.2: Sequences of DNA oligos used as Northern blot probes.
cDNA Synthesis
Total RNA was isolated as described previously (see Section "RNA Isolation" on page 115)
and cDNA was synthesized with oligo-d(T) primers using the First Strand cDNA Syn-
thesis Kit (Fermentas, Burlington, Canada) as instructed by the manufacturer.
Genotyping
Mouse embryonic fibroblast were genotyped approximately every 10 passages when in
culture. DNA was isolated using a QIAamp DNA Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions for isolation of genomic DNA from cultured
cells. A touch down PCR was performed with the primers 23F (5’-ATTGTTACCAGCG
CTTAGAATTCC-3’), 458F (5’-TCGGAATAGGAACTTCGTTTAAAC-3’) and 460R
(5’-GTACGTCTACAATTGTCTATG-3’) as described elsewhere [4]. PCR products
were analyzed on a 1% agarose gel stained with ethidiumbromide.
In Vitro RISC Activity Assay
Two different RNAs were used as in vitro cleavage substrates in this study. The RNA
targeted by the exogenous siRNA 5’-UCGAAGUAUUCCGCGUACGUdT-3’ has been
described by Martinez et al. in 2002 [214] and contains the target site flanked by se-
quences of firefly luciferase. For cleavage directed by the endogenous miR-19b an RNA
described by Meister et al. in 2004 [220] was used. RNA was in vitro transcribed from
PCR transcripts with T7 RNA polymerase (Fermentas, Burlington, Canada) in in vitro
transcription buffer at 37°C for 3 h. The RNA was purified on an 8% denaturing poly-
acrylamide gel (SequaGel®-Kit, National Diagnostics, Atlanta, USA), detected by UV
shadowing and eluted over night in RNA elution buffer. After recovery by ethanol pre-
cipitation, the RNA was cap-labelled with guanyltransferase in the presence of 32P-GTP
in GT buffer supplemented with 1,25% RiboLock RNase inhibitor (Fermentas, Burling-
ton, Canada), 25µM S-adenosyl methionine and 50mM DTT for 3 h at 37°C. To purify
the labeled RNA, it was separated from free nucleotides on an 8% denaturing polyacry-
lamide gel, detected by autoradiography on MR films (Kodak, Stuttgart, Germany),
eluted over night in RNA elution buffer and precipitated with ethanol.
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For the activity reaction AGO2 containing samples were preincubated in reaction buffer
supplemented with 20 nM exogenous siRNA for 15min at 30°C. When using the miR-19b
target RNA this preincubation step was omitted. One Bq/cm2 of labeled target RNA
were then added to the samples and the reaction was incubated at 30°C for 1.5 h. The
reaction was stopped by the addition of Protease K buffer. The RNA was isolated as
described previously (see Section "RNA Isolation" on page 115) and analyzed on an
8% denaturing polyacrylamide sequencing gel. In order to be able to identify the spe-
cific cleavage product the labeled target RNA was digested with RNase T1 (Fermentas,
Burlington, Canada) in T1 reaction buffer and used as a size marker in the gel elec-
trophoresis. The detection of signals was realized with MS films and an intensifying
screen at -80°C.
Dicer Activity Assay
Dicer activity was tested by using two different internally labeled RNAs. The template
for pri-miR-27a RNA has been described previously [172, 220] and for the pre-miR-27a
template the two DNA oligos 5’-TAATACGACTCACTATAGCTGAGGAGCAGGG
CTTAGCTGCTTGTGAGCAGGGTCCACACCAGTCGTGTTCACAGTGGCTAAG
TTCCGCCCCCCAGC-3’ and 5’-GCTGGGGGGCGGAACTTAGCCACTGTGAACA
CGACTTGGTGTGGACCCTGCTCCAAGCAGCTAAGCCCTGCTCCTCAGCTAT
AGTGAGTCGTATTAA-3’ were annealed. RNA was produced by in vitro transcrip-
tion of the DNA template with T7 RNA polymerase (Fermentas, Burlington, Canada)
in transcription buffer supplemented with 32P-UTP for 2 h at 37°C. The reaction was
stopped by adding an equal volume of RNA sample buffer and incubation at 95°C for
5min. For use as a size marker a mixture of 19, 21 and 24 nt or 21 nt only RNA oli-
gos were labeled with 32P-ATP by T4 Polynucleotide kinase (Fermentas, Burlington,
Canada) for 5min at 37°C. To purify labeled RNAs they were separated from free nu-
cleotides on an 8% denaturing polyacrylamide gel, detected by autoradiography with
MR film (Kodak, Stuttgart, Germany), eluted over night in RNA elution buffer and
recovered by ethanol precipitation.
The activity reaction was carried out in reaction buffer supplemented with 10 U/ml
RiboLock (Fermentas, Burlington, Canada) and 2Bq/cm2 RNA substrate for 1 h at
37°C. The addition of Protease K buffer stopped the reaction and RNA was isolated
as described previously. Samples were analyzed on 15% denaturing polyacrylamide gels
and signal detection was carried out with MS films and an intensifying screen at -80°C.
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4.2.2 Cell Culture
Cultivation of Mammalian Cells
Mammalian cells were cultured in DMEM at 37°C and 5%CO2. In order to split cells
the medium was removed, the cells were washed once with PBS and were detached by
treatment with Trypsin-EDTA (PAA, Pasching, Austria). Trypsin was inhibited by the
addition of DMEM. Detached cells were pelleted by centrifugation at 200 g for 5min and
plated on fresh plates.
Calcium Phosphate Transfection
Cells were grown to 30% confluency and medium was changed 3-5 h prior to infection.
For transfection of a 15 cm plate, 10-15 µg of plasmid DNA was diluted in 246mM CaCl2
and added to an equal volume of 2x HEPES buffer while vortexing. The mixure was
incubated at room temperature for 30min and added drop wise to the medium in the
culture plate. Medium was exchanged only if required by the vitality of the cells. Cells
were harvested 2 d after transfection, flash frozen and stored at -80°C.
Generation of Mouse Embryonic Fibroblasts Stably Expressing FLAG/HA-Tagged
Murine AGO2
The MEF cell lines expressing F/H-tagged murine AGO2 were generated in collabora-
tion with Elke Glasmacher from the Research Group Vigo Heissmeyer at the Helmholtz
Center Munich. In short, retroviral supernatants were produced in HEK293T cells by
calcium phosphate transfection of amphotropic packaging vectors expressing F/H-AGO2
and IRES-GFP or IRES-GFP alone. Supernatants were collected 72 h post transfection,
filtered through 0.45mm filters and used for spin-infections of Dicer -/- and Dicer +/+
MEF cells at 900 g for 1 hour at RT [254]. The media was replaced after 24 h. Dicer -/-
and Dicer +/+ expressing F/H-AGO2 were grown in DMEM with 10% FCS, 1000U/ml
penicillin-streptomycin and 10mM HEPES.
Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC)
The Mann department kindly provided SILAC media containing amino acids with heavy
or light isotopes. Cells were cultured in SILAC medium to 90% confluency, detached
from the plate by trypsin digestion and pelleted by centrifugation (300 g, 5min, RT).
The medium was aspirated, the were cells resuspended in SILAC medium and cultured
at 37°C and 5% CO2. To ensure full incorporation of SILAC amino acids, the cells were
grown in SILAC media for at least ten doublings.
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To asses the incorporation rate and arginine-proline conversion total protein in whole
cell lysate from heavy labeled cells was checked by LC-MS. The incorporation rate for
every identified peptide was determined as follows:
1− 1
(1 +Ratio H/L)
(4.2.1)
The overall incorporation rate was calculated as the maximum of the density distribution
of all quantified peptides.
Arginine to proline conversion would generate an additional peak for all proline contain-
ing peptides of +6 Da. In order to detect arginine to proline the 10 most intense proline
containing peptides were manually inspected for this additional isotope cluster.
4.2.3 Antibody Generation
The monoclonal rat anti-AGO2(6F4) antibody was generated in collaboration with Eliz-
abeth Kremmer at the Helmholtz Center Munich as described previously [20]. For im-
munization the N-terminal peptide H-APTTSPIPGYAFKP-OH of mouse Argonaute2
(Peptide Specialty Laboratories, Heidelberg, Germany) was used.
4.2.4 Purification of Protein Complexes for Electron Microscopy
Sucrose Density Centrifugation
Lysates were prepared as described previously (see "Whole Cell Lysate Preparation" on
page 112). For the purification of the PRMT5/MEP50 untransfected HEK293T were
lysed. The purification of the AGO2/Dicer complex was carried out from HEK293T cells
transfected with pVP5–hAGO2 and pDest26-cmyc-hDicer. The lysates were loaded onto
sucrose density gradients with 15-55% (w/v) sucrose in the respective gradient buffer and
separated by centrifugation (17 h, 4°C, 30000 rpm) in a SW32 T rotor.
Immunoprecipitation with anti-FLAG M2 Affinity Gel
Anti-FLAG M2 Affinity Gel (Sigma, St. Louis, USA) was used for the immunoprecip-
itation of FLAG/HA-tagged AGO2 or the PRMT5/MEP50 complex. The beads were
washed twice with PBS and 500µl beads were added directly to the combined sucrose
gradient fractions 3-8 for AGO2 precipitation or 4-9 for precipitation of PRMT5. After
incubation for 4 h at 4°C with light rotation the beads were washed three times with
IP wash buffer and two times with elution buffer. Bound protein was eluted from the
beads with 1mg/ml 3x FLAG peptide (H-MDTKDHDGDYDHDlDYLDDDDL-OH) in
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elution buffer for 1 h at 4°C with light rotation. The elution step was repeated twice
and all three eluates were combined. The total volume was reduced to 300µl by con-
centration in centrifugal filter units with a molecular weight cut off of 30 kDa (Vivaspin
500, Sartorius, Göttingen, Germany, or Microcon Ultracell YM-30, Millipore, Billerica,
USA).
Glycerol Density Centrifugation (GraFix)
The concentrated sample was loaded onto a 10-30% glycerol gradient in gradient buffer.
For GraFix gradients [150], 0.1% glutaraldehyde was added to the 30% glycerol solution
prior to gradient mixing. The gradients were centrifuged with 42500 rpm at 4°C for 16 h
in an SW 60 rotor and fractionated manually.
Electron Microscopy
The electron micrographs shown in Figure 2.1.2 were taken by Ilonka Bartozek at the
Holger Stark Laboratory at the MPI for Biophysical Chemistry in Göttingen.
All further work was carried out by members of the Beckmann Group at the Ludwigs-
Maximilians University Munich. Negative staining of the samples with uranyl acetate
for electron microscopy was performed by Charlotte Ungewickell. Micrographs were
recorded on a 120 kV Tecnai G2 Spirit (FEI, Oregon, USA) by Otto Berninghausen and
Charlotte Ungewickell. Martin Turk performed all data analysis and 3D reconstructions.
In short, about 6000 particles were picked automatically with a template based particle
selection tool, manually adjusting the threshold values for each micrograph. Particles
with positive staining or a flat appearance as well as particles not discernible from
background were sorted out manually. The remaining 1700 particles were normalized,
band pass filtered, centered and masked in IMAGIC. Class averages were generated by
multi-variant statistical analysis and multi reference alignment in IMAGIC. Three class
averages with obvious size differences were selected and particles were sub-classified into
three groups based on the selected class averages. For each group 10 initial models were
generated using common lines and the best initial model was submitted to 50 rounds of
refinement by projection matching in EMAN2.
4.2.5 Purification of Protein Complexes for Mass Spectrometry Analysis
Preparation of Antibody Matrix by Direct Coupling
Antibodies against endogenous proteins were coupled to Protein G Sepharose beads as
described previously (see Section "Antibody Matrix Preparation" on page 113) with
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the alteration that beads were washed twice with 10 volumes of 0.2mM sodium borate
pH 9.0 after incubation. The beads were then resuspended in 10 volumes of 200mM
sodium borate and solid dimethylpimelimidate was added to reach a final concentration
of 20mM. The reaction was incubated at RT for 30min and stopped by washing the
beads once in 200mM ethanolamine, pH 8.0 and followed by incubation in 200mM
ethanolamine, pH 8.0 at RT for 2 h with gentle mixing. The beads were washed twice
with PBS and either used directly or stored in PBS with 0.01% sodium azide at 4°C for
up to 8 weeks.
Immunoprecipitation of Endogenous AGO2-Containing Complexes
Lysates from SILAC labeled cells were prepared as described previously (see Section
"Whole Cell Lysate Preparation" on page 112). Five mg of total lysate protein were
incubated with 50µl antibody coupled beads for 4 h at 4°C with rotation. If necessary,
the lysate volume was equalized by adding lysis buffer. After protein binding, the beads
were washed three times with IP wash buffer followed by two washing steps with elution
buffer. The samples were combined and for IPs with the anti-AGO2(6F4) antibody
bound protein was eluted from the beads in elution buffer with 500µg/ml AGO2 peptide
(H-APTTSPIPGYAFKP-OH) for 1 h at RT and shaking at 1000 rpm. In IPs using
the anti-AGO2(C43C6) antibody (Cell Signalling, Danvers, USA), bound protein was
eluted from the beads by adding an equal volume of 2x Novex Sample Buffer (Invitrogen,
Carlsbad, USA) with 20mM DTT followed by an incubation at 75°C for 10min.
Immunoprecipitation of FLAG/HA-tagged AGO2-Containing Complexes
SILAC labeled MEFs were lysed in lysis buffer as described earlier (see Section "Whole
Cell Lysate Preparation" on page 112). For immunoprecipitation, 3-4 mg total lysate
protein were incubated with 50µl M2 anti-FLAGM2 affinity gel (Sigma, St. Louis, USA)
for 4 h at 4°C with rotation. In the cases where the experiments addressed the RNA
dependency of the interactions, 100 µg/ml RNase A (Fermentas, Burlington, Canada)
was added either at the beginning of the 4 h incubation or 20min prior to the washing
steps. Beads were washed three times with IP wash buffer and twice with elution buffer.
Samples were combined and bound protein was eluted with 500µg/ml 3x FLAG peptide
in elution buffer for 90min at 4°C with shaking at 800 rpm.
Large RNA Binding Assay
Lysate preparation and immunoprecipitations were conducted as described above with
the alteration that 100 µg/ml RNase A (Fermentas, Burlington, Canada) was added
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either at the beginning of the 4 h incubation or 20min prior to the washing steps. RNAs
were isolated by Protease K digest and phenol-chlorophorm extraction as described
(see Section "RNA isolation" on page 115). Precipitated RNAs were resuspended in
a formaldehyde containing, denaturing loading buffer and were either visualized with
ethidium bromide staining after size separation in an 1% TBE buffered agarose gel or
analyzed by Northern blotting as described previously (see Section "Northern Blotting"
on page 115).
In Gel Trypsin Digest, Peptide Extraction and Stage Tipping
The protein samples were separated on NuPAGE Novex 4-12% Bis-Tris gels (Invitrogen,
Carlsbad, USA) and stained with the Novex Colloidal Blue Stain Kit (Invitrogen, Carls-
bad, USA) according to the manufacturers instruction. Each lane was cut into eight slices
and each slice was cut into 1mm x 1mm cubes. Gel pieces were destained in 25mM am-
monium bicarbonate and 50% ethanol for 10min at RT and 1200 rpm. This destaining
step was repeated until no more coomassie was visible. The gel pieces were dehydrated
by adding 100% actetonitrile and dried in a vacuum centrifuge. Disulfide bonds on
cysteine were reduced with 1mM DTT in 50mM ammonium bicarbonate for 45min at
56°C and shaking at 800 rpm followed by alkylation of cysteins by 5mM iodacetamide
50mM ammonium bicarbonate for 30 min at RT in the dark. Samples were washed
twice with 50mM ammonium bicarbonate, dehydrated twice with 100% acetonitrile and
dried in a vacuum centrifuge. Proteins were digested with 13 ng/µl trypsin (sequenc-
ing grade, modified; Promega, Madison, USA) in 50mM ammonium bicarbonate over
night at 37°C. The digestion was stopped by the addition of 30% (v/v) acetronitrile and
3% (v/v) trifluoroacetic acid in 50mM ammonium bicarbonate. Samples were incubated
at RT for 30min and the extract was collected in a fresh reaction tube. Extraction of
proteins was continued with 100% acetonitrile at RT until the gel cubes were completely
dehydrated. The volume of the extract was reduced to 1/5 of initial volume by vacuum
centrifugation and the pH was lowered by addition of 40µl buffer A*. Stage tips for
desalting of the samples were prepared by assembling C18 material (3M, St. Paul, USA)
in a pipette tip. The C18 material was activated with methanol and equilibrated with
buffer A*. After protein sample loading stage tips were washed twice with buffer A.
Loaded stage tips were stored at 4°C until mass spectrometry analysis.
4.2.6 Mass Spectrometry Analysis and Data Processing
Peptides were eluted from stage tips with 40µl buffer B, evaporated to 4µl in a vacuum
centrifuge and 4 µl buffer A were added. Peptides were separated on line to the mass
122
4 Material and Methods
spectrometer by using an easy nano-LC system (Proxeon Biosystems, Thermo Fisher
Scientific, Waltham, USA). 4 µl sample were loaded with a constant flow of 700 nl/min
onto a 15 cm fused silica emitter with an inner diameter of 75µm (Proxeon Biosys-
tems,Thermo Fisher Scientific, Waltham, USA) packed in-house with RP ReproSil-Pur
C18-AQ 3µm resin (Dr. Maisch, Ammerbuch-Entringen, Germany). Peptides were
eluted with a segmented gradient of 5–60% solvent B over 105min with a constant flow
of 250 nl/min. The nano-LC system was coupled to a mass spectrometer (LTQ-Orbitrap
or LTQ-Orbitrap Velos, Thermo Fisher Scientific, Waltham, USA) via a nanoscale LC
interface (Proxeon Biosystems, Thermo Fisher Scientific, Waltham, USA). The spray
voltage was set between 2.0 and 2.2 kV, and the temperature of the heated capillary was
set to 200°C.
Survey full-scan MS spectra (m/z = 300–2000) were acquired in the Orbitrap with a
resolution of 60,000 at the theoretical m/z = 400 after accumulation of 1 000 000 ions in
the Orbitrap. The five most intense ions from the preview survey scan delivered by the
Orbitrap were sequenced by centromere identifier (collision energy 35%) in the LTQ after
accumulation of 5 000 ions concurrently to full scan acquisition in the Orbitrap. Maximal
filling times were 1 000ms for the full scans and 150ms for the MS/MS. Precursor ion
charge state screening was enabled and all unassigned charge states as well as singly
charged peptides were rejected. The dynamic exclusion list was restricted to a maximum
of 500 entries with a maximum retention period of 90 s and a relative mass window of
10 ppm. Orbitrap measurements were performed with the lock mass option enabled for
survey scans to improve mass accuracy [242].
Raw MS data was analyzed using the in-house developed software MaxQuant (version
1.1.1.27, [48]). Data was searched against an IPI mouse database (version 3.68), sup-
plemented with frequently observed contaminants, employing a reverse database search
strategy for FDR estimation [260]. Carbamidomethylated cysteins were set as fixed,
oxidation of methionine and N-terminal acetylation as variable modifications. Mass de-
viation of 0.5D was set as maximum allowed for MS/MS peaks, and a maximum of two
missed cleavages were allowed. Maximum false discovery rates were set to 0.01 both
on peptide and protein levels. Minimum required peptide length was six amino acids.
Corresponding forward and reverse experiments were analyzed together and specified as
‘forward’ and ‘reverse’ in the experimental design.
Raw MS data, unfilted proteingroups tables and peptides tables can be downloaded from
https://proteomecommons.org/tranche using the following hash:
a6LrT+dbaF4jmWZcpYPJuvIzNTFmI0VhkHfqhh4SwQ8l68MSFv5dnfBw35h8RNo99y
QZUIAhTvWHpL+xXo7dW25eigAAAAAAAABXfA==
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All further analysis was done in a script based manner employing R (http://www.r-
project.org). Proteingroups were further filtered requiring at least two unique peptides
per protein identification, and 2 ratio counts (quantification events) in the forward as
well as in the reverse experiment. For all analysis log2 transformed normalized ratios (as
computed by MaxQuant) were used. To visualize the data, the logarithmized normalized
ratios of the forward and reverse experiments are plotted against each other. For the
hierarchical clustering proteins were considered that show a ratio of above 3.8 and below
0.3 in the forward and the reverse experiment, respectively, for the wt F/H-AGO2 vs wt
GFP dataset and 3.0 and 0.3 for the ko F/H-AGO2 vs ko GFP dataset. The cut offs were
derived manually from the ratio plots. In addition, quantification of the protein in at
least 2 out of 3 experiments was required. The three separate experiments were combined
using the Uniprot identifier, and proteins were clustered employing an euclidian distance
matrix. Columns were not clustered.
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